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Abstract
In the work described in this thesis, CD-based rotaxanes were prepared and their 
solid-state structures/packing, morphology and crystal growth behaviour were 
explored. Encapsulation o f profluorescent nitroxides through rotaxane formation 
demonstrated the use o f CD-based rotaxanes to change the reactivity o f CD guests 
and therefore preserve their properties.
In Chapter 2, the rotaxane 1.17 having a stilbene-based axle and 3,5-dimethylaniline 
blocking groups, as well as the rotaxane 1.18 having an azobenzene-based axle and 
2,6-dimethylaniline blocking groups were prepared to complete the set o f rotaxanes 
1.9, 1.10, 1.17 and 1.18 with 2,6-dimethylaniline and 3,5-dimethylaniline blocking 
groups, with azobenzene- and stilbene-based axles.
Chapter 3 describes the solid-state structures/packing, morphology and crystal growth 
o f the set o f rotaxanes 1.9, 1.10, 1.17 and 1.18. Observation o f crystal morphology 
using SEM and microscope images, suggests not only that crystal shape and size can 
be controlled depending on the choice o f blocking groups and varying the conditions 
o f crystal growth, but also that crystal packing is reflected in the crystal growth and 
the final shape o f the crystals. Thus, crystal engineering can be bottomed-up to make 
nano-molecular architecture to micrometre scale or beyond.
In Chapter 4, the unsymmetrically capped rotaxanes 4.1 and 4.2 were purposely 
designed and prepared using a crystal engineering approach such that they can be 
used to regulate the crystal growth o f the self-assembling rotaxane 1.9 through co-
crystallisation. 2D NMR spectroscopy was used to determine the orientation o f the 
CDs with respect to the dumbbells and assign the structures o f the rotaxane isomers 
4.1 and 4.2. Co-crystallisation experiments showed that the rotaxanes 4.1 and 4.2 act 
as crystal growth inhibitors o f the rotaxane 1.9. In addition, a method to prepare 
supersaturated solutions from a mixture o f amorphous and crystalline rotaxane was 
developed for crystal growth studies.
The unsymmetrically capped rotaxane 5.5 with 3,5-dimethylaniline and trinitrophenyl 
blocking groups on either end that can form j t - j i  interactions was prepared in Chapter
5. Co-crystallisation experiments with the rotaxanes 1.9 and 5.5 illustrate that 
blocking groups of rotaxanes can be used as synthons to guide intermolecular self- 
assembly to regulate the formation of fibrous structures. Therefore crystal engineering 
using CD-based rotaxanes is a versatile approach towards regulating self-assembly 
and understanding molecular level interactions in the solid-state. These interactions 
may be used to fine-tune physical, chemical, photochemical or electrical properties of 
the end product that is fabricated through a bottom-up approach.
New paramagnetic profluorescent nitroxides, the rotaxanes 1.33, 1.35 and 1.36, as 
well as the previously reported rotaxane 1.34 were prepared and their 
photoisomerisation and decomposition behaviour in comparison to the corresponding 
dumbbells 1.37 and 1.38 were examined in Chapters 6 and 7. UV/visible 
spectroscopy and HPLC analysis illustrated that the profluorescent probes of the 
dumbbells 1.37 and 1.38 were preserved through formation of the CD-rotaxanes 1.33, 
1.34, 1.35 and 1.36 making them advantageous for fluorescence detection.
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CHAPTER 1 - Introduction
1.1 Supramolecular Chemistry
The capability to generate very small structures is important in modern science and 
technology. The physical approach to miniaturisation has limitations that can be 
overcome by a synthetic chemical approach, known as the ‘bottom-up* approach,1 to 
construct from a molecular-level.2'3 This approach involves engineering molecular 
components that are able to assemble into a supramolecular structure capable of 
performing a specific function. This falls into the discipline of supramolecular 
chemistry, defined as ‘chemistry beyond the molecule’. It concerns two or more 
chemical species held together by intermolecular forces such as electrostatic 
interactions, hydrogen bonding and van der Waals forces.4 These types of non-covalent 
interactions are important in understanding natural biological systems such as DNA, 
where two strands of nucleotides are held together via hydrogen bonding.5 
Furthermore, molecular machines and devices have been designed to mimic natural 
systems or perform specific functions such as rotational movement,6,7 shuttling,8'9 
switching,1011 and entrapment.12'13
1.2 Cyclodextrins
Cyclodextrins (CDs) are widely used as building blocks for supramolecular chemistry. 
They are 1,4-a-linked cyclic oligomers of six or more D-glucopyranose subunits in a 
toroidal structure (Figure 1.1).14 The most widely occurring CDs have six to eight 
glucopyranose subunits.15 a-CD 1.1 is the smallest CD with six glucopyranose 
subunits, while ß-CD 1.2 and y-CD 1.3 consist of seven and eight subunits 
respectively. The primary hydroxyl groups of the CD are located on the narrower end 
of the cavity, while secondary hydroxyl groups are on the wider end of the CD cavity. 
This feature provides CDs with a hydrophilic exterior, which accounts for their 
aqueous solubility.16 The inside of the CD cavity on the other hand, is hydrophobic due 
to CD-C3 and C5 hydrogens and the ether-like oxygens.16 Hence the formation of CD 
inclusion complexes with hydrophobic guests is favoured in aqueous media through 
the displacement of water molecules from the hydrophobic CD cavity.14’17
1
Secondary 
hydroxyl groups
Hydrophobic
cavity
/  Primary 
hydroxyl groups
Figure 1.1. Structure of a-CD 1.1, ß-CD 1.2 and y-CD 1.3 (left) and a schematic
representation as a truncated cone (right). The narrower end of the cone is lined by the 
CD-C6 primary hydroxyl groups while the wider end of the cone is lined by the CD- 
C2 and C3 secondary hydroxyl groups.
The ability of CDs to form inclusion complexes with hydrophobic guests, and 
therefore increase the solubility of molecules that are otherwise poorly soluble in 
water, is widely utilised in areas including the pharmaceutical, food, cosmetics, 
toiletries, chemical and biotechnological industries.17’18 CDs are also used in 
analytical chemistry17 to separate chiral and other molecules, and as catalysts15,19 and 
molecular reactors20 in chemical reactions. CDs can be chemically modified to 
improve their solubility and complexation behaviour, or to introduce groups with 
specific functions.2122 Modified CDs are most frequently prepared through 
functionalisation at their primary or secondary hydroxyl groups. Supramolecular 
structures are derived from non-covalent interactions of CDs with guest molecules.
1.3 Rotaxanes
Rotaxanes are supramolecular species comprising macrocycles surrounding axles that 
are bonded to bulky blocking groups so as to prevent the macrocycles and axles from 
dissociating (Figure 1.2).23,24 Unlike typical molecular structures, rotaxanes consist of 
two or more distinct molecules which are not joined by covalent bonds. These 
molecules are mechanically interlocked, and the supramolecular species have 
chemical and physical properties that are different from their non-interlocked 
components. Furthermore, the interlocked structures cannot dissociate without 
cleavage of one or more covalent bonds.
2
__ I j  y
axle macrocycle blocking groups rotaxane
Figure 1.2. A schematic representation of a molecular axle, macrocycle and blocking 
groups forming a rotaxane.
CDs are ideal for use as macrocycles in rotaxane synthesis since, in aqueous solution, 
they spontaneously form host-guest complexes with hydrophobic species that can then 
be the axles. 14 25 Accordingly, CD host-guest complexes are being used to produce 
rotaxanes and related supramolecular species that can potentially form working 
molecular sensors and machines, and microelectronic devices.^ '
1.4 Cyclodextrin Based Rotaxanes
The first crystal packing of a CD-based rotaxane, the stilbene 1.4, was reported by 
Onagi et al.30 X-Ray crystallographic analysis of the rotaxane 1.4 showed molecular 
strands aligned along a single axis through k - j i stacking of the blocking groups that 
were twisted out of the plane of the axle and insulated by the CDs (Figure 1.3). The 
dumbbell of the rotaxane 1.4, lacking the CD macrocycle, formed a complex network 
of molecules aligned along multiple axes and showing diverse intermolecular 
interactions.
3
Figure 1.3. Crystal packing of the rotaxane 1.4 showing insulated strands along a 
single axis.30
The crystal structure of a CD-based rotaxane, the tetraacid 1.5, had been reported 
earlier by Stanier et al., but it was only later that Terao et ai, analysed the crystal 
packing of this material to find that it also displayed insulated molecular wires with 
71-71 stacking33'35 of the isophthalic acid blocking groups, with those being co-planar 
with the stilbene moiety (Figure 1.4). In this case, the CDs are aligned head-to-tail in 
one direction interspersed by others at right angles, notably different from the crystal 
packing of the rotaxane 1.4, where the CDs are aligned faithfully along a single axis, 
but the lack of co-planarity of the blocking groups with the axle with the rotaxane 1.4 
prevents extended ^-electron delocalisation through jr-stacking to produce an 
insulated molecular wire.
HOoC
COoH
HOoC
COoH
4
Figure 1.4. Crystal packing of the rotaxane 1.5.
When oriented along a single axis, CDs can align in head-to-head, tail-to-tail and 
head-to-tail fashions. Head-to-head and tail-to-tail alignment leads to 
centrosymmetric packing while head-to-tail packing can lead to either 
centrosymmetric or non-centrosymmetric packing depending on the rows of CDs all 
facing the same direction (non-centrosymmetric packing) or different directions 
(centrosymmetric packing) (Figure 1.5).3(1 The latter results in non-polar crystals, 
while non-centrosymmetric packing leads to the formation of polar crystals, due to the 
dipole of the CDs.14 Polar cry stals can form as a result of other interactions 
overcoming the energetically unfavourable dipolar interactions of unidirectionally 
aligned CDs.
(a)
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(b)
Figure 1.5. Schematic representations of CD alignments showing (a) head-to-head 
and tail-to-tail centrosymmetric, (b) head-to-tail centrosymmetric and (c) head-to-tail 
non-centrosymmetric packing.
CD-based rotaxanes inherit the dipole of the CDs.14 Thus unidirectionally aligned 
dipoles of rotaxanes form non-centrosymmetric crystals.36 The crystal packing of the 
series of rotaxanes 1.6-1.8, analogous to the rotaxane 1.4, modified with substituents 
at the 3- and 3’-positions of the stilbene moiety were reported by Onagi et ö /.,30 and 
Cieslinski et al. The crystal structures showed the substituents provide slight 
changes in the conformations of the dumbbells, which are sufficient to change the 
directionality of the CDs in the crystal packing.30,37 Each of the rotaxanes 1.4 and 1.6- 
1.8 showed the CDs aligned along a single axis. The rotaxane 1.4 (Figure 1.3) and the 
difluoride 1.7 (Figure 1.6 (b)) showed head-to-head and tail-to-tail alignment of the 
CDs, forming centrosymmetric, non-polar crystals. The dimethoxystilbene 1.6 
showed head-to-tail alignment of the CDs, where alternating rows have the CDs 
facing opposite directions, also forming centrosymmetric, non-polar crystals (Figure 
1.6 (a)). On the other hand, the dichloride 1.8 showed rows of CDs all aligned head-
6
to-tail in the same direction to give a non-centrosymmetric, polar crystal (Figure 1.6
(c)).
1.6 R = OMe
1.7 R = F
1.8 R = Cl
Figure 1.6. Crystal packing (left) and schematic representation of the alignment of the 
CDs (right) of two adjacent molecular fibres in (a) the dimethoxystilbene 1.6, (b) the 
difluoride 1.7 and (c) the dichloride 1.8.37 Reproduced with permission from Taylor & 
Francis.
Recently, Maniam et al., reported the synthesis of the rotaxane 1.9, where a-CD, an 
azobenzenedicarboxylic acid and 3,5-dimethylaniline were assembled through amide 
bond formation. X-Ray crystallographic analysis showed that in the solid-state the 
axles form linearly aligned molecular fibres along a single axis, with ji-jt stacking of 
the blocking groups associated with adjacent molecules, while the fibres are insulated 
by the CDs (Figure 1.7). Extended conjugation within each rotaxane through co-
planarity between the axle and the blocking groups is also evident.
7
Figure 1.7. Crystal packing of the rotaxane 1.9 showing (a) alignment into insulated
o
molecular fibres, and (b) jt - jt  stacking between the blocking groups.
In solution, the absorption of the rotaxane 1.9 in MeOH and DMSO was found to 
obey Beer’s law, but in water, when the absorbance was measured at various 
concentrations, unusual spectroscopic behaviour was observed (Figure 1.8). For 
example, at 350 nm where an azobenzene moiety absorbs,39 the absorbance of a 100 
pM solution was significantly less than the expected value of twice the absorbance of 
a 50 pM solution. When absorbance at 350 nm was plotted against the concentration, 
the deviation from Beer’s law was found to occur at about 16 pM concentration and 
above. In addition, when the deviation occurred, absorbance at wavelengths higher 
than 350 nm was also observed, which is characteristic of formation of aggregates 
with extended conjugation.40 This was attributed to the rotaxane 1.9 assembling 
through jt-jr stacking of the blocking groups to form polymeric aggregates in aqueous 
solution.
The CD insulates the axle, so only the blocking groups are exposed to form 
jr-jT interactions. These must be intermolecular in such a way that the rotaxane 1.9 
forms molecular wires. The ji - ji interactions between the blocking groups of adjacent 
rotaxanes affect the spectral characteristics of the azobenzene moiety, so the axles 
must be fully conjugated with the blocking groups. These features are evidence that in
8
solution the rotaxane 1.9 aggregates in a liquid crystal-like41'42 fashion as organised 
molecular wires.
-----100 pM
50 pM 
25 pM 
10 pM
-----5 pM
-----2.5 pM
-----1 pM
Figure 1.8. Absorbance spectrum of the rotaxane 1.9 in water at the concentrations 
indicated.
An azobenzene is generally non-fluorescent in solution.39 However, irradiation of 
solutions of the rotaxane 1.9 at 480 nm, which is near the wavelength where atypical 
absorbance is observed, resulted in fluorescence at 520 nm. This unusual fluorescence 
behaviour supports the self-assembly of the rotaxane 1.9 into molecular wires in 
aqueous solution through intermolecular jt - jt  interactions.
The analogous rotaxane 1.10 was also made, where a stilbene-based axle was used 
instead of an azobenzene-based axle, and 2,6- instead of 3,5-dimethylaniline blocking 
groups were used. The absence of conjugation along the axle in this case is seen in 
the solid-state where the plane of the dimethylaniline blocking groups is twisted 
approximately 90° from that of the stilbene moiety (Figure 1.9). This conformation 
prevents the overlap of adjacent blocking groups necessary for k - k  stacking of the 
type seen with the rotaxane 1.9. This prevents close-packing of the CDs along one 
axis. Instead, CDs oriented in one direction alternate with others aligned at right 
angles (Figure 1.10).
9
Figure 1.9. (a) Steric interactions prevent co-planarity of the blocking groups with the 
axle in the rotaxane 1. 10, and (b) the absence of such steric interactions with the 
rotaxane 1.9.3 8
Figure 1.10. Crystal packing of the rotaxane 1.10 showing orientation of CDs in one
• • • • • ”3 0
direction (purple) interspersed by others aligned at right angles (green).
1.5 Crystal Engineering
Having observed this interesting crystal packing behaviour of CD-based rotaxanes, it 
was decided to explore them using a crystal engineering approach. Desiraju43 defined 
crystal engineering as ‘the understanding of intermolecular interactions in the context 
of crystal packing and the utilisation of such understanding in design of new solids 
with desired physical and chemical properties.’ An approach to designing crystals 
with predicable structure is to use supramolecular ‘synthons’ that represent molecular 
building blocks and determine the features of crystal packing though molecular 
recognition.44 For example, the crystal structure of hydrogen cyanide 1.11 consists of 
linear chains all pointing in the same direction based on C-H - N hydrogen bonds 
(Figure 1.11 (a)).45 Crystal packing of cyanoacetylene 1.12, 4-ethynylcyanobenzene
10
1.13, and 4-cyano-4'-ethynylbiphenyl 1.1446 also show linear chains with C-H • N 
hydrogen bonds conserved (Figure 1.11 (b), (c) and (d)). Hence regardless of the 
nature of the hydrocarbon fragment that comes between the CH and N, the C-H - N 
hydrogen bonds exemplified by hydrogen cyanide 1.11 result in linear chains.
(a)
H—
1.11
H—= N ----- -H—= N -------H—= N
(b)
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(C)
H—= — — = N ....... -H—= — — = N ......... -H—= — — = N
ORTEP diagram of 4-ethynylcyanobenzene with thermal ellipsoids at 50% 
probability.
C 4 /N 4  a
h — — = n
1.13
12
(d )
Figure 1.11. Crystal packing diagrams43,44 (top) and schematic representations47 
(bottom) of (a) hydrogen cyanide 1.11, (b) cyanoacetylene 1.12, (c) 4- 
ethynylcyanobenzene 1.13 (shown in thermal ellipsoids at 50% probability as there is 
50% occupancy of cyano and ethynyl groups at each end of the molecule) and (d) 4- 
cyano-4'-ethynylbiphenyl 1.14 showing C-H---N hydrogen bonding interactions. 
Crystal packing diagram reproduced with permission from Elsevier.
Whilst molecular similarity also leads to packing similarity, leading to predictable 
crystal structures,48 Thakur et al.,49 demonstrated that crystal packing depends not 
only on the nature of the functional groups, but also the positioning of the functional 
groups in the molecule. Fluorobenzene 1.15 and benzonitrile, pyridine, pyridine-jV- 
oxide and cyanobenzene represent a structure type that forms tetragonal packing. 
Fluorobenzene 1.15 forms tetragonal packing through two principal types of 
interaction. The first is the C-H F interaction between the hydrogens that are ortho 
to the fluorine and the fluorine of neighbouring fluorobenzene. The second is the CH- 
jc interaction between the hydrogens that are meta to the fluorine and the 
neighbouring phenyl ring acceptor as shown in Figure 1.12.49 Despite the similar 
shape and size of 1,2,3,5-tetrafluorobenzene 1.16 to those of the molecules that adopt 
the tetragonal fluorobenzene 1.15 structure, the lack of hydrogens in the 3- and 5- 
positions means that tetragonal packing would require unfavourable C-F - Ji 
interactions. Instead, ji - jt  stacking of 1,2,3,5-tetrafluorobenzene 1.16 results, as 
shown in Figure 1.13. This illustrates that crystal engineering requires understanding 
of the dominating interactions for the self-assembly.
13
Figure 1.12. Crystal packing of fluorobenzene 1.15 showing tetragonal interactions, 
with C-H -F interaction between the hydrogens that are ortho to the fluorine and the 
fluorine of neighbouring fluorobenzene (red), as well as C H - ji  interaction between 
the hydrogens that are meta to the fluorine and the neighbouring fluorobenzene rings 
(green).
Figure 1.13. Crystal packing of 1,2,3,5-tetrafluorobenzene 1.16 showing ji-jt 
interactions.
Crystallisation occurs not only when molecules self-assemble but also when 
supermolecules further self-assemble.50 Crystal structure and packing of native CDs 
has been studied extensively.51 The crystal structures collectively show intramolecular 
hydrogen bonds between the 0(2)H and 0 (3 )H hydroxyl groups of adjacent 
glucopyranose units, which contribute to the stable conformation of CDs.16 a-CD 1.1, 
ß-CD 1.2 and y-CD 1.3 crystallise from water as hydrates. a-CD 1.1 crystallises with
14
651’52 or 7.5753 water molecules, while ß-CD 1.2 crystallises with 1252 and y-CD 1.3 
crystallises with 17 water molecules/4 The water molecules fill the CD cavity and 
external interstices between molecules either in fixed positions (Figure 1.14) or 
statistically distributed over a number of disordered sites (Figure 1.15). CDs also 
crystallise from mixtures of water and other solvents including methanol,55,56 
ethanol,57 2-propanol58 and DMF.59
Figure 1.14. Crystal structure of the a-CD 1.1 hexahydrate,16,18 containing two 
included molecules of water (WA and WB). Four molecules of water which are not 
included in the CD cavity are not shown. Hydrogen bonding interactions are indicated 
by dashed lines. Reproduced with permission from Academic Press, London.
15
Figure 1.15. Crystal structure of the ß-CD 1.2 dodecahydrate.60 The 6.5 water 
molecules distributed statistically over 9 sites inside the CD cavity are shown as 
ellipsoids. Water molecules which are not included in the CD cavity are not shown. 
Reproduced with permission from Elsevier.
When a molar excess of guest is added, the inclusion complex may be isolated in 
crystalline form. Crystal structures of CD inclusion complexes provide information on 
host-guest interactions as well as the geometry of the host and guest molecules.16 CD 
complexes can crystallise in a channel-type or cage-type structure depending on the 
size and ionic character of the guest molecule.61 The channel-type structure has the 
CDs packed on top of each other to form continuous channels occupied by the guests 
(Figure 1.16 (a)). The cage-type structure has both ends of the CD cavity blocked by 
neighbouring CDs in a herringbone arrangement (Figure 1.16 (b)) or a brick 
arrangement where the CDs are packed in layers of sheets, offset from each other 
(Figure 1.16 (c)).16,61 Channel-type complexes generally show disorder of guest 
molecules.62,63 Cage-type complexes, on the other hand, generally show disorder 
when guest molecules are smaller than the cavity,58,60,64 but order when the guest 
molecules are of compatible size.65,66
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Figure 1.16. Schematic representation of (a) the channel-type, (b) the herringbone- 
type cage and (c) the brick-type cage crystal packing of CD inclusion complexes.16 
Reproduced with permission from Academic Press, London.
Crystal structures and packing of modified CDs have also been extensively studied. 
Methylated CDs show increased cavity size due to methyl groups aligned in rings at 
both ends, resulting in guest molecules including differently to native CDs.67'69 
Monosubstituted CDs may include a substituent group of an adjacent molecule. For 
example, 6-deoxy-6-(phenylthio)-ß-CD shows the phenylthio substituent included in 
the cavity of an adjacent CD to form an extended polymeric structure (Figure 1.17).70 
Alternatively, self-inclusion complexes may form where the substituent group is 
included in the cavity of the attached CD. A 6-deoxy-6-cyclo(L-histidyl-L-leucyl)-ß- 
CD forms a self-inclusion complex where the cyclo((L-histidyl-L-leucyl) moiety bends 
to include in the CD cavity as shown in Figure 1.18.
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Figure 1.17. Crystal packing of 6-deoxy-6-(phenylthio)-ß-CD.70 The phenyl moiety 
and water molecules are shown in filled circles. The molecules are arranged along a 4- 
fold screw axis represented by the vertical line. The phenyl group is inserted in the 
cavity of an adjacent molecule. Reproduced with permission from The Royal Society 
of Chemistry.
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Figure 1.18. Crystal structure of a 6-deoxy-6-cyclo(L-histidyl-L-leucyl)-ß-CD.71 (a) 
View along the side of the CD. The cyclo(L-histidyl-L-leucyl) moiety shown in filled 
circles includes in the CD cavity, (b) View from the narrower end of the CD cavity 
showing attachment of the cyclo(L-histidyl-L-leucyl) moiety at the CD-C6 position. 
Reproduced with permission from The National Academy of Sciences, USA.
Obtaining crystals of CD-based rotaxanes is of interest as they have guest molecules 
that do not dissociate and show more ordered geometry inside the cavity. As seen with 
the rotaxane 1.9. solid-state studies may be a starting point to understanding 
molecular level interactions in solids and in solution. The solid-state studies may be 
used to fine-tune physical, chemical, photochemical or electrical properties of the end 
product that is fabricated through a bottom-up approach.
Given the solid-state behaviour of the rotaxanes 1.9 and 1.10 with different blocking 
groups and axles, one of the aims of this project was to prepare the complementary 
rotaxane 1.17 having a stilbene-based axle and 3,5-dimethylaniline blocking groups, 
as well as the rotaxane 1.18 having an azobenzene-based axle and 2,6-dimethylaniline 
blocking groups. Subject to their successful synthesis, the intention was to explore the 
crystal structure and the crystal packing behaviour of the rotaxanes 1.17 and 1.18 in 
comparison to those of the rotaxanes 1.9 and 1.10. In particular, through the study of 
crystal packing and morphology of rotaxanes, it was of interest to see if the blocking 
groups of rotaxanes could be used as synthons to guide intermolecular self-assembly 
to regulate the formation of fibrous structures. Based on this work, examining the 
crystal growth behaviour, and furthermore, interfering with crystal growth using 
unsymmetrically capped rotaxanes was to be investigated. Gaining insight into the
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molecular level interactions is necessary to design supramolecular assemblies that can 
be bottomed-up to control the morphology and size of rotaxane crystals.
1.6 Rotaxanes to Preserv e the Fluorescence of Profluorescent Nitroxides
As discussed above, CD-based rotaxanes are of interest for crystal engineering 
studies. In addition, CD-based rotaxanes can be used to change the properties of guest 
molecules. ' ' In the second part of this thesis, preventing photoisomerisation of 
profluorescent nitroxide guest molecules, and consequently preserving the 
profluorescent properties through formation of CD-based rotaxanes was of interest.
Aminyl oxides, aminoxyl radicals, nitroxyl radicals, or more commonly, nitroxides, 
are free radicals that have the general formula R(NO’)R\ The persistency of 
nitroxides results from electron delocalisation between the two heteroatoms through 
resonance as shown in Scheme 1.1.78,79 Owing to the persistent nature of the free
OA Of f O'V t  9 0 7
radicals, nitroxides are commonly used as spin labels, ’ spin traps, antioxidants 
and in radical polymerisations.84,85
R
: N-O' ----------*•
Scheme 1.1. Resonance structures of nitroxides.
Nitroxides have also been recognised as effective profluorescent probes for oxidative 
change and free radical generation.86' 91 When a nitroxide is attached to a fluorophore,
Rn
; n - o
/
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the electronic interaction of the unpaired electron with the fluorophore enhances 
intersystem crossing, causing fluorescence from the first excited singlet state to 
decrease, and hence quench the fluorescence signal. Despite the persistency of 
nitroxides towards other nitroxides, they can readily abstract hydrogen or react with 
alkyl radicals to form hydroxylamines or alkoxyamines. The species then becomes 
diamagnetic and is now fluorescent and can be detected through fluorescence 
spectroscopy (Scheme 1.2).89 90 Therefore nitroxides that are attached to fluorophores 
can be exploited as pro fluorescent probes as the fluorescence of the fluorophores is 
quenched until it gets restored through the nitroxides reacting with free radicals.
N - O - R
Scheme 1.2. Reduction of a profluorescent nitroxide to give a fluorescent species.
Earlier studies of profluorescent nitroxides consisted of nitroxides covalently linked to 
fluorophores via ester, ' amine, amide and sulfonamide linkages. More 
recently, the Bottle group95 96 has investigated the chemistry of profluorescent 1,1,3,3- 
tetramethylisoindoline-2-yloxyl 1.19 where the nitroxide is directly fused to the 
fluorophore. In the fused system, the close proximity of the nitroso radical and the 
fluorophore allows effective quenching of the fluorescence which can be restored 
upon trapping free radicals to form diamagnetic species.97 The aromatic ring of 
l,l,3,3-tetramethylisoindoline-2-yloxyl 1.19 allows further functionalisation,90,98' 100 
and the narrower linewidth and simpler EPR spectra of isoindoline nitroxides 
compared to other nitroxides makes them ideal for detection. In addition, isoindoline 
nitroxides are more robust under harsh conditions101 such as extreme heat or pH, 
relative to the earlier profluorescent nitroxides reported in the literature, where the 
fluorophore is linked to the nitroxide via more labile linkages.86'88,92'94 These 
properties make profluorescent isoindoline nitroxides ideal for detection of free 
radicals in cells102,103 and in pollution,104' 106 and for monitoring material 
degradation.99'107' 109 Profluorescent isoindoline nitroxides in the literature include the 
fluorescamine 1.20, the phenanthrene 1.21 and the naphthalene 1.22.
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Compounds that contain the stilbene functionality are often used as fluorescent probes 
due to their high quantum yields and short excited states.110 For this reason, the 
stilbene-based nitroxide 1.23 has also been developed as a versatile fluorescent 
probe,90 however, the /nms-stilbene 1.23 can undergo trans-cis isomerisation when 
exposed to light. The extinction coefficient of a c/s-stilbene is less than 14% of the 
trans-isomer around the Xmax of the /raws-stilbene, and the fluorescence of the cis- 
stilbene is less than 1% of that from the /ratts-stilbene.111 Hence trans-cis 
isomerisation causes loss of fluorescence.111’113
To sustain the profluorescent properties of fluorescent probes that contain the stilbene 
functionality, the aim of the work discussed in the latter parts of this thesis was to 
prevent the stilbene moiety of a compound related to the stilbene 1.23 from 
undergoing isomerisation by preparing rotaxanes where the stilbene-based axle is 
mechanically entrapped in a-CD 1.1. In the study of photochemistry of stilbene-based 
CD rotaxanes by Stainer et al.}b the /nms-stilbene moiety of the rotaxane 1.24 
undergoes photoisomerisation resulting in the a-CD macrocycle shifting away from 
the centre of the stilbene moiety as the cavity of the a-CD is not wide enough to 
include a c/s-stilbene moiety (Scheme 1.3). In the case of the stilbene-based rotaxane 
1.26, trans-cis isomerisation is prevented, again, as the cavity of the a-CD is not wide 
enough to include a c/T-stilbene moiety and the CD cannot shuttle away from the
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stilbene moiety towards the bulky blocking groups. By comparison, the analogous 
rotaxane 1.27 with ß-CD in the place of a-CD shows trans-cis isomerisation as the 
wider cavity of the ß-CD can include a c/s-stilbene moiety. Hence based on these 
reports, the objective was to prepare rotaxanes of a stilbene based nitroxide, related to 
the stilbene 1.23, to hinder trans-cis isomerisation due to the combination of the 
limited size of the a-CD cavity, and the length of the dumbbell being insufficient for 
the CD to shift away from the stilbene moiety. Another aim was to improve the 
solubility in aqueous media through encapsulation of the stilbene moiety by CD such 
that the fluorescence probe could be used under physiological conditions and in vivo 
studies.
Scheme 1.3. The rotaxane 1.24 showing shuttling of the CD for trans-cis 
isomerisation to occur.
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1.27
Nitroxides show increased EPR spectroscopic signals when included in the cavity of a 
C D ."4-117 CD inclusion complexes with nitroxides118’12^ and nitroxide labeled CDs,126’ 
131 where the nitroxide is covalently attached to the CD, have been reported in the 
literature. They are used to monitor supramolecular assemblies,128’131 host-guest 
complexations118' 121’123’125'127’128 and aggregation of CDs.122'130 Nevertheless, only a 
few nitroxide based CD rotaxanes have been reported.
• I D
Mezzina et al., reported the synthesis of the first nitroxide based CD rotaxane 1.28. 
The rotaxane 1.28 was prepared using a-CD 1.1 as the macrocycle, sebacoylchloride 
as the axle and 4-amino-2,2,6,6-tetramethylpiperidine-A-oxyl (4-amino-TEMPO) as 
the blocking group. Thermal lability studies using EPR spectroscopy indicated that 
the rotaxane 1.28 was non-labile when heated at 60 °C for 14 days.
1.28
Another example of a nitroxide based CD rotaxane is the [l]rotaxane 1.29 reported by 
Franchi et a /.133 The nitroxide moiety is mechanically trapped inside the cavity of the 
CD through a covalent link to the primary end of the CD. The trapping of the 2,2,6,6- 
tetramethylpiperidine-A-oxyl (TEMPO) moiety leads to EPR signal enhancement and 
increased persistency against reductive conditions compared to unprotected TEMPO.
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More recently, Casati et al.,134 prepared a-CD 1.1 based rotaxanes, the nitroxides 1.30 
and 1.31, having 4-oxy-TEMPO as the blocking group on one end of the axle. The 
unsymmetrically capped dumbbell gave the isomeric rotaxanes 1.30 and 1.31 
differing by virtue of the orientation of the CD on the dumbbell. Furthermore, the 
double spin labeled [2]rotaxane 1.32 was reported, where the dumbbell as well as the 
a-CD is substituted with the TEMPO moiety.
1.31
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Maniam135 reported the synthesis of the water-soluble and stable profluorescent 
paramagnetic rotaxane 1.34 and the corresponding dumbbell 1.37. Compared to the 
dumbbell 1.37 that is virtually insoluble in water, the rotaxane 1.34 has increased 
water solubility. NMR spectroscopic studies indicated that the rotaxane 1.34 has 
enhanced resistance against degradation compared to the dumbbell 1.37. Therefore 
continuing on from earlier work done by Maniam, * the compounds 1.33, 1.34, 1.35,
1.36, 1.37 and 1.38 were prepared in this work. The photoisomerisation behaviour of 
the compounds 1.33, 1.34, 1.35, 1.36, 1.37 and 1.38 w'as studied to compare the 
effects on photoisomerisation behaviour of the dumbbells 1.37 and 1.38 alone, and 
when they are included in a-CD in the form of the rotaxanes 1.33, 1.34, 1.35 and
1.36. The photoisomerisation behaviour depending on 2,6- or 3,5-dimethylaniline 
blocking groups as well as the orientation of the CD macrocycle was also compared.
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CHAPTER 2 - Results and Discussion 
Synthesis of a-Cyclodextrin [2]Rotaxanes with Aniline-based Blocking
Groups
2.1 Introduction
As described in the Introduction, the aim of the work described in this Chapter was to 
prepare the rotaxanes 1.17 and 1.18. analogous to the rotaxanes 1.9 and 1.10. 
Maniam ' used 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMT-MM )136,137 as the amide coupling reagent for the synthesis of the CD-based 
[2]rotaxanes 1.9 and 1.10. The synthesis of the rotaxane 1.9 involved forming the 
inclusion complex of the azobenzene 2.1 with a-CD 1.1, followed by the addition of
T O
DMT-MM and the aniline 2.2 as shown in Scheme 2.1. The synthesis of the 
rotaxane 1.10 involved forming the inclusion complex of the stilbene 2.3 with a-CD
1.1, followed by the addition of DMT-MM and the aniline 2.4 as shown in Scheme
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2.2. In the present work, this methodology using the inexpensive, water-soluble
amide coupling agent, DMT-MM was further employed.
Scheme 2.1. Synthesis of the rotaxane 1.9.38
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2.2 Synthesis and Conformational Analysis
Initially, the synthesis of the rotaxane 1.17 was attempted by adapting the procedure 
of Maniam et al., by equilibrating the stilbene 2.3 in carbonate buffer (pH 10) with 
excess a-CD 1.1. The stilbene 2.3, however, was found to be insoluble in the buffer, 
unlike the azobenzene 2.1. Hence the rotaxane 1.17 was prepared according to 
Scheme 2.3. The stilbene 2.3 was equilibrated with excess a-CD 1.1 and three molar 
equivalents of TEA in water for the inclusion complex 2.5 to form. The TEA provides 
the basic conditions required to maintain the nucleophilicity of the aniline 2.2 as well 
as the formation of the stilbene bis(triethyl)ammonium salt, which has enhanced 
solubility compared to the disodium salt in ionic solution. The bis(triethyl)ammonium 
salt was not fully soluble. Then, the aniline 2.3 and a large excess of DMT-MM were 
added. Formation of the product 1.17 was monitored by TLC. The TLC of the 
reaction mixture showed a component with a different R\ value to a-CD 1.1, yet 
showing both the UV absorbance of an aromatic compound and the pink colouration 
characteristic of a CD on exposure to acidic naphthalene-1,3-diol. The rotaxane
1.17 was isolated in 2% yield through reverse phase HPLC and its ESI mass spectrum 
showed an (M-H)' ion of m/z 1446. A low yield was obtained in comparison to the 
27% yield of the azobenzene analogue 1.9* despite the large excess of DMT-MM for
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Figure 2.1. 500 MHz 'H NMR spectrum of the rotaxane 1.17 in CD3OD.
Methodology employed by Inoue and co-workers139'140 was applied to determine the 
position of the CD along the axle and the conformation of the rotaxane 1.17. Figure 
2.2 shows a section of the DQF-COSY NMR spectrum of the rotaxane 1.17, where 
the CD proton cross-peaks are found. The Cl anomeric protons resonate the most 
downfield, and those resonances are well separated from the resonances of the C2-C6 
protons. Characteristically the Cl protons’ resonance is observed at about 64.8.141 
While this region of the spectrum is partially obscured by the OH signal, a signal at 
64.94 is observed, and therefore assigned to the CD-C1 protons. A 'H-’H correlation 
between these protons and those giving rise to the signal at 63.47 is seen, and the 
latter is therefore assigned to the CD-C2 protons. Likewise, there is a cross-peak 
between the resonance at 63.47 (CD-C2) and the resonance at 63.87 which is 
therefore attributed to the CD-C3 protons. This resonance at 63.87 (CD-C3) also 
shows a cross-peak with the resonance at 63.57 which is therefore assigned to the CD- 
C4 protons. Again, the resonance at 63.57 (CD-C4) also shows a cross-peak with the 
resonance at 63.90 which is therefore assigned to the CD-C5 protons. Finally, the 
resonances at 63.75 and 3.60 corresponding to the CD-C6 protons show cross-peaks 
with each other.
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optimisation. This is presumably due to the relatively low solubility of the stilbene 2.3 
that does not fully dissolve even when the bis(triethyl)ammonium salt is formed. 
Rotaxane formation using these types of reactions also leads to side products as 
discussed later with the rotaxane 1.18. contributing to the low yield.
1 equiv.
DMT-MM 30 equiv.
2.2
4 equiv.
Scheme 2.3. Synthesis of the rotaxane 1.17.
The ID 'H NMR spectrum of the rotaxane 1.17 confirms the presence of the 
components, showing resonances of CD, stilbene and arylamino protons (Figure 2.1). 
The signals at 67.39 and 7.34 which each integrate for two protons correspond to the 
2- and 6-protons of each arylamino group. The 2- and 6-protons of each arylamino 
group are chemically equivalent due to rotation around the aryl group to nitrogen 
bond, but the arylamino groups are non-equivalent because of the asymmetry of the 
CD. Accordingly, the methyl substituents of the blocking groups are observed as two 
partially resolved apparent singlets at 62.34 and 2.33.
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Figure 2.2. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the rotaxane 
1.17 in CD3OD showing cross-peaks between CD proton signals.
The structural assignment can then be completed by analysis of the nuclear 
Overhauser effect (NOE) interactions in the ROESY NMR spectrum. Figure 2.3 
shows a section of the 2D ROESY NMR spectrum with cross-peaks for the stilbene 
protons. Since cross-peaks are observed between the resonances of olefinic protons F 
and G, and proton resonances at 67.67 and 8.12, these resonances are assigned to 
protons H and E adjacent to the olefinic protons.
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Figure 2.3. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 
1.17 in C D 3O D  showing cross-peaks between stilbene proton resonances.
Figure 2.4 shows a section of the 2D ROESY NMR spectrum with axle and aniline 
aromatic proton resonance cross-peaks with those of methyl and CD protons. The 
presence of the NOE cross-peaks labelled NOEI, NOE2 and NOE3 indicate the 
resonances at 67.39, 7.34 and 6.84 correspond to the aniline protons C, J, A and L. 
Looking at the cross-peaks between the aromatic and CD protons, the CD 
conformation can be assigned. Protons D and E show NOEs with the CD-C3 protons, 
hence they are next to the wider end of the CD. The olefinic protons F and G show 
NOEs with CD-C5 protons. While protons I show an NOE with one of the CD-C6 
protons, protons H show NOEs with the CD-C5 and both the CD-C6 protons, hence
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they are next to the narrow end of the CD. Overall the CD is located on the middle of 
the stilbene moiety as shown in Figure 2.4.
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Figure 2.4. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 
1.17 in CD3OD showing stilbene and aniline aromatic proton resonance cross-peaks 
with those of methyl and CD protons.
The procedure used to prepare the rotaxane 1.18 is shown in Scheme 2.4. Initially, the 
synthesis was attempted using TEA, due to the successful synthesis of the rotaxane 
1.17 using TEA. Figure 2.5 shows the chromatogram obtained through reverse phase 
HPLC of the crude reaction mixture using TEA. Fractions were isolated and analysed 
using ESI mass spectrometry. The material corresponding to the peak indicated by the 
pink asterisk showed an ion at m/z 1472, which corresponds to the sodiated ion of the 
rotaxane 1.18. The sample corresponding to the peak indicated by the blue asterisk 
showed an ion at m/z 1417 which corresponds to a-CD substituted with three 
dimethoxytriazinyl groups from the DMT-MM. Finally, the material giving rise to the
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peak indicated by the yellow asterisk showed an ion at m/z 1590 which corresponds to 
the rotaxane 1.18 substituted with one dimethoxytriazinyl group. The pKa of the 
secondary hydroxyl groups of a CD is around 12, while the pKa of the primary 
hydroxyl groups is around 15-16.17142143 Hence under basic conditions using TEA, 
secondary hydroxyl groups are more likely to become deprotonated and act as
nucleophiles, initiating side reactions. Therefore, although the exact structures of
reaction side products have not been fully determined, they can be attributed to
substitution on the secondary side of the CD.
f
2.1 1.1
- \ y
1 equiv. 3 equiv.
DMT-MM 30 equiv.,
Phosphate Buffer pH 7
▼
2.4
4 equiv.
Scheme 2.4. Synthesis of the rotaxane 1.18.
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Figure 2.5. Chromatogram obtained through reverse phase HPLC of the crude 
product mixture when TEA was used to prepare the rotaxane 1.18.
In a second attempt to prepare the rotaxane 1.18, nucleophilic substitution of the CD 
was to be avoided. Hence the reaction mixture was maintained at pH 7 using a buffer 
system. Unwanted side products such as tri-substituted a-CD ana mono-substituted 
rotaxane, observed when TEA was used, were no longer observed at pH 7. In order to 
optimise the reaction conditions, the formation of the desired product 1.18 was 
monitored every hour using reverse phase HPLC as shown in Figure 2.6. As time 
progressed, an increase in peak area of the desired product 1.18 was seen up to four 
hours, after which time no further increase was observed.
= 1.18
Figure 2.6. Reverse phase HPLC chromatogram of the crude product mixture 
showing formation of the desired product 1.18 over 6 h when phosphate buffer was 
used.
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Next, the optimal amount of the coupling agent DMT-MM was tested. The formation 
of the desired product 1.18 was monitored every hour using reverse phase HPLC and 
plotted against time when varying amounts of DMT-MM were used (Figure 2.7). The 
rate of reaction was the fastest when forty equivalents of DMT-MM were used 
(shown by the red line) as suggested by the steepest slope on the graph. However, 
forty equivalents made the reaction mixture go cloudy. Hence thirty equivalents of 
DMT-MM were used to keep the solution homogeneous.
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Figure 2.7. Plot of the product 1.18 peak area on the reverse phase HPLC 
chromatogram versus time when 2, 4, 10, 20, 30 and 40 equivalents of DMT-MM 
were added to the reaction mixture.
Finally, the optimal amount of the aniline 2.4 was determined. The formation of the 
desired product 1.18 indicated with a pink asterisk was monitored using reverse phase 
HPLC when four, eight and twelve equivalents of the aniline 2.4 were used (Figure 
2.8). Four equivalents of the aniline 2.4 was found to give the optimal formation of 
the rotaxane 1.18 (shown in green), while larger amounts of the aniline 2.4 resulted in 
less of this product.
Hence the rotaxane 1.18 was prepared using these optimised conditions according to 
Scheme 2.4. The azobenzene 2.1 was equilibrated with excess a-CD 1.1 in phosphate 
buffer at pH 7. Then, four equivalents of the aniline 2.4 and thirty equivalents of 
DMT-MM were added. The formation of the product 1.18 was monitored by TLC.
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The TLC of the reaction mixture showed a component with a different R{ value to a- 
CD 1.1, yet showing both the UV absorbance of an aromatic compound and the pink 
colouration of a CD on exposure to acidic naphthalene-1,3-diol. The rotaxane 1.18 
was isolated in 8% yield through reverse phase HPLC and its ESI mass spectrum 
showed an ion at m/z 1472 which corresponds to the sodiated molecular ion.
= 1.18
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Figure 2.8. Reverse phase HPLC chromatogram showing formation of the desired 
product 1.18 when 4, 8 and 12 equivalents o f the aniline 2.4 were added to the 
reaction mixture.
The ID 'H NMR spectrum of the rotaxane 1.18 confirms the presence of the 
components, showing resonances of CD, azobenzene and arylamino protons (Figure 
2.9).
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Figure 2.9. 500 MHz 'H NMR spectrum of the rotaxane 1.18 in CD3OD.
The general protocol to determine the position of the CD along the axle and the 
conformation of CD-based [2]rotaxanes was followed for the rotaxane 1.18. Figure 
2.10 shows a section of the DQF-COSY NMR spectrum of the rotaxane 1.18, where 
the CD proton cross-peaks are found. The most down field CD resonance at 64.91 is 
assigned to the CD-C1 anomeric protons. A 'H-'FI correlation between these protons 
and those giving rise to the signal at 63.43 is seen, and the latter is therefore assigned 
to the CD-C2 protons. Likewise, there is a cross-peak between the resonance at 63.43 
(CD-C2) and the resonance at 63.77 which is therefore attributed to the CD-C3 
protons. This resonance at 63.77 (CD-C3) also shows a cross-peak with the resonance 
at 63.51 which is therefore assigned to the CD-C4 protons. Again, the resonance at 
63.51 (CD-C4) also shows a cross-peak with the resonance at 63.82 which is therefore 
assigned to the CD-C5 protons. Finally, the resonances at 63.74 and 3.60 
corresponding to the CD-C6 protons show cross-peaks with each other.
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Figure 2.10. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the 
rotaxane 1.18 in CD3OD showing cross-peaks between CD proton signals.
Figure 2.11 shows a section of the 2D ROESY NMR spectrum with axle and aniline 
aromatic proton resonance cross-peaks with those of methyl and CD protons. The 
presence of the NOE cross-peak labelled NOE1 indicates that the resonance at 68.32 
corresponds to the azobenzene protons D in proximity to the methyl protons C. 
Likewise, the NOE cross-peak labelled NOE2 indicates the resonance at 68.27 
corresponds to the azobenzene protons G in proximity to the methyl protons H. 
Looking at the cross-peaks between the aromatic and CD protons, the location of the 
CD along the azobenzene axle can be assigned. Protons D show an NOE with the CD- 
C3 protons, hence they are next to the wider end of the CD. Protons E show NOEs 
with the CD-C3 and CD-C5 protons. Hence protons D and protons E are assigned to 
one phenyl group. The azobenzene protons F and G show NOEs with the CD-C5 and 
CD-C6 protons, hence they are assigned to the other phenyl group that is next to the 
narrow end of the CD. Protons F show stronger NOEs with the CD-C5 and CD-C6 
protons compared to protons G. Over all, the CD is located around the middle of the 
azobenzene moiety as shown in Figure 2.11.
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Figure 2.11. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 
1.12 in CD3OD showing azobenzene and aniline aromatic proton resonance cross-
peaks with those of methyl and CD protons.
Having prepared the rotaxanes 1.17 and 1.18, this completed the set 1.9, 1.10, 1.17 
and 1.18 with 2,6-dimethylaniline and 3,5-dimethylaniline blocking groups, with 
azobenzene- and stilbene-based axles. Growing crystals of the rotaxanes 1.17 and 
1.18 to obtain X-ray crystal packing data, and investigating relationships between the 
crystal growth and the crystal packing of the rotaxanes 1.9, 1.10, 1.17 and 1.18 was 
the next objective.
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CHAPTER 3 - Results and Discussion 
Solid-state Structure, Morphology and Crystal Growth of a-Cyclodextrin
[2]Rotaxanes
3.1 Self-assembly in the Solid-state
Having prepared the rotaxanes 1.17 and 1.18, crystals were grown to compare and 
contrast with the crystal packing of the rotaxanes 1.9 and 1.10. Crystals of the 
rotaxanes 1.17 and 1.18 were obtained through slow evaporation of MeOH/water over 
a period of several days or weeks. The rotaxanes 1.17 and 1.18 are more soluble in 
MeOH than water, hence, crystallisation occurred as MeOH selectively evaporated 
and a supersaturated solution resulted. The X-ray crystallographic analysis of the
->o
rotaxanes 1.9 and 1.10 has been reported previously as discussed in Chapter 1. The 
solid-state structures of the rotaxanes 1.17 and 1.18 were examined using X-ray 
crystallography. The crystallographic data of the rotaxanes 1.17 and 1.18 are 
presented in Appendix 1.
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The crystal structure of the rotaxane 1.10 was reported by Maniam et al. (Figure 
3.1). The crystal belongs to the orthorhombic space group, and there are four rotaxane 
molecules in the unit cell. The stilbene is planar, and as discussed in the Introduction, 
the planes of the dimethylaniline blocking groups are twisted approximately 90° from 
that of the stilbene moiety. In comparison, the rotaxane 1.18 crystal also belongs to 
the orthorhombic space group, and has four rotaxane molecules in the unit cell. The 
crystal structure shows that the azobenzene is planar and the planes of the 
dimethylaniline blocking groups are twisted approximately 90° from that of the 
azobenzene moiety (Figure 3.2). The crystal packing of the rotaxane 1.18 shows that 
the CDs oriented in one direction (green) alternate with others aligned at right angles 
(red) as shown in Figure 3.3, remarkably similar to the crystal packing seen with the
T O
rotaxane 1.10 (Figure 1.10). There is no overlap between the dumbbells of the 
rotaxanes that are aligned in the same direction, and the rotaxanes do not form fibres. 
In Figure 3.3, the rotaxanes that appear to form fibres with CDs (green) aligning in a 
head-to-tail direction, horizontal to the page, are in fact offset on planes going into the 
page. Overall, the very similar conformations and crystal packing indicate that 
changing the axle from a stilbene moiety to an azobenzene moiety does not 
significantly affect the crystal packing of the rotaxanes 1.10 and 1.18 with 2,6- 
dimethylaniline blocking groups.
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Figure 3.1. Crystal structure of the rotaxane 1.10 reported by Maniam et al., 
displayed in stick style. Solvent molecules are removed for clarity. Black = carbon, 
white = hydrogen, blue = nitrogen and red = oxygen.
Figure 3.2. Crystal structure of the rotaxane 1.18 displayed in stick style. Solvent 
molecules are removed for clarity. Black = carbon, white = hydrogen, blue = nitrogen 
and red = oxygen.
Figure 3.3. Crystal packing of the rotaxane 1.18 showing orientation of the CDs in 
one direction (green) interspersed by others aligned at right angles (red). Displayed in 
stick style. Hydrogen atoms and solvent molecules are removed for clarity.
43
1 ü
The crystal structure of the rotaxane 1.9 was reported by Maniam et al. (Figure 3.4). 
The crystal belongs to the orthorhombic space group, and there are four rotaxane 
molecules in the unit cell. The azobenzene is planar, and as discussed in the 
Introduction, the planes of the dimethylaniline blocking groups are co-planar to the 
azobenzene axle. In contrast, the crystal of the rotaxane 1.17 belongs to the 
monoclinic space group. There are two rotaxane molecules in the unit cell. The crystal 
structure shows that the planes of the two phenyl rings of the stilbene moiety are 
twisted at approximately 30° from each other (Figure 3.5). The plane of the aniline 
moiety on the wider end of the CD cavity is twisted approximately 90° from that of 
the adjacent phenyl ring, thus it is not conjugated with the stilbene axle. The plane of 
the aniline moiety at the narrower end of the CD cavity is twisted at approximately 
30° from its adjacent phenyl ring. This is in contrast to the strictly co-planar 
azobenzene axle and blocking groups seen in the crystal structure of the rotaxane 1.9 
(Figure 1.7). The crystal packing of the rotaxane 1.17 shows a herringbone type 
packing of the dumbbells (Figure 3.6 (a)), which allows ji-jt stacking of the blocking 
group on the narrower end of the CD cavity and one stilbene phenyl ring of the 
adjacent dumbbell to be accommodated (Figure 3.6 (b)). The degree of extended 
conjugation along the molecular fibre is reduced, however, due to the deviation from 
strict co-planarity. The CDs display a head-to-tail alignment along a single axis. 
While the rotaxane 1.9, which is also aligned head-to-tail, shows alternating rows 
having the CDs facing opposite directions, making it centrosymmetric around the 2- 
fold axis of the crystal, the rotaxane 1.17 has the CDs all facing the same direction. 
This results in the formation of a non-centrosymmetric polar crystal,36 as per the 
rotaxane 1.8 crystal observed by Cieslinski et al. Overall, using the stilbene axle in 
place of the azobenzene axle, which is insulated in the cavity of the CD, changes the 
solid-state structural configuration and crystal packing behaviour of the rotaxanes 1.9 
and 1.17 with 3,5-dimethylaniline blocking groups. Despite the change in space group 
and the solid-state structural configuration, the linear alignment of the rotaxanes 1.9 
and 1.17 is retained.
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Figure 3.4. Crystal structure of the rotaxane 1.9 reported by Maniam et al., 
displayed in stick style. Solvent molecules are removed for clarity. Black = carbon, 
white = hydrogen, blue = nitrogen and red = oxygen.
Figure 3.5. Crystal structure of the rotaxane 1.17 displayed in stick style. Solvent 
molecules are removed for clarity. Black = carbon, white = hydrogen, blue = nitrogen 
and red = oxygen.
45
(b)
Figure 3.6. Crystal packing of the rotaxane 1.17 showing (a) alignment into insulated 
molecular fibres, and (b) j i- ji stacking between the blocking group and the adjacent 
stilbene phenyl ring of the dumbbell. Displayed in stick style. Hydrogen atoms and 
solvent molecules are removed for clarity.
The rotaxanes 1.9 and 1.17 are different only in the linkage (-N=N- or -C=C-) that 
bridges the two phenyl rings of the axle moiety that is included inside the CD cavity. 
This slight difference results in a different crystal structure. Some molecules can form 
crystals that have different crystal structures and packing, known as polymorphs. 144' 145 
Hence a possible explanation for the different crystal structures and packing of the 
rotaxanes 1.9 and 1.17 is formation of polymorphs. To examine whether the structure 
and packing seen in Figure 1.7 is representative of the structure and packing of the 
rotaxane 1.9, or if others are possible, crystals of the rotaxane 1.9 were prepared again 
through slow evaporation of MeOH/water over a period of several weeks. A grown 
crystal was examined using X-ray crystallography. The X-ray diffraction data showed 
the same crystal diffraction pattern and the crystals grown from two different 
solutions belong to the same space group. To unambiguously identify whether the 
different crystal structure and packing of the rotaxanes 1.9 and 1.17 is a consequence 
of polymorph formation, a more thorough investigation involving examination of 
numerous crystals with different sizes and shapes of the rotaxanes 1.9 and 1.17 in 
various growth conditions would be required. Hence this study is not conclusive, but, 
examination of two different crystals of the rotaxane 1.9 at least suggests that the 
difference in solid-state behaviour of the rotaxanes 1.9 and 1.17 is not due to 
formation of polymorphs.
An alternative explanation for the different crystal structures and packing of the 
rotaxanes 1.9 and 1.17 could be related to the energy required for the blocking group
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to twist out of the plane of the axle being greater for the azobenzene based dumbbell 
compared to the stilbene analogue. Stilbenes and azobenzenes have different 
isomerisation behaviours. As described in the Introduction, stilbenes undergo 
photochemical trans-cis and cis-trans isomerisation, where irreversible side reactions 
can cause decomposition of the material.146,147 Azobenzenes, on the other hand, 
undergo clean, fully reversible isomerisation. In addition, the cA-azobenzene can also 
thermally relax back to the trans state.148,149 Therefore it can be speculated that a 
lower energy is required to twist the azobenzene from a planar, conjugated structure. 
As a result of weak conjugation within the azobenzene moiety, the conjugation 
between the azobenzene and the blocking groups may be increased. It could be that 
because the blocking groups are strongly conjugated to the azobenzene, the energy 
required to rotate the plane of the blocking group out of the plane of the azobenzene 
axle is greater compared to the stilbene analogue. Therefore, the rotaxane 1.17 with a 
stilbene based axle has one blocking group twisted out of the plane of the axle, while 
it is energetically unfavourable to have the blocking group of the azobenzene based 
rotaxane 1.9 similarly twisted out of the plane of the axle. This different twisting of 
the planes of the blocking groups in the crystal structures might determine the 
intermolecular interactions between adjacent rotaxanes, resulting in different crystal 
packing.
3.2 SEM and Optical Microscope Images
Having examined the crystal structures and packing of the rotaxanes 1.9, 1.10, 1.17 
and 1.18, the morphology of the crystals was observed using SEM and optical 
microscopy to examine whether there would be any relationship between crystal 
packing and morphology. The rotaxanes 1.17 and 1.18 were available through 
synthesis discussed in Chapter 2. The rotaxanes 1.9 and 1.10 were prepared according
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to the procedure of Maniam et al., for comparison of the set of all four rotaxanes. 
Crystals for X-ray crystallography had been grown through slow evaporation of 
MeOH/water. MeOH aids to dissolve rotaxanes to produce supersaturated solutions as 
they selectively evaporate. Hence it was thought that the crystals were effectively 
grown from water, however, depending on the amount of MeOH used, the speed of 
evaporation and crystallisation varies, resulting in crystal growth in an uncontrolled 
manner. Consequently, crystals for microscopy were grown from water to obtain 
reproducibility.
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Crystals obtained by evaporating aliquots of solutions of the rotaxanes 1.9, 1.10. 1.17 
and 1.18 were mounted on carbon tape to observe using SEM. Figure 3.7 shows the 
morphology of the rotaxanes 1.9, 1.10, 1.17 and 1.18. The solution of the rotaxane 1.9 
gave needle shaped crystals as shown in Figure 3.7 (a). The shapes of crystals can be 
determined by preferential growth along certain axes, which is governed by the 
kinetics of the molecular growth process through which assembly occurs.150 Therefore, 
observation of needle shaped crystals suggests that there is a preferential growth along 
one axis of the crystal. This preferential growth can be attributed to the kinetic jt-jt 
interaction between 3,5-dimethylaniline blocking groups of the linearly aligned 
rotaxanes observed in the crystal packing (Figure 1.7). The kinetically 
driven jt-jt interaction in water is due to hydrophobic interactions of the hydrophobic 
blocking groups. Therefore, needle shaped crystals grown from water are reflective of 
the crystal packing of the rotaxane 1.9.
The rotaxane 1.17 also results in needle shaped crystals (Figure 3.7 (c)). Observation 
of needle shaped crystals again suggests that there is a preferential growth along one 
axis of the crystal. This preferential growth can be attributed to the linear alignment of 
the rotaxanes through the kinetic j i - j i  interaction between the blocking group and a 
stilbene phenyl ring on the adjacent rotaxane observed in the crystal packing (Figure 
3.6). The kinetically driven j i - j i  interaction in water is again attributable to 
hydrophobic interactions of the hydrophobic blocking group and axle. Therefore, as 
per the rotaxane 1.9, needle shaped crystals of the rotaxane 1.17 grown from water are 
consistent with its crystal packing behaviour.
Non-needle shaped crystals were obtained from the solutions of the rotaxanes 1.10 
and 1.18 (Figure 3.7 (b) and (d)). Observation of non-needle shaped crystals suggests 
that there is no preferential growth along one axis of the crystals. In the crystals, the 
rotaxanes 1.10 and 1.18, with 2,6-dimethylaniline blocking groups, do not align along 
a single axis, but align in one direction, interspersed by others at right angles (Figure 
1.10 and Figure 3.3). Therefore, when rotaxanes do not align along a single axis, it 
appears that they do not adopt needle shaped morphology. Overall, observation of 
SEM images of crystals suggests a correlation between the linearly aligned crystal
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packing of the rotaxanes 1.9 and 1.17 though ji - j i stacking and the morphology of 
needle shaped crystals. On the contrary, the rotaxanes 1.10 and 1.18 that do not show 
crystal packing aligned along a single axis, do not adopt needle shaped morphology. 
Thus, a correlation between non-linear crystal packing and non-needle shaped crystal 
morphology is also evident.
(a) (b)
Figure 3.7. SEM images of crystals grown from solutions of (a) the rotaxane 1.9, (b) 
the rotaxane 1.10, (c) the rotaxane 1.17, and (d) the rotaxane 1.18.
Having observed that the needle shaped morphology seems to be related to the kinetic 
process of ji - j i interactions between adjacent rotaxanes that are linearly aligned in the 
solid-state, it was of interest to examine whether this initial needle shaped 
morphology results in continued preferential growth along one axis. Hence, the 
relative rates of crystal growth along the axes of the crystals of the rotaxanes 1.9 and 
1.17 grown from water was monitored using an optical microscope. To prepare 
supersaturated solutions, each of the rotaxanes 1.9 and 1.17 was added to water, and 
each mixture was heated and filtered before the solutions were left to stand for days at 
25 °C while being monitored under an optical microscope fitted with a polarising
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lens. The polarising lens prevents unpolarised light from passing. As crystals polarise 
light, they are more clearly observed, as the polarised light contrasts the black 
background. Images of crystals from the supersaturated solutions are shown in Figure 
3.8. In each image, an individual crystal is circled to compare the changes in crystal 
dimensions with time.
Over time, the solution of the rotaxane 1.9 formed yellow, needle shaped crystals. The 
image taken after 24 h shows a crystal circled that is 1.3 mm in length and 0.14 mm in 
width (Figure 3.8 (a) left). After 54 h the crystals did not grow further. The fully 
grown crystal was 2.5 mm in length and 0.18 mm in width (Figure 3.8 (a) right). The 
microscope view is limited to two dimensions, however, needle shaped crystals would 
have approximately the same height and width, as plates would not all stand on their 
sides. From the two dimensional view, the length of the crystal almost doubled while 
the width increased by less than a third. Hence, the growth is predominantly along a 
single axis. Therefore, the kinetic process of jt-jt interactions between adjacent 
rotaxanes that are linearly aligned in the solid-state, which determined the initial 
needle shaped morphology, also results in continued preferential growth along an 
axis.
The solution of the rotaxane 1.17 also formed yellow, needle shaped crystals. The 
image taken after 47 h shows a crystal circled that is 1.3 mm in length and 0.22 mm in 
width (Figure 3.8 (c) left). At this point, the crystals were already almost fully grown. 
After 72 h the fully grown crystal was 1.4 mm in length and 0.22 mm in width 
(Figure 3.8 (c) right). While the length of the crystals grew marginally, there was no 
apparent change in the width. However, a corresponding growth along the width is 
within error range and not practical to measure. Therefore, it cannot be 
unambiguously determined whether there is continued preference in growth along a 
single axis. This is not inconsistent with needle shaped crystals continuing to grow 
along a single axis, however, as the final shape of the crystals remained as needles.
Given that non-needle shaped morphology was observed for the rotaxanes 1.10 and 
1.18 that are non-linearly aligned in the solid-state, it seemed unlikely that the non-
needle shaped crystals would develop further selectively along one axis. To examine
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the relative rates of crystal growth along the axes of the crystals of the rotaxanes 1.10 
and 1.18, solutions were prepared and monitored as per the rotaxanes 1.9 and 1.17. 
The solution of the rotaxane 1.10 formed yellow, non-uniform shaped crystals. The 
shapes of the crystals varied from trapezoidal to rectangular. The image taken after 7 
h shows a trapezoid shaped crystal circled that is 1.0 and 0.7 mm in length on the 
parallel sides, and 0.5 mm in height (Figure 3.8 (b) left). After 50 h the crystal grew 
to 2.5 and 1.7 mm on the parallel sides, and 1.2 mm in height, and did not grow 
further (Figure 3.8 (b) right). It was not practical to determine whether the crystals 
were increasing in depth, as the microscope view is limited to two dimensions. From 
the two dimensional view, crystal dimensions increased by approximately 2.5 times in 
all directions. Hence, the non-needle shaped crystal continued to show proportional 
growth rather than preferential growth along one axis. This is consistent with the 
crystal packing, where the rotaxanes align in one direction, interspersed by others at 
right angles (Figure 1.10).
The solution of the rotaxane 1.18 formed orange, non-needle shaped crystals. The 
shapes of the crystals varied from trapezoidal to hexagonal and triangular, amongst 
others. The image taken after 20 h shows a trapezoid shaped crystal that is 0.8 and 0.6 
mm in length on the parallel sides, and 1.0 mm in height (Figure 3.8 (d) left). After 
45 h the crystal grew to 1.1 and 0.8 mm on the parallel sides, and 1.4 mm in height 
(Figure 3.8 (d) right). Each of the crystal dimension increased by approximately 1.4 
times over time. Hence, the non-needle shaped crystal also continued to show 
proportional growth in this case. Again, this is consistent with the crystal packing, 
where rotaxanes align in one direction, interspersed by others at right angles (Figure 
3.3). Overall, when rotaxanes show alignment along a single axis in the crystal 
packing as per the rotaxanes 1.9 and 1.17, needle shaped crystals form, and the crystal 
growth is predominantly along a single axis. When rotaxanes show alignment along 
two axes in the crystal packing as per the rotaxanes 1.10 and 1.18, non-needle shaped 
crystals form and the crystals grow proportionally along several dimensions.
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(d)
Figure 3.8. Microscope images of crystals grown from supersaturated solutions of (a) 
the rotaxane 1.9 after 24 h (left) and after 54 h (right), (b) the rotaxane 1.10 after 7 h 
(left) and after 50 h (right), (c) the rotaxane 1.17 after 47 h (left) and after 72 h (right), 
and (d) the rotaxane 1.18 after 20 h (left) and after 45 h (right).
3.3 Crystal Growth Behaviour
Having monitored the crystal growth in the preliminary experiments described above, 
the effects of varying time, temperature and concentration on ciystal growth were 
then studied in more detail. The rotaxane 1.9 was chosen for these studies, as it shows 
alignment and preferential growth along one axis, and the crystal packing shows a 
clear correlation with the morphology and growth. These experiments were monitored 
using an optical microscope fitted with a polarising lens.
Firstly, the rotaxane 1.9 was added to water, and the mixture was heated below 
boiling point to prepare a 250 pM solution, and the solution was left to stand for days 
at 25 °C. In the preliminary experiments, the concentration of the supersaturated 
solution was unknown as the rotaxane 1.9 had been added to water, and any 
undissolved material after the mixture was heated had been filtered. In this study, the 
concentration of the supersaturated solution was known as the mixture was heated to 
give a clear solution, to ensure that all of the rotaxane 1.9 added was dissolved. 
Figure 3.9 shows crystals of the rotaxane 1.9 grown from a 250 pM solution after 2 
and 90 h respectively. At each time frame, grown crystals were uniform in size. 
Hence, a crystal that does not distinctively deviate from the mean size was arbitrarily 
chosen at both time frames and the crystal dimensions were measured. The image 
taken after 2 h shows crystals that are 0.23 mm in width and 0.96 mm in length 
(Figure 3.9 (a)). After 90 h the crystal grew to 1.60 mm in length while the width did 
not grow further (Figure 3.9 (b)). Comparing the dimensions of the crystals over
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time, the length of the crystal has almost doubled while the width showed no 
significant growth, resulting in needle shaped crystals. Hence, this is consistent with 
the preliminary growth experiment, which suggests that when rotaxanes align along a 
single axis in the crystal packing, crystals grow preferentially along a single axis. As 
crystals grow longer over time, the crystal length of the rotaxane 1.9 can be 
manipulated by changing the duration of crystal growth.
Figure 3.9. Optical microscope images of crystals grown from a 250 pM solution of 
the rotaxane 1.9 after (a) 2 h and (b) 90 h at 25 °C.
To investigate the effect of varying the concentration of the rotaxane 1.9 in solution 
on crystal growth, the rotaxane 1.9 was added to water, and the mixture was heated 
below boiling point to prepare a 25 pM solution, before the solution was left to stand 
for days at 25 °C. Crystals grown from a 25 pM solution of the rotaxane 1.9 over 90 h 
were compared with those grown from a 250 pM solution over 90 h (Figure 3.10). 
The crystals that are out of focus under the microscope appear thicker than those that 
are in focus. However, at each concentration, uniform size needles were obtained. 
More crystals come out of solution at higher concentration. At 25 pM, crystals come 
out of solution, as the solution is above saturation concentration. Therefore, the 250 
pM solution has significantly more material dissolved above saturation compared to 
the 25 pM solution, accounting for more crystals coming out of solution. The crystals 
grown from the 25 pM solution of the rotaxane 1.9 are 0.23 mm in width and 0.52 
mm in length (Figure 3.10 (a)). The crystals grown from the 250 pM solution of the 
rotaxane 1.9 grew to 1.60 mm in length while the width did not increase (Figure 3.10 
(b)). Comparing the dimension of the crystals at two different concentrations, the 
widths show no significant difference, while the lengths of the crystals grown from a
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250 pM solution are more than triple the length of those grown from a 25 pM 
solution. This suggests that at higher concentrations, crystal growth is faster and the 
crystals grow further. Crystals growing longer at higher concentrations is consistent 
with the time dependent crystal growth experiment above that shows that crystals 
grow longer as they grow further. Hence, the crystal length of the rotaxane 1.9 can be 
manipulated not only by changing the duration of crystal growth, but also by changing 
the concentration of the rotaxane solution.
(a)
Figure 3.10. Optical microscope images of crystals grown from (a) 25 pM and (b) 
250 pM solutions of the rotaxane 1.9 after 90 h at 25 °C.
To investigate the effect of varying the temperature on crystal growth, crystals were 
also grown from solutions of the rotaxane 1.9 (250 pM) at 4 and 18 °C. Figure 3.11 
shows microscope images of the crystals grown at 4 and 18 °C after 72 h. Crystals 
grown at 4 °C were monitored without a polarising lens as the crystals are too fine to 
be observed otherwise. The lengths of the crystals cannot be measured from the 
image, as the crystals are too long to see the ends. Crystals grown at 18 °C can be 
monitored with a polarising lens and the ends of the crystal were observed. Thus, 
visual inspection of the crystals shows that longer and thinner crystals are grown at 
the lower temperature. The crystals grown from a solution of the rotaxane 1.9 (250 
pM) at 25 °C are not directly comparable to those grown at 4 and 18 °C, as at 25 °C, 
the solution was monitored after 90 h instead of 72 h. Nevertheless, crystals grown at 
25 °C show the thickest and shortest needles, consistent with longer and thinner 
crystals growing at lower temperatures (Figure 3.11 (c)). Crystals grow faster at 
lower temperatures resulting in kinetically favoured crystal growth. Therefore, 
crystals that grow longer and thinner at lower temperatures indicate that kinetically
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favoured jt-jt interactions of the rotaxanes result in preferential growth along one 
axis, also seen in the time and concentration dependent crystal growth experiments 
above. The thickness and the length of the crystals can be controlled by varying the 
temperature at which the crystals are grown.
(a) (b)
Figure 3.11. Optical microscope images of crystals grown from 250 pM solutions of 
the rotaxane 1.9 at (a) 4 °C (72 h), (b) 18 °C (72 h) and (c) 25 °C (90 h).
To investigate whether needle shaped crystal formation is not only kinetically 
favourable, but also thermodynamically favourable, needle shaped crystals of the 
rotaxane 1.9 were sonicated. The needle shaped crystals broke into blocks where the 
lengths and widths are similar and did not break further (Figure 3.12 (b)). The 
mechanical vibration from sonication creates stress on the needle shaped crystals. As 
a result, shearing of the crystals occurs when the stress is stronger than the strength of 
the crystal in the direction of shearing. When shearing force is applied to long 
needles, the needles break along the weakest cross sections, which are initially 
perpendicular to the length of the crystals. The final shape of the resulting crystals 
reflects the thermodynamic stability of the intermolecular interactions along the
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various axes of the crystals. Shearing is more likely if the interactions are weaker, and 
if the axis is longer and therefore, the sheer stress is larger. Shearing of the needle 
shaped crystals into blocks where the lengths and widths are similar indicates that the 
interactions between molecules are similar in strength in all directions. Accordingly, 
obtaining block shaped crystals suggests that crystal growth along a single axis is a 
kinetic process, where there is no thermodynamic preference for the crystals to grow 
this way. Thus, to regulate the shape and size of the crystals of the rotaxane 1.9, 
regulating the conditions that affect the kinetics of the crystal growth is required.
(a) (b)
Figure 3.12. Optical microscope images of crystals grown from a solution of the 
rotaxane 1.9 (a) before and (b) after sonication.
3.4 Conclusion
X-Ray crystal packing of the rotaxanes 1.9, 1.10, 1.17 and 1.18 suggests that the 
blocking groups of the rotaxanes guide the self-assembly, resulting in different 
alignment in the solid-state depending on the choice of 2,6- or 3,5-dimethylaniline 
blocking groups. From SEM and optical microscope images, it can be inferred that the 
crystal packing of the rotaxanes 1.9, 1.10, 1.17 and 1.18 is reflected in the crystal 
growth and morphology of the crystals. Hence, crystals can be engineered to give 
needle or non-needle shaped crystals depending on the choice of 2,6- or 3,5- 
dimethylaniline blocking groups. Furthermore, the shape and size of the needle 
shaped crystals of the rotaxane 1.9 can be manipulated by varying the time, 
temperature and concentration in which the crystals are grown. Therefore, crystal 
engineering can be bottomed-up to make nano-molecular architectures of micrometre 
scale or beyond.
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CHAPTER 4 - Results and Discussion 
Regulation of Crystal Growth of an a-Cyclodextrin [2]Rotaxane
4.1 Introduction
Having established ways to control crystal shape and size depending on the choice of 
blocking groups of rotaxanes or varying the conditions of crystal growth, regulation 
of crystal growth was of interest. For this reason, the two unsymmetrically capped 
rotaxanes 4.1 and 4.2 that are structurally similar to the rotaxanes 1.9 and 1.18 were 
designed as crystal growth inhibitors. Each is capped with a 3,5-dimethylaniline 
blocking group on one end and a 2,6-dimethylaniline blocking group on the other end. 
From the crystal structure and packing of the rotaxane 1.9, it was envisaged that the 
3,5-dimethylaniline blocking group of the rotaxanes 4.1 and 4.2 would be co-planar to 
the axle, allowing incorporation to the growing chains of molecular fibres of the 
rotaxane 1.9 though j i - j i  interactions. On the other hand, from the crystal structure 
and packing of the rotaxane 1.18, it was envisaged that the 2,6-dimethylaniline 
blocking group of the rotaxanes 4.1 and 4.2 would be out-of-plane to the axle, and 
consequently not form j i - j i  interactions. Hence, if one of the rotaxanes 4.1 and 4.2 
was incorporated at the end of the growing molecular fibres of the rotaxane 1.9 
through the 3,5-dimethylaniline blocking group, crystals might not be able to grow 
further as the 2,6-dimethylaniline blocking group exposed might prohibit further 
growth. Through co-crystallisation1 S1 of the rotaxanes 4.1 and/or 4.2 with the rotaxane 
1.9, the growth of the molecular fibres might therefore be regulated.
4.2 Synthesis and Conformational Analysis
In Chapter 2, a typical threading approach1^2 shown in Figure 4.1 (a) was used to 
prepare the rotaxanes 1.17 and 1.18. In order to synthesise the unsymmetrically 
capped rotaxanes 4.1 and 4.2, a variation of the threading approach was employed
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(Figure 4.1 (b)). Unlike the typical threading approach where the axle is threaded into 
the macrocycle and capped with bulky blocking groups on both ends of the axle, the 
variation of the threading approach involved threading a monocapped axle into the 
macrocycle and capping the other end of the monocapped axle with a blocking group. 
Depending on the reactivity of 2,6-dimethylaniline 2.4 relative to 3,5-dimethylaniline 
2.2, the synthesis of rotaxanes using a typical threading approach would result in 
formation of a mixture of compounds including the symmetric rotaxanes 1.9 and 1.18. 
Hence the strategy was to first make a monocapped axle and then couple this with the 
other blocking group in the presence of a-CD 1.1 to form the unsymmetrically capped 
rotaxanes 4.1 and 4.2 selectively and obtain better yields. It was decided to introduce 
2,6-dimethylaniline 2.4 first, as amide coupling with this more hindered aniline was 
expected to be less favourable in the final step. Reaction with the reactive azobenzene- 
4,4’-dicarbonyl dichloride 4.3 was performed in organic solvent, avoiding water which 
is required for association of an axle with a CD to make a rotaxane but would also 
hydrolyse the dicarbonyl dichloride 4.3. 3,5-Dimethylaniline 2.2 was to be introduced 
to the hydrolysed monocapped axle 4.4 in water to cap the axle that had been threaded 
through the CD.
(a)
i threading
(b)
i a  -  j ä - t t  . j  a ju
Figure 4.1. Schematic representation of (a) the typical assembly of a rotaxane via the 
threading approach and (b) a variation of the threading approach used to prepare 
unsymmetrically capped rotaxanes.
The monocapped axle 4.4 was therefore prepared by treating the dicarbonyl dichloride 
4.3 with slightly more than one equivalent of 2,6-dimethylaniline 2.4, followed by 
hydrolysis, which resulted in a mixture of azobenzene-4,4'-dicarboxylic acid 2.1, the 
desired monocapped axle 4.4, and the dicapped axle 4.5 (Scheme 4.1). The
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monoamide 4.4 was isolated using column chromatography on silica gel in 42% yield 
and its mass spectrum showed a molecular ion with m/z 373. The 'H NMR spectrum 
showed the presence of aniline protons and protons corresponding to an 
unsymmetrically substituted azobenzene, confirming the formation of the desired 
product 4.4.
(i)
(ii) H20
v
Scheme 4.1. Synthesis of the monocapped azobenzene 4.4.
With the monocapped azobenzene 4.4 in hand, the unsymmetrically capped rotaxanes 
4.1 and 4.2 were prepared according to Scheme 4.2. The monocapped azobenzene 4.4 
was equilibrated with excess a-CD 1.1 and slightly more than one equivalent of TEA 
in water for the inclusion complexes 4.6 and 4.7 to form. Four molar equivalents of 
DMT-MM and three molar equivalents of 3,5-dimethylaniline 2.2 were then added 
and the progress of the reaction was monitored using TLC. A new spot was detected
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that showed both the characteristic UV absorbance of the axle component and the 
pink colouration of a CD when treated with acidic naphthalene- 1,3-diol. Another 
four molar equivalents of DMT-MM and three molar equivalents of 3,5- 
dimethylaniline 2.2 were then added as the TLC showed the reaction was incomplete, 
presumably due to DMT-MM hydrolysis. Although only one new spot was detected 
by TLC, two components that presumably co-eluted on TLC were separated by HPLC 
in yields of 34% and 22%. MALDI-TOF mass spectrometry of each component 
showed an ion at m/z 1450 which corresponds to the protonated ion of the rotaxanes 
4.1 and 4.2. The rotaxanes 4.1 and 4.2 are isomers due to the orientation of the CD 
annulus, thus a single synthetic procedure yields two rotaxanes at the same time.
1.1
3 equiv.
TEA 1.3 equiv., 
H ,0
DMT-MM 8 equiv.,
in n 2
A
2.2
V 6 equiv.
Scheme 4.2. Synthesis of the unsymmetrically capped [2]rotaxanes 4.1 and 4.2.
Two fractions, each containing an unsymmetrically capped rotaxane isomer, were
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collected through HPLC. The first eluting fraction was assigned as the rotaxane 4.1 
and the later fraction as the rotaxane 4.2 by NMR analysis described below. The ID 
'H NMR spectrum of the first eluting fraction confirms the presence of the 
components of an unsymmetrically capped rotaxane, showing resonances of CD, 
unsymmetrically substituted azobenzene and arylamino protons (Figure 4.2). The 
apparent singlet at 87.17 which integrates for three protons indicates that the protons 
in the 3-, 4- and 5-positions of the 2,6-dimethylaniline group resonate at the same 
frequency, not giving rise to coupling, as observed in the 'H NMR spectrum of the 
monocapped axle 4.4. The singlet observed at 86.87 integrates for one proton and 
corresponds to the para-proton of the 3,5-dimethylaniline group. The singlet observed 
at 87.45 which integrates for two protons indicates that the 2- and 6-positions of the 
3,5-dimethylaniline group are chemically equivalent, presumably due to rotation 
around the aryl group to nitrogen bond on the NMR time scale at 25 °C. Accordingly, 
the two sets of singlets at 82.35 and 2.31 can be assigned one each to the methyl 
groups of the 2,6- and 3,5-dimethylaniline groups, as the methyl groups within the 
same blocking group are likely to be chemically equivalent.
Figure 4.2. 500 MHz 'H NMR spectrum of the rotaxane 4.1 in CD3OD.
To unambiguously determine the orientation of the CDs with respect to the dumbbells 
and assign the structures of the rotaxane isomers, 2D NMR analysis was carried out 
following the general protocol used in Chapter 2. Figure 4.3 shows a section of the 
DQF-COSY NMR spectrum of the first eluting isomer, where CD proton cross-peaks 
are found. While the region of the spectrum where the Cl protons’ resonance is 
typically found is obscured by the OH signal, a 'H-'H correlation between these
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protons and those giving rise to the signal at 83.42 is seen, and the latter is therefore 
assigned to the CD-C2 protons. Likewise, there is a cross-peak between the resonance 
at 53.42 (CD-C2) and the resonance at 83.77 which is therefore attributed to the CD- 
C3 protons. This resonance at 83.77 (CD-C3) also shows a cross-peak with the 
resonance at 53.50, which is therefore assigned to the CD-C4 protons. Again, the 
resonance at 83.50 (CD-C4) also shows a cross-peak with the resonance at 53.83 
which is therefore assigned to the CD-C5 protons. Finally, the resonances at both 
53.72 and 3.59 corresponding to the CD-C6 protons show cross-peaks with each 
other.
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Figure 4.3. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the rotaxane 
4.1 in CD3OD showing cross-peaks between CD proton signals.
Figure 4.4 shows a section of the 2D ROESY NMR spectrum with axle and aniline 
aromatic proton resonance cross-peaks with those of methyl and CD protons. The 
presence of the NOE cross-peak labelled NOE1 between the resonance of the 2,6- 
dimethylaniline aromatic protons and the resonance at 82.31 shows that the latter 
corresponds to the methyls of the 2,6-dimethylaniline group (protons H). Likewise, 
the NOE cross-peaks labelled NOE2 and NOE3 between the resonances of the 3,5- 
dimethylaniline aromatic protons and the resonance at 82.35 indicate that the latter 
corresponds to the methyls of the 3,5-dimethylaniline moiety (protons B). The NOE
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cross-peak labelled NOE4 indicates that the azobenzene protons G are in proximity to 
the 2,6-dimethylaniline methyl protons H. Protons G show coupling with protons F, 
and protons D and E with each other. Hence protons G and F are assigned to one 
phenyl group of the azobenzene and protons D and E to the other. Protons E and F are 
located next to the centre of the azobenzene moiety as they both show extensive 
NOEs with the CD-C5 protons. Protons E also show an NOE with the CD-C3 protons 
while protons F show NOEs with both of the CD-C6 protons. Thus, localisation of the 
CD over the middle of the azobenzene is observed where the narrow end of the CD 
corresponding to the CD-C6 OH groups is closest to the 2,6-dimethylaniline blocking 
group. This structure is therefore assigned as the rotaxane 4.1.
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Figure 4.4. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 4.1 
in CD3OD showing azobenzene and aniline aromatic proton resonance cross-peaks 
with those of methyl and CD protons.
Figure 4.5 shows the 'H NMR spectrum of the second eluting fraction collected from 
the HPLC. Similar to the case of the rotaxane 4.1, the NMR spectrum confirmed the 
presence of the rotaxane components, showing resonances of CD, azobenzene and 
aniline protons. Also as per the rotaxane 4.1, the general protocol was followed to 
determine the orientation of the CD and the conformation of this rotaxane.
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Figure 4.5. 500 MHz 'H NMR spectrum of the rotaxane 4.2 in CD3OD.
The CD proton resonances were assigned in the same manner as per the rotaxane 4.1. 
Figure 4.6 shows a section of the DQF-COSY NMR spectrum, where CD proton 
cross-peaks are found. While the region of the spectrum where the Cl protons' 
resonance is typically observed is obscured by the OH signal, a 'H -'H  correlation 
between protons in this region and those giving rise to the signal at 83.43 is seen, and 
the latter is therefore assigned to the CD-C2 protons. Likewise, there is a cross-peak 
between the resonance at 83.43 (CD-C2) and a resonance at 83.77 which is therefore 
attributed to the CD-C3 protons. This resonance at 83.77 (CD-C3) also shows a cross-
peak with the resonance at 83.51, which is therefore assigned to the CD-C4 protons. 
Again, the resonance at 83.51 (CD-C4) also shows a cross-peak with the resonance at 
83.81 which is therefore assigned to the CD-C5 protons. Finally, the resonances at 
both 83.74 and 3.59 corresponding to the CD-C6  protons show cross-peaks with each 
other.
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Figure 4.6. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the rotaxane 
4.2 in CD3OD showing cross-peaks between CD proton signals.
Figure 4.7 shows a section of the 2D ROESY NMR spectrum with axle and aniline 
aromatic proton resonance cross-peaks with those of methyl and CD protons. The 
presence of the NOE cross-peak labelled NOE1 between the resonance of the 2,6- 
dimethylaniline aromatic protons and the resonance at 62.39 shows that the latter 
corresponds to the methyls of the 2,6-dimethylaniline group (protons H). Likewise, 
the NOE cross-peaks labelled NOE2 and NOE3 between the resonances of the 3,5- 
dimethylaniline aromatic protons and the resonance at 62.34 indicate that the latter 
corresponds to the methyls of the 3,5-dimethylaniline group (protons B). Protons G 
show coupling with protons F, and protons D and E with each other. Hence protons G 
and F are assigned to one phenyl group of the azobenzene and protons D and E to 
another. Looking at the cross-peaks between the aromatic and CD protons, the 
location of the CD along the azobenzene axle can be assigned. Protons E show NOEs
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with both the CD-C6 protons, hence they are next to the narrow end of the CD. 
Protons F and G both have strong NOE interactions with the CD-C3 protons, located 
on the wider end of the CD. Azobenzene protons G are in proximity to the 2,6- 
dimethylaniline methyl protons H as shown by the cross-peak labelled NOE4. There 
is no NOE interaction between CD protons and protons D. Thus, localisation of the 
CD towards one end of the azobenzene dumbbell unit is observed where the wider 
end of the CD is closest to the 2,6-dimethylaniline blocking group as shown in Figure 
4.7. This confirms that the structure corresponds to the rotaxane 4.2.
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Figure 4.7. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 4.2 
in CD3OD showing azobenzene and aniline aromatic proton resonance cross-peaks 
with those of methyl and CD protons.
4.3 X-Ray Crystallographic Analysis of Unsymmetrically Capped [2]Rotaxanes
Having obtained the purposely designed rotaxanes 4.1 and 4.2, the crystal structures 
were studied to examine whether the planarity of the blocking groups with respect to 
the azobenzene axles was as predicted. Crystallisation of the rotaxanes 4.1 and 4.2 
required longer times and was found to be significantly more difficult compared to 
that of the rotaxane 1.9. After a number of attempts, crystals of the rotaxanes 4.1 and 
4.2 were obtained through slow evaporation of MeOH/water over a period of several
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weeks. The solid-state structures of the rotaxanes 4.1 and 4.2 were examined using X- 
ray crystallography. The crystallographic data of the rotaxanes 4.1 and 4.2 are 
presented in Appendix 1.
Crystals of the rotaxane 4.1 belong to the orthorhombic space group and have four 
molecules per unit cell. The crystal structure shows that the 3,5-dimethylaniline 
blocking group is twisted roughly 45° to the closest ring of the azobenzene moiety, 
whereas the 2,6-dimethylaniline blocking group is twisted approximately 90° to the 
closest ring of the azobenzene moiety (Figure 4.8). The crystal packing of the 
rotaxane 4.1 reveals a highly ordered structure where the CDs are all aligned head-to- 
tail along a single axis (Figure 4.9). Alternating pairs of rows of the CDs face 
opposite directions giving rise to centrosymmetric, non-polar crystals. Hydrogen 
bonding interactions of CDs in the neighbouring rows are observed. Twisting of the 
3,5-dimethylaniline blocking group 45° out-of-plane of the azobenzene suggests that 
unlike the rotaxane 1.9, the crystal packing interactions do not allow the 3,5- 
dimethylaniline blocking group to be in the same plane as the azobenzene. As this 
geometry may be caused by crystal packing, studying the conformation in solution 
was required to determine whether the expected planarity of the blocking groups with 
respect to the azobenzene axle of the rotaxane 4.1 was likely to be suitable for the 
rotaxane 4.1 to co-crystallise with the rotaxane 1.9, and consequently inhibit the 
crystal growth of the rotaxane 1.9.
Figure 4.8. Crystal structure of the rotaxane 4.1 displayed in stick style. Solvent 
molecules are removed for clarity. Black = carbon, white = hydrogen, blue = nitrogen 
and red = oxygen.
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Figure 4.9. Crystal packing of the rotaxane 4.1 showing alignment into insulated 
molecular fibres. Displayed in stick style. Hydrogen atoms and solvent molecules are 
removed for clarity.
In contrast to those of the rotaxane 4.1, crystals of the rotaxane 4.2 belong to the 
monoclinic space group and have two molecules per unit cell. The crystal structure 
shows an unusual bend in the dumbbell (Figure 4.10). The 3,5-dimethylaniline 
blocking group is twisted roughly 30° from the plane of the azobenzene moiety, 
whereas, the 2,6-dimethylaniline blocking group is twisted approximately 90° from 
the plane of the azobenzene moiety, comparable to the features of the rotaxane 4.1. 
The crystal packing of the rotaxane 4.2 also shows the CDs aligned head-to-tail along 
each row (Figure 4.11). Every alternating row of the CDs faces the opposite direction, 
giving rise to centrosymmetric, non-polar crystals. Hydrogen bonding interactions of 
CDs in the neighbouring rows are observed. Twisting of the 3,5-dimethylaniline 
blocking group 30° out-of-plane of the azobenzene suggests that like the rotaxane 4.1, 
the crystal packing interactions do not allow the 3,5-dimethylaniline blocking group 
to be in the same plane as the azobenzene in the solid-state. The solid-state 
conformation is not necessarily the same as that in solution. Therefore, studying the 
conformation in solution was also required to determine whether the expected 
planarity of the blocking groups with respect to the azobenzene axle of the rotaxane 
4.2 was again likely to be suitable for the rotaxane 4.2 to co-crystallise with the 
rotaxane 1.9, and consequently inhibit the crystal growth of the rotaxane 1.9.
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Figure 4.10. Crystal structure of the rotaxane 4.2 displayed in stick style. Solvent 
molecules are removed for clarity. Black = carbon, white = hydrogen, blue = nitrogen 
and red = oxygen.
Figure 4.11. Crystal packing of the rotaxane 4.2 showing alignment into insulated 
molecular fibres. Displayed in stick style. Hydrogen atoms and solvent molecules are 
removed for clarity.
4.4 Conformational Analysis of Unsymmetrically Capped [2]Rotaxanes in 
Solution
Having examined the solid-state structures of the rotaxanes 1.9 and 1.18 in the work 
reported in Chapter 3 and the rotaxanes 4.1 and 4.2 as described above, it was 
apparent that unlike the rotaxane 1.9, the crystal packing interactions of the rotaxanes 
4.1 and 4.2 do not allow the 3,5-dimethylaniline blocking group to be in the same 
plane as the axle. However, whether co-crystallisation can occur or not is more 
dependent on the conformation of rotaxanes in solution rather than the solid-state. The 
solution conformations are the lowest energy conformations the rotaxanes would 
prefer to adopt in the absence of any long range structural order. Therefore, to study
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the conformations of the unsymmetrically capped rotaxanes 4.1 and 4.2 in comparison 
to those of the analogous symmetrically capped rotaxanes 1.9 and 1.18 in solution, the 
absorbance spectra of the set of rotaxanes 1.9, 1.18, 4.1 and 4.2 in solution were 
obtained. Each of the rotaxanes 1.9, 1.18, 4.1 and 4.2 was dissolved in water and the 
absorbance of each solution was measured using a UV/visible spectrometer. The 
molar extinction coefficients of the rotaxanes 1.9, 1.18. 4.1 and 4.2 are similar. 
Nevertheless, concentrations of the rotaxanes 1.9, 1.18, 4.1 and 4.2 were not 
measured accurately given the small quantities that were weighed. Hence the 
UV/visible spectra were adjusted to about the same absorbance near 350 nm and 
overlaid for the convenience of comparison (Figure 4.12). The rotaxane 1.9 has the 
longest absorption wavelength with a ^maxat 352 nm. The absorbance spectra of the 
unsymmetrically capped rotaxanes 4.1 and 4.2 are blue shifted to a shorter wavelength 
(^ max = 346 nm). Finally, the absorbance spectrum of the rotaxane 1.18 is further blue 
shifted ( k m a x  —  340 nm). The longest absorption wavelength of the rotaxane 1.9 
suggests that this rotaxane has the highest degree of conjugation and that the 
dumbbell is therefore fully co-planar, while the rotaxanes 4.1 and 4.2 are less 
conjugated with one of the blocking groups twisted out of the plane of the 
azobenzene. Finally, the spectrum of the rotaxane 1.18, which is most blue shifted, 
suggests that the rotaxane 1.18 has the lowest degree of conjugation and that the 
blocking groups on both ends are twisted out of the plane of the azobenzene.
Although the solid-state structures of the rotaxanes 4.1 and 4.2 have the 3,5- 
dimethylaniline blocking group twisted out-of-plane of the azobenzene, the 
conformational analysis of the rotaxanes 4.1 and 4.2 in solution suggests that the 3,5- 
dimethylaniline blocking group is co-planar to the azobenzene in this phase. This 
supports the suggestion made above that the solid-state conformations are likely to be 
affected by crystal packing interactions, and are not a reflection of the conformations 
in solution. Given the apparent planarity of the 3,5-dimethylaniline blocking groups 
with respect to the azobenzene axles of the rotaxanes 4.1 and 4.2 in solution, the 
rotaxanes 4.1 and 4.2 met the design criteria to test the hypothesis outlined at the 
beginning of this Chapter that co-crystallisation of the rotaxanes 4.1 and/or 4.2 with 
the rotaxane 1.9 might result in inhibition of crystal growth.
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Figure 4.12. Overlay of UV/visible spectra of solutions of the rotaxane 1.9 (dark 
blue), the rotaxane 4.1 (pink), the rotaxane 4.2 (yellow) and the rotaxane 1.18 
(skyblue) in water.
4.5 Attempted Preparation of Amorphous Solids of a-Cyclodextrin [2]Rotaxanes
For co-crystallisation of the rotaxane 1.9 with the rotaxanes 4.1 and/or 4.2, preparation 
of supersaturated solutions of these compounds was required. In the work described in 
Chapter 3, solutions of the rotaxanes 1.9, 1.10, 1.17 and 1.18 were prepared by adding 
each compound to water and heating the mixtures, then leaving them to stand. Crystals 
came out of solution indicating that the solutions were saturated, however, more of the 
rotaxanes 1.9, 1.10, 1.17 and 1.18 dissolved, as observed by UV/visible spectroscopy 
in each case, when more solid compound was added. Amorphous solids are potentially 
more soluble than their crystalline forms, forming metastable highly supersaturated 
solutions, which can cause precipitation or nucleation followed by growth of crystals 
with higher crystal lattice energies.153,154 Hence the rotaxanes 1.9, 1.10, 1.17 and 1.18 
were thought to be mixtures of crystalline and amorphous forms, and the amorphous 
forms continued to dissolve in solutions already saturated with respect to the 
crystalline forms. Using amorphous materials is a useful way to prepare solutions 
supersaturated with respect to the crystalline forms of those materials. However, when 
a mixture of crystalline and amorphous solids dissolves, seed crystals that are invisible 
to the naked eye may remain, affecting crystallisation in an unpredictable and irregular
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manner. Consequently, a method to prepare completely amorphous solids was sought 
in order to prepare homogeneous supersaturated solutions, required for reliable and 
reproducible crystal growth regulation studies. Experiments were carried out with the 
rotaxanes 1.9, 1.10, 1.17 and 1.18. Those using the rotaxane 1.9 are described below 
but similar results were obtained with the other compounds.
In an attempt to prepare amorphous material, the rotaxane 1.9 was dissolved in MeOH 
and the solvent was removed using a rotary evaporator. Although the solvent was 
removed rapidly, crystallisation during evaporation of the solvent was not eliminated. 
Subsequently, the rotaxane 1.9 was added to water to make up a 5 pM solution, which 
was then lyophilised. As shown on the following pages, a 5 pM solution is below 
saturation with respect to the crystalline form, so it is reasonable to expect all the 
rotaxane 1.9 dissolved. Even so, SEM images showed that this attempt gave a solid 
that was a mixture of crystalline and amorphous material as shown in Figure 4.13 (a). 
Lyophilisation involves freezing the solution and applying vacuum such that 
sublimation occurs. Sublimation proceeds without the solution phase where material 
can dissolve and re-orient for crystallisation to occur. Observation of a mixture of 
crystalline and amorphous solids suggests that perfect sublimation does not occur 
during lyophilisation, but that the frozen mixture partially melts at least locally, 
allowing crystallisation to occur.
In a further attempt, the rotaxane 1.9 was added to a MeOH/water solution to make up 
a 5 pM solution. MeOH was removed using a rotary evaporator, and the resulting 
solution was lyophilised. This attempt also gave a solid that was a mixture of 
crystalline and amorphous forms as shown in Figure 4.13 (b). The rotaxane 1.9 is 
significantly more soluble in MeOH compared to water. However, preparation of an 
amorphous solid by dissolving the rotaxane 1.9 in a MeOH/water mixture initially to 
ensure dissolution of any crystals was unsuccessful.
In another attempt to ensure that the rotaxane 1.9 was fully dissolved in solution 
before lyophilisation, the rotaxane 1.9 dissolved in MeOH was added dropwise to 
water to make up a 5 pM solution. As a precaution, that solution was filtered through 
a 0.45 pm pore membrane filter. The resulting solution was reduced to remove MeOH
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using a rotary evaporator and lyophilised, but again, the solid obtained was partially 
crystalline (Figure 4.13 (c)). The SEM image shows that the crystals have a width of 
around 0.36 pm, which means that they would pass through a 0.45 pm membrane 
filter. Hence even filtration does not guarantee the absence of seed crystals.
In yet a further attempt to prepare amorphous material, the rotaxane 1.9 was added to 
/-BuOH/water co-solvent systems (3% /-BuOH, 10% /-BuOH) to make up 5 pM 
solutions, and each solution was lyophilised. Preparation of amorphous complexes of 
hydroxypropyl-ß-CD by lyophilisation from a /-BuOH system has been reported 
previously.155'156 /-BuOH is known to be an ideal freeze-drying medium as it is an 
organic solvent that is miscible with water, has a high freezing point and vapour
1 S7
pressure, and alters the crystal habit of ice to aid the sublimation process. 
Accordingly a /-BuOH/water co-solvent system has been reported to produce porous 
powder forms.158 159 Even so. this process did not eliminate crystals, as a mixture of 
amorphous and crystalline material was obtained as shown in Figure 4.13 (d). As 
obtaining purely amorphous materials was found to be difficult, an alternative method 
to prepare supersaturated solutions was required.
74
(C) (d)
Figure 4.13. SEM images of samples of the rotaxane 1.9 showing mixtures of 
crystalline and amorphous forms obtained by lyophilisation of (a) a 5 pM aqueous 
solution, (b) a 5 pM MeOH/water solution after MeOH had evaporated, (c) a filtered 
5 pM MeOH/water solution after MeOH had evaporated and (d) a 5 pM 3% t- 
BuOH/water solution.
4.6 Determination of the Solubility of a-Cyclodextrin [2]Rotaxanes
Due to the difficulty in preparing amorphous solids, a more conventional method was 
used to prepare supersaturated solutions, which involved heating, for reliablity and 
reproduciblity in crystal growth regulation studies. First, in order to obtain solutions 
of the rotaxane 1.9, determining the solubility at different temperatures was required. 
A 100 pM solution of the rotaxane 1.9 in water was prepared at 80 °C. Maintaining 
the initial temperature, the stock solution was then diluted to 5, 10, 20 and 50 pM. 
The UV/visible spectrum of each solution was recorded and the absorbance of each 
solution was plotted against concentration as shown in Figure 4.14. Initially, all 
solutions were clear and the absorbance shows linear increase with increasing 
concentration drawn in black line. The UV/visible spectrum of each solution was 
recorded again after incubation at 80 °C for 7 days. There is no change in absorbance 
before and after incubation. On that basis, material was fully dissolved at 80 °C and 
the saturation concentration is at least 100 pM at that temperature. Solubility studies 
were also done at 50 °C and 10 °C. After incubation for 7 days the absorbance of the 
supernatant of each solution did not change further. Comparing the absorbance before 
and after equilibration at 50 °C, the absorbance of a 100 pM mixture has decreased as 
shown by the red asterisk. The absorbance can be extrapolated to the black line and 
shows a concentration of 66 pM. Therefore, the saturation concentration at 50 °C was 
determined to be 66 pM. Similarly, at 10 °C, the saturation concentration was
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determined to be 16 pM shown by the red circles. Similar studies were also carried 
out to determine the solubilities of the rotaxanes 4.1 and 4.2. The saturation 
concentrations with respect to the crystalline forms of the rotaxanes 4.1 and 4.2 at 
room temperature were found to be 70 and 190 pM respectively. Therefore, the 
rotaxanes 4.1 and 4.2 are more soluble in water compared to the rotaxane 1.9.
On the basis that a 100 pM solution of the rotaxane 1.9 was determined to be 
completely dissolved at 80 °C, but supersaturated at 30 °C, a 100 pM solution was 
prepared at 80 °C. This solution was left to stand at 30 °C and the UV/visible spectra 
were recorded at intervals as shown in Figure 4.15. The initial solution showed a 
narrow absorbance band at 350 nm that did not change for 5 days. After 5 days, 
crystals came out of solution, and the absorbance at 350 nm decreased over time. No 
further change in absorbance was observed after 11 days. This indicates that the 
supersaturated solution equilibrated to saturation concentration, causing the 
absorbance at 350 nm to decrease over time. The delay in the onset of this 
crystallisation indicates that heating is an effective way of removing seed crystals and 
preparing supersaturated solutions such that a typical crystallisation process occurs as 
these solutions are equilibrated to saturation concentration.
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Figure 4.14. Solubility plot of the rotaxane 1.9 in water at 10, 50 and 80 °C.
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Figure 4.15. UV/visible spectra of a 100 pM mixture of the rotaxane 1.9 in water, 
monitored at time intervals during incubation at 30 °C.
4.7 Crystal Growth Inhibition Study
Having established that the saturation concentration of the rotaxane 1.9 is 16 pM at 10 
°C, 66 pM at 50 °C, and 100 pM or higher at 80 °C, it is clear that the rotaxane 1.9 
can completely dissolve up to at least 100 pM at 80 °C. Therefore, this method of 
heating at higher temperatures and equilibrating at lower temperatures was used to 
prepare supersaturated solutions required for experiments to regulate crystal growth. 
Four solutions containing 0, 10, 50 or 100 pM of the rotaxane 4.1 and 100 pM of the 
rotaxane 1.9 were prepared. As described in the previous section, the solubility of the 
rotaxane 4.1 is higher than that of the rotaxane 1.9, hence, solutions of the rotaxane 
4.1 at 100 pM or lower were also able to be prepared through heating above 80 °C 
and cooling at lower temperature. The resulting clear solutions were left to stand for 
3.5 days while being monitored using an optical microscope fitted with a polarising 
lens (Figure 4.16). Inspection of the crystals grown from a solution of the rotaxane 
1.9 (100 pM) gave long needles that are on average 1.17 mm in length (Table 4.1 
Entry 1). The length of the crystals grown decreased with increasing concentration of
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the rotaxane 4.1. When crystals were grown from a solution of the rotaxane 1.9 (100 
pM) and the rotaxane 4.1 (100 pM), the length of the needles decreased to 0.28 mm 
on average. Furthermore, when a solution that had an even higher concentration of the 
rotaxane 4.1 (200 pM) and 100 pM of the rotaxane 1.9 was left to stand, 
crystallisation did not occur over a month. Inverse correlation between the crystal 
length and the concentration of the rotaxane 4.1 indicates that the rotaxane 4.1 
terminates needle elongation.
In order to investigate whether the rotaxane 4.1 interferes with crystal growth by 
simply associating and disassociating with the growing fibres of the rotaxane 1.9 or 
by incorporating in the crystal lattice, and if the latter to determine the level of 
incorporation, crystals were collected by centrifugation, dissolved in MeOH and 
analysed using HPLC to measure the relative proportions of the rotaxanes 1.9 and 4.1 
(Table 4.1). The molar extinction coefficients of the rotaxanes 1.9 and 4.1 are similar, 
hence the areas under the peaks in the HPLC chromatogram were integrated to 
estimate the percentage compositions. When 10 pM of the rotaxane 4.1 was present in 
the mixture that was left to stand, the area under the peak corresponding to the 
rotaxane 4.1 was 0.9% of the total peak area (Table 4.1 Entry 2). When 100 pM of the 
rotaxane 4.1 was present in the mixture that was left to stand, the area under the peak 
corresponding to the rotaxane 4.1 increased to 3.4% of the total (Table 4.1 Entry 4). 
This shows that the rotaxane 4.1 is incorporated into the crystals of the rotaxane 1.9. 
The percentage composition of the rotaxane 4.1 is inversely proportional to crystal 
length. Therefore, the amount of crystal length truncation depends on the amount of 
the rotaxane 4.1 incorporated. A solution containing 10 pM of the rotaxane 4.1 
yielded crystals which are on average 0.59 mm in length. The length of a single unit 
of the rotaxane 1.9 being approximately 2.2 nm, roughly 270,000 units of the rotaxane 
1.9 are aligned linearly to constitute a single molecular fibre with that length. If the 
rotaxane 4.1 only incorporated to the ends of the growing chains of the rotaxane 1.9, 
the incorporation frequency of the rotaxane 4.1 would only be 2 in 270,000. 
Incorporation of 2 in 270,000 units equates to roughly 0.0007% of the total crystal 
composition. A much higher incorporation rate of the rotaxane 4.1 (0.9%) suggests 
that the crystal of the rotaxane 1.9 continues to grow around incorporated molecules 
of the rotaxane 4.1 as shown in Figure 4.17. Presumably, when the number of crystal
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lattice defects becomes large enough, the crystals do not grow further and therefore 
become truncated. Overall, the rotaxane 4.1 acts as a crystal growth inhibitor of the 
rotaxane 1.9, as designed.
(a) (b)
Figure 4.16. Optical microscope images of crystals grown after 3.5 days from 
solutions of (a) 100 pM of the rotaxane 1.9, (b) 100 pM of the rotaxane 1.9 and 10 
pM of the rotaxane 4.1, (c) 100 pM of the rotaxane 1.9 and 50 pM of the rotaxane 4.1 
and (d) 100 pM of the rotaxane 1.9 and 100 pM of the rotaxane 4.1.
Entry
Concentration 
of the rotaxane 
1.9 (pM)
Concentration 
of the rotaxane 
4.1 (pM)
Average 
length of 
crystals 
(mm)
Number of 
rotaxanes aligned 
along the
molecular fibre of 
the grown crystals
Composition 
of the rotaxane 
4.1 in the grown 
crystals (%)
1 100 0 1.17 530000 0
2 100 10 0.59 270000 0.9
3 100 50 0.30 140000 2.5
4 100 100 0.28 130000 3.4
Table 4.1. Analysis of lengths and compositions of crystals shown in Figure 4.16.
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Figure 4.17. A model illustration of the rotaxane 1.9 crystal growing around an 
incorporated molecule of the rotaxane 4.1 and further incorporation of the rotaxane 
4.1 eventually terminating crystal growth.
Given that the rotaxane 4.1 shows crystal growth regulation through co-
crystallisation, the ability to regulate crystal growth using the orientational isomer, the 
rotaxane 4.2, was examined for comparison using the conditions described above. 
Inspection of the crystals grown from four solutions containing 0, 10, 50 or 100 pM 
of the rotaxane 4.2 and 100 pM of the rotaxane 1.9 did not show large differences in 
crystal length. Therefore, crystal growth studies were repeated using solutions with 
higher concentrations (0, 100, 150 or 200 pM) of the rotaxane 4.2 with 100 pM of the 
rotaxane 1.9, that were left to stand for 36 days (Figure 4.18). Inspection of the 
crystals grown from a solution of the rotaxane 1.9 (100 pM) gave long needles that 
are on average 1.76 mm in length (Table 4.2 Entry 1). The length of the crystals 
grown decreased with increasing concentration of the rotaxane 4.2. When crystals 
were grown from a solution of the rotaxane 1.9 (100 pM) and the rotaxane 4.2 (200 
pM), the length of the needles decreased to 0.82 mm on average (Table 4.2 Entry 4). 
As per the rotaxane 4.1, an inverse correlation between the crystal length and the 
concentration of the rotaxane 4.2 is indicates that the rotaxane 4.2 terminates needle 
elongation.
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In order to investigate whether the rotaxane 4.2 interferes with crystal growth by 
simply associating and disassociating with the growing fibres of the rotaxane 1.9 or 
by incorporating in the crystal lattice, and if the latter to determine the level of 
incorporation, crystals were collected by centrifugation, dissolved in MeOH and 
analysed using HPLC to measure the relative proportions of the rotaxanes 1.9 and 4.2 
(Table 4.2). The molar extinction coefficients of the rotaxanes 1.9 and 4.2 are also 
similar, hence the areas under the peaks in the HPLC chromatogram were integrated 
to estimate the percentage compositions. When 100 pM of the rotaxane 4.2 was 
present in the mixture that was left to stand, the area under the peak corresponding to 
the rotaxane 4.2 was 2.5% of the total peak area (Table 4.2 Entry 2). When 200 pM of 
the rotaxane 4.2 was present in the mixture that was left to stand, the area under the 
peak corresponding to the rotaxane 4.2 increased to 7.2% of the total (Table 4.2 Entry 
4). This shows that the rotaxane 4.2 is incorporated into the crystals of the rotaxane 
1.9. As per the rotaxane 4.1, the amount of crystal length truncation is proportional to 
the amount of the rotaxane 4.2 incorporated.
In contrast to crystals being fully grown after 3.5 days and not growing further when 
the rotaxane 4.1 was added, the crystal growth was much slower when the rotaxane 
4.2 was added (36 days). Crystals were grown from different stock solutions of the 
rotaxane 1.9 in these experiments, and therefore the lengths of the crystals grown 
from the control experiment with 100 pM of the rotaxane 1.9 are not identical in each 
experiment (Table 4.1 Entry 1 and Table 4.2 Entry 1). Comparing the crystal growth 
inhibition of the rotaxanes 4.1 and 4.2, an addition of 10 pM of the rotaxane 4.1 was 
required to truncate the crystal length by approximately half. On the other hand, even 
an addition of 150 pM of the rotaxane 4.2 was insufficient to truncate the crystal 
length by a half (Table 4.1 Entry 2 and Table 4.2 Entry 3). When 10 pM of the 
rotaxane 4.1 was added, 0.9% of the crystal composition corresponded to the rotaxane 
4.1, compared to 4.4% of the crystal composition corresponding to the rotaxane 4.2 
when 150 pM of the rotaxane 4.2 was added. The smaller percentage composition of 
the rotaxane 4.1 required to truncate the crystal length by approximately a half 
suggests that the rotaxane 4.1 terminates crystal growth more effectively. Higher 
degree of incorporation of the rotaxane 4.2 may delay needle elongation as the
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rotaxane 1.9 needs to grow around the defects in the crystal lattice. This may cause 
the crystals to grow over a longer period of time with the rotaxane 4.2.
A possible rationalisation for why the effectiveness to truncate crystal growth is 
different for the rotaxanes 4.1 and 4.2 is described below, although the factors 
affecting the process of crystal growth truncation are complex and difficult to fully 
rationalise. CD-based rotaxanes typically show head-to-tail alignment of the CDs in 
the crystal packing, presumably due to the dipole of the CDs. The 3,5-dimethylaniline 
blocking group is next to the tail end of the CD for the rotaxane 4.1, while the 3,5- 
dimethylaniline blocking group is next to the head end of the CD for the rotaxane 4.2. 
If the incorporation of the rotaxanes 4.1 and 4.2 to the crystals of the rotaxane 1.9 also 
occurs in a head-to-tail fashion, the rotaxane 4.1 would be expected to incorporate 
only on the head end of the rotaxane 1.9 while the rotaxane 4.2 would be expected to 
incorporate only on the tail end. Consequently, the different interactions involved by 
incorporation into either the head or the tail end of the rotaxane 1.9 may contribute to 
the effectiveness of the rotaxanes 4.1 and 4.2 to terminate crystal growth being 
different.
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(C) (d)
Figure 4.18. Optical microscope images of crystals grown after 36 days from 
solutions of (a) 100 pM of the rotaxane 1.9, (b) 100 pM of the rotaxane 1.9 and 100 
pM of the rotaxane 4.2, (c) 100 pM of the rotaxane 1.9 and 150 pM of the rotaxane 
4.2 and (d) 100 pM of the rotaxane 1.9 and 200 pM of the rotaxane 4.2.
Entry
Concentration 
of the rotaxane 
1.9 (pM)
Concentration 
of the rotaxane 
4.2 (pM)
Average 
length of 
crystals 
(mm)
Number of 
rotaxanes aligned 
along the
molecular fibre of 
the grown crystals
Composition 
of the rotaxane 
4.2 in the grown 
crystals (%)
1 100 0 1.76 800000 0
2 100 100 1.57 710000 2.5
3 100 150 1.02 460000 4.4
4 100 200 0.82 370000 7.2
Table 4.2. Analysis o 'lengths and compositions of crystals shown in Figure 4.18.
It appears that the rotaxanes 4.1 and 4.2 act as crystal growth inhibitors by 
incorporating into the growing chains of molecular fibres of the rotaxane 1.9. This is 
presumably due to the conformation of the 3,5-dimethylaniline blocking group being 
co-planar to the axle and therefore being able to form jt-ji interactions with the 
structurally similar rotaxane 1.9, while the conformation of the 2,6-dimethylaniline 
blocking group is out-of-plane of the axle and cannot form jt-jt interactions to 
continue crystal growth. For this to be correct, the rotaxane 1.18 with 2,6- 
dimethylaniline blocking groups on both ends would not be expected to form jt-ji 
interactions with the rotaxane 1.9 and thus would not affect the crystal growth of the 
rotaxane 1.9. To examine this hypothesis, crystal growth was monitored using four 
solutions that contained 0, 10, 50 or 100 pM of the rotaxane 1.18 and 100 pM of the
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rotaxane 1.9. Figure 4.19 shows optical microscope images of crystals formed after 
10 days. Visual inspection shows that the length of the crystals grown from all four 
solutions is unaffected, and HPLC analysis of the crystals collected from each 
solution showed only a single peak corresponding to the rotaxane 1.9, which shows 
that there is no incorporation of the rotaxanes 1.18 in the crystal lattice of the rotaxane 
1.9. This is consistent with the expectation that as the rotaxane 1.18 has blocking 
groups on both ends that are unable to form the appropriate jt - jt  interactions, 
consequent incorporation into the molecular fibres of the rotaxane 1.9 does not occur. 
Thus, crystal growth of the rotaxane 1.9 is not inhibited by the rotaxane 1.18.
(a) (b)
Figure 4.19. Optical microscope images of crystals grown after 10 days from 
solutions of (a) 100 pM of the rotaxane 1.9, (b) 100 pM of the rotaxane 1.9 and 10 
pM of the rotaxane 1.18, (c) 100 pM of the rotaxane 1.9 and 50 pM of the rotaxane 
1.18 and (d) 100 pM of the rotaxane 1.9 and 100 pM of the rotaxane 1.18.
4.8 Conclusion
In conclusion, the purposely designed rotaxanes 4.1 and 4.2 showed crystal growth 
inhibition of the rotaxane 1.9. It appears that when the rotaxanes 4.1 and 4.2 
incorporate into the growing crystals of the rotaxane 1.9, the rotaxane 1.9 grows 
around the incorporated molecules until the number of the crystal lattice defects
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increases to the point that crystal growth eventually terminates. If this is the case, 
microscopy techniques such as TEM or STM could be used to investigate the crystal 
lattice defects to see, for example, whether they are concentrated on the ends of the 
crystals. Furthermore, as the crystal packing of the rotaxane 1.9 shows molecules 
aligned head-to-tail with alternating rows facing opposite directions, the mis- 
incorporated rotaxanes 4.1 and 4.2 which are expected to interact with either the head 
or tail end are likely to be observed on the ends of alternating rows of the rotaxane 
1.9. The rotaxane 4.1 shows more effective inhibition of crystal growth. Therefore, 
more irregularity in the crystal lattice of the rotaxane 1.9 would expected to be 
observed by microscopy when the rotaxane 4.2 is incorporated compared to the 
rotaxane 4.1, as the rotaxane 1.9 appears to grow around the incorporated molecules 
of the rotaxane 4.2 better without terminating crystal growth.
During the crystal growth inhibition studies, an interesting liquid-phase behavior was 
observed. When a large amount of the rotaxane 4.1 was added to a supersaturated 
solution of the rotaxane 1.9, crystallisation did not occur, but instead the rotaxane 1.9 
remained in solution. The focus of this Chapter was to regulate the growth of 
molecular fibres in the solid-state. The process of manipulating the self-assembly of 
CD-based rotaxanes in solution is likely to be similar in some ways to the process in 
the solid-state. Therefore, this technology may not be limited to the application in the 
solid-state but also applicable to aggregates in solution and lyotropic liquid crystalline 
materials.160’161 Future work could therefore be directed to regulating self-assembly of 
rotaxanes in the solution phase.
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CHAPTER 5 -  Conclusions and Future Directions 
for Crystal Engineering with a-Cyclodextrin Based Rotaxanes
In the work described in the previous Chapters of this thesis, CD-based rotaxanes 
were prepared and their solid-state structures/packing, morphology and crystal growth 
behaviour were explored. The rotaxane 1.17 having a stilbene-based axle and 3,5- 
dimethylaniline blocking groups, as well as the rotaxane 1.18 having an azobenzene- 
based axle and 2,6-dimethylaniline blocking groups were prepared to complete the set 
of rotaxanes 1.9, 1.10, 1.17 and 1.18 with 2,6-dimethylaniline and 3,5-dimethylaniline 
blocking groups, with azobenzene- and stilbene-based axles. Observation of crystal 
morphology and growth using SEM and microscope images suggests not only that 
crystal shape and size can be controlled depending on the choice of blocking groups 
and varying the conditions of crystal growth, but also that crystal packing is reflected 
in the crystal growth and the final shape of the crystals. Thus crystal engineering can 
be bottomed-up to make nano-molecular architectures to micrometre scale or beyond.
Crystal engineering may be used to fine-tune physical, chemical, photochemical or 
electronic properties of molecular and supramolecular devices and machines that are 
fabricated through a bottom-up approach. Another way to regulate the degree of 
conjugation in molecular fibres would be to build a conjugated system where the 
backbones of rotaxanes are polyconjugated. The resultant conjugated poly rotaxane 
system would have a higher degree of conjugation compared to extended conjugation 
through ji-jt interactions shown in the crystal packing of the rotaxane 1.9. It is 
conceivable that conjugated poly rotaxanes could be prepared using building blocks 
such as the rotaxane 5.1. If the 2,5-dimethylaniline blocking groups maintained co-
planarity with the axle, the rotaxane 5.1 would be fully conjugated. Conjugated 
polyrotaxanes might then be accessible if the dumbbells of the rotaxane 5.1 were 
coupled with conjugated linkers through Heck reaction " as shown in Scheme 5.1. 
This type of polyrotaxane could potentially be developed into molecular wires for 
electronic communication, or into materials that expand and shrink on exposure to 
external stimuli due to linkers that can undergo isomerisation.
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Scheme 5.1. Proposed synthesis of the polyrotaxane 5.3.
Alternatively, a much wider range of rotaxanes including unsymmetrically capped 
rotaxanes might be designed using a crystal engineering approach where the blocking 
groups act as synthons to guide intermolecular self-assembly and regulate the degree 
of conjugation in molecular fibres of aligned rotaxanes. In Chapter 4, the 
unsymmetrically capped rotaxanes 4.1 and 4.2 were used to regulate the crystal 
growth of the self-assembling rotaxane 1.9 through co-crystallisation. This type of 
crystal growth regulation is unlikely to be restricted to rotaxanes with 3,5- 
dimethylaniline blocking groups but to be extendable to other types of blocking 
groups and rotaxanes that form fibres through t c - j i  interactions. The possibilities for 
regulating crystal growth using different rotaxanes with different blocking groups that 
can be used as crystal synthons are vast. While it was not practical to examine all 
possibilities, preliminary crystal engineering experiments were carried out with 
another CD-based rotaxane. The rotaxane 1.4 with trinitrophenyl blocking groups also 
forms linearly aligned fibres through jt-jt interactions of the blocking groups that are 
twisted out of the plane of the axle as described in the Introduction.163 Given their two 
different blocking groups having potential to form jt - j i interactions, the two 
unsymmetrically capped rotaxanes 5.4 and 5.5 that are structurally similar to the 
rotaxanes 1.4 and 1.9 were designed. Each is capped with a 3,5-dimethylaniline 
blocking group on one end and a trinitrophenyl blocking group on the other end. From
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the crystal structure and packing of the rotaxane 1.9, it was envisaged that the 3,5- 
dimethylaniline blocking group of the rotaxanes 5.4 and 5.5 would allow j i- ji  
interactions between 3,5-dimethylaniline blocking groups of adjacent rotaxanes. 
Likewise, from the crystal structure and packing of the rotaxane 1.4, it was envisaged 
that the rotaxanes 5.4 and 5.5 could form jt - jt  interactions between trinitrophenyl 
blocking groups of adjacent rotaxanes. Alternatively, j i- j i interactions between the 
3,5-dimethylaniline blocking groups and the trinitrophenyl blocking groups of 
adjacent rotaxanes might occur.
5.1 Synthesis
The synthesis of the rotaxanes 5.4 and 5.5 was attempted using a variation of the 
threading approach described in Chapter 4. First, the stilbene axle 5.8 was prepared by 
palladium-catalysed Heck coupling of 4-vinylaniline 5.6 and 4-iodobenzoic acid 5.7 
according to literature procedures.164 The stilbene 5.8 was capped with the aniline 2.2 
using the amide coupling agent, BOP (Scheme 5.2). The aniline 2.2 was used as both 
the capping reagent and solvent. Having an excess of the aniline 2.2 ensured that the 
amino group of the stilbene 5.8 did not act as a nucleophile, without having to protect 
and deprotect it.
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oBOP,
Scheme 5.2. Synthesis of the amide 5.9.
With the monocapped axle 5.9 in hand, the rotaxane 5.5 was prepared following the 
procedure adapted from Easton et a/.163 The synthesis involved equilibrating the 
aminostilbene 5.9 in sodium carbonate buffer (pH 10) with a large excess of a-CD 1.1 
(Scheme 5.3). An increased amount of buffer and a-CD 1.1 was used compared to the 
literature conditions to solubilise the aminostilbene 5.9. Then, the dihydrate of 2,4,6- 
trinitrobenzene-1-sulfonic acid sodium salt 5.10 was added. The ESI mass spectrum 
of the reaction mixture showed an ion at m/z 1549, which corresponds to the sodiated 
ion of the rotaxane 5.5. The product 5.5 was not observed on TLC, however, as only 
small amounts were formed. Instead, the reaction mixture was analysed by HPLC. 
The HPLC trace of the reaction mixture showed a peak that had the absorbance of 
both the stilbene and the 2,4,6-trinitrophenyl blocking group. This peak was isolated 
through reverse phase HPLC to give the rotaxane 5.5 in 2% yield. The low yield is 
presumably due to the low solubility of the monocapped axle 5.9 in water, or a low 
tendency for the CD 1.1 forming an inclusion complex with the axle 5.9. In theory,
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both of the rotaxanes 5.4 and 5.5 could have formed. However, formation of only the 
one was detected by HPLC and this was determined to be the rotaxane 5.5 through 
structural analysis as discussed below.
1 equiv.
40 equiv.
NaHC03, pH 10
y 2 equiv.
Scheme 5.3. Synthesis of the rotaxane 5.5
5.2 Conformational Analysis Using NMR Spectroscopy and X-Ray 
Crystallography
The ID 'H NMR spectrum of the rotaxane 5.5 confirms the presence of the 
components, showing resonances of CD, stilbene, dimethylphenyl and trinitrophenyl 
protons (Figure 5.1).
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Figure 5.1. 500 MHz ‘H NMR spectrum of the rotaxane 5.5 in CD3OD.
The general protocol used in Chapter 2 to assign structures of CD-based [2]rotaxanes 
was followed for the rotaxane 5.5 in an attempt to assign the structure using 2D NMR 
experiments. Figure 5.2 shows a section of the DQF-COSY NMR spectrum of the 
rotaxane 5.5, where the CD proton cross-peaks are found. The most down field CD 
resonance at 64.93 is assigned to the CD-C1 anomeric protons. A 'H-'H correlation 
between these protons and those giving rise to the signal at 63.45 is seen, and the 
latter is therefore assigned to the CD-C2 protons. Likewise, there is a cross-peak 
between the resonance at 63.45 (CD-C2) and the resonance at 63.86 which is 
therefore attributed to the CD-C3 protons. This resonance at 63.86 (CD-C3) also 
shows a cross-peak with the resonance at 63.58 which is therefore assigned to the CD- 
C4 protons. Again, the resonance at 63.58 (CD-C4) also shows a cross-peak with the 
resonance at 63.87 which is therefore assigned to the CD-C5 protons. Finally, the 
resonances at 63.75 and 3.64 corresponding to the CD-C6 protons show cross-peaks 
with each other.
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Figure 5.2. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the rotaxane 
5.5 in CD3OD showing cross-peaks between CD proton signals.
The structural assignment can then be continued by analysis of the nuclear 
Overhauser effect (NOE) interactions in the ROESY NMR spectrum. Figure 5.3 
shows a section of the 2D ROESY NMR spectrum with cross-peaks for the stilbene 
protons. Since cross-peaks are observed between the resonances of olefinic protons C 
and D, and proton resonances at 67.45 and 8.08, these resonances are assigned to 
protons E and B in proximity to the olefinic protons.
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Figure 5.3. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 5.5 
in CD3OD showing cross-peaks between stilbene proton resonances.
Figure 5.4 shows a section of the 2D ROESY NMR spectrum with axle and aniline 
aromatic proton resonance cross-peaks with those of methyl and CD protons. The 
presence of the NOE cross-peak labelled NOE1 shows the resonance at 67.38 
corresponds to the aniline aromatic protons. Assignment of the CD conformation was 
attempted looking at the cross-peaks between the aromatic and CD protons. Protons A 
and B show strong NOEs with the CD-C3 protons, hence they are next to the wider 
end of the CD. The olefinic protons C and D show NOEs with CD-C5 protons. 
Protons E show NOEs with both the CD-C5 and CD-C6  protons, hence they are next 
to the narrow end of the CD. There is no NOE interaction seen between CD protons 
and protons F. Thus, the CD is localised over one end of the stilbene as shown in 
Figure 5.4. Due to the lack of NOE interaction between protons of the blocking 
groups and CD protons or axle protons, the orientation of the CD with respect to the 
dumbbell cannot be assigned using 2D ROESY NMR spectroscopy. Hence the 
structural assignment of the rotaxane 5.5 was completed using X-ray crystallography.
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Figure 5.4. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 5.5 
in CD3OD showing stilbene and aniline aromatic proton resonance cross-peaks with 
those of methyl and CD protons.
Crystals of the rotaxane 5.5 were obtained through slow evaporation of MeOH/water 
over a period of several weeks. The solid-state structure was examined using X-ray 
crystallography. The crystallographic data are presented in Appendix 1. The rotaxane 
5.5 belongs to the monoclinic space group and there are two molecules per unit cell. 
The stilbene axle is planar. The plane of the trinitrophenyl blocking group is twisted 
approximately 45° from that of the stilbene moiety. Meanwhile, the plane of the 3,5- 
dimethylaniline blocking group is twisted approximately 30° from that of the stilbene 
moiety.
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X-Ray crystallography shows the orientation of the rotaxane 5.5 with the wider end of 
the CD nearest to the 3,5-dimethylaniline blocking group (Figure 5.5). The formation 
of the rotaxane 5.5 occurs through threading of the CD 1.1 from the wider end of the 
cavity to form an inclusion complex, followed by capping with the 2,4,6- 
trinitrobenzene-1-sulfonic acid 5.10. It may be that threading only occurs in this 
direction as the dipoles of the monocapped axle 5.9 and the CD 1.1 do not allow the 
CD 1.1 to thread from the narrower end of the cavity. Alternatively, if inclusion does 
occur through threading of the CD 1.1 from the narrower end, it may be that the CD 
1.1 is localised in proximity of the amino group of the monocapped axle 5.9 such that 
capping of the inclusion complex is limited by steric hindrance, resulting in the 
formation of only the single isomeric rotaxane 5.5.
Figure 5.5. Crystal structure of the rotaxane 5.5 displayed in stick style. Solvent 
molecules are removed for clarity. Black = carbon, white = hydrogen, blue = nitrogen 
and red = oxygen.
5.3 X-Ray Crystal Packing of Unsymmetrically Capped [2]Rotaxane
X-Ray crystallography also gives crystal packing information which reveals that the 
rotaxane 5.5 forms molecular fibres along a single axis through jt-jt interactions 
between the 3,5-dimethylaniline blocking group and the trinitrophenyl blocking group 
of adjacent rotaxanes (Figure 5.6). The CDs of the rotaxane 5.5 are aligned head-to- 
tail with alternating rows of CDs facing opposite directions to form centrosymmetric 
non-polar crystals. The conformation of the rotaxane 5.5 in the solid-state allows jt - jt  
interactions through the 3,5-dimethylaniline as well as the trinitrophenyl blocking 
groups.
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(a)
Figure 5.6. Crystal packing of the rotaxane 5.5 showing (a) formation of aligned 
fibres and (b) the hetero-blocking group ji - ji interaction. Displayed in stick style. 
Hydrogen atoms and solvent molecules are removed for clarity.
5.4 Co-crystallisation Using an Unsymmetrically Capped [2]Rotaxane
Given that the trinitrophenyl blocking group of the rotaxane 5.5 shows a j i- ji 
interaction with the 3,5-dimethylaniline blocking group of an adjacent species in the 
solid-state, through jt-jt interactions of the blocking groups on either end of the 
rotaxane 5.5, it seemed likely that the rotaxane 5.5 might incorporate into the crystal 
lattice of the rotaxane 1.9. Hence it was of interest to examine whether the rotaxane
5.5 could incorporate into the growing chains of the rotaxane 1.9, and if so, whether 
incorporation lead to termination of crystal growth as observed with the rotaxanes 4.1 
and 4.2 in the work described in Chapter 4. Accordingly, an experiment was designed 
to observe the crystal growth from four solutions containing the rotaxane 5.5 (0, 10,
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50 or 100 pM) and 100 pM of the rotaxane 1.9. The solutions were left to stand for 4 
days while being monitored using an optical microscope fitted with a polarising lens 
(Figure 5.7). Inspection of the crystals grown from a solution of the rotaxane 1.9 (100 
pM) gave long needles that are on average 0.90 mm in length (Table 5.1 Entry 1). 
The length of the crystals grown decreased with increasing concentration of the 
rotaxane 5.5. When the crystals were grown form a solution of the rotaxane 1.9 (100 
pM) and the rotaxane 5.5 (100 pM), the length of the needles decreased to 0.45 mm 
on average (Table 5.1 Entry 4). An inverse correlation between the crystal length and 
the concentration of the rotaxane 5.5 indicates that the rotaxane 5.5 interferes with the 
crystal growth of the rotaxane 1.9 and terminates needle elongation as seen with the 
rotaxanes 4.1 and 4.2.
To investigate if the rotaxane 5.5 incorporates in the crystal lattice of the rotaxane 1.9, 
crystals were collected by centrifugation, dissolved in MeOH and analysed using 
HPLC to measure the relative proportions of the rotaxanes 1.9 and 5.5 (Table 5.1). To 
compare the areas under the peaks that are due to the rotaxanes 1.9 and 5.5 in the 
HPLC chromatogram, the isosbestic point of the two rotaxanes 1.9 and 5.5 was first 
measured by injecting an equimolar solution of the two rotaxanes 1.9 and 5.5 onto the 
HPLC. The areas under the peaks in the HPLC chromatogram were then integrated at 
the isosbestic point (332 nm) to estimate the percentage compositions. When 10 pM 
of the rotaxane 5.5 was present in the mixture that was left to stand, the area under the 
peak corresponding to the rotaxane 5.5 was 0.7% of the total peak area (Table 5.1, 
Entry 2). When 100 pM of the rotaxane 5.5 was present in the mixture that was left to 
stand, the area under the peak corresponding to the rotaxane 5.5 increased to 5.0% in 
total (Table 5.1, Entry 4). The percentage composition of the rotaxane 5.5 is inversely 
proportional to crystal length. Although it may be possible for the rotaxane 5.5 to 
incorporate into the growing chains of the rotaxane 1.9 through both trinitrophenyl as 
well as 3,5-dimethylaniline blocking groups, termination of crystal growth through 
incorporation suggests that the rotaxane 5.5 does not fit in the crystal lattice of the 
rotaxane 1.9 perfectly. As the rotaxane 5.5 continues to incorporate, crystal growth is 
eventually terminated as the crystal has too many crystal lattice defects to continue its 
growth.
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Figure 5.7. Optical microscope images of crystals grown after 4 days from solutions 
of (a) 100 pM of the rotaxane 1.9, (b) 100 pM of the rotaxane 1.9 and 10 pM of the 
rotaxane 5.5, (c) 100 pM of the rotaxane 1.9 and 50 pM of the rotaxane 5.5 and (d) 
100 pM of the rotaxane 1.9 and 100 pM of the rotaxane 5.5.
Entry
Concentration 
of the rotaxane 
1.9 (pM)
Concentration 
of the rotaxane 
5.5 (pM)
Average 
length of 
crystals 
(mm)
Number of 
rotaxanes aligned 
along the
molecular fibre of 
the grown crystals
Composition 
of the rotaxane 
5.5 in the grown 
crystals (%)
1 100 0 0.90 410000 0
2 100 10 0.80 360000 0.7
3 100 50 0.55 250000 3.9
4 100 100 0.45 200000 5.0
Table 5.1. Analysis of lengths and compositions of crystals shown in Figure 5.7.
5.5 Conclusion and Future Directions
The unsymmetrically capped rotaxane 5.5 was designed using a crystal engineering 
approach where the blocking groups can be used as synthons to guide intermolecular
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self-assembly and regulate the formation of fibrous structures. The crystals of the 
rotaxane 1.9 have extended conjugation along the crystal fibres through jt - jt  
interactions of the blocking groups that are co-planar to the axles, however, when the 
rotaxane 5.5 incorporates into the crystals of the rotaxane 1.9, extended conjugation 
would be limited as the trinitrophenyl blocking groups of the rotaxane 5.5 are expected 
to be out-of-plane of the axle. As a result, further to regulating self-assembly of 
rotaxanes, this opens up the possibility of using the unsymmetrically capped rotaxane 
5.5 to explore regulating the degree of extended conjugation within molecular fibres of 
the rotaxane 1.9. Only two different types of blocking groups have been studied, 
however, crystal growth experiments of the rotaxane 1.9 with the rotaxanes 4.1, 4.2 
and 5.5 suggest that regulation of crystal growth can be extended to other types of 
blocking groups. Additionally, it would be interesting to investigate the crystal growth 
regulation of not only the rotaxane 1.9 but also other rotaxanes that form fibres 
through ji-jt interactions. These preliminary experiments with the rotaxane 5.5 
illustrate that crystal engineering using CD-based rotaxanes is a versatile approach 
towards regulating self-assembly and understanding molecular level interactions in the 
solid-state. Based on the understanding of self-assembly in the solid-state, it is likely 
that the work can also be further extended to the solution phase to regulate aggregates 
in solution and lyotropic liquid crystalline materials.
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CHAPTER 6 - Results and Discussion 
Synthesis of Rotaxanes to Preserve the Fluorescence of Paramagnetic
Profluorescent Nitroxides
6.1 Synthesis and Conformational Analysis
As described in the Introduction, the objective of the work described in this Chapter 
was to prepare the rotaxanes 1.33, 1.34, 1.35 and 1.36 in an attempt to prevent trans- 
cis isomerisation, and consequently sustain the fluorescence of the corresponding 
dumbbells 1.37 and 1.38. The rotaxanes 1.33 and 1.34 were prepared following a 
procedure adapted from Maniam. ~ Although only the isolation of the single isomer 
1.34 was reported by Maniam, theoretically, there are two isomers differing in the 
orientation of the CD with respect to the dumbbell that could form.134,165'169 The 
profluorescent nitroxide axle 6.1 was equilibrated with excess a-CD 1.1 and two 
molar equivalents of TEA in water. Then DMT-MM was added, followed by 2,6- 
dimethylaniline 2.4 (Scheme 6.1). Only one new spot was detected by TLC, however, 
two components that presumably co-eluted on TLC were separated by HPLC (Figure 
6.1). ESI mass spectrometry of each component showed a protonated molecular ion at 
m/z 1413 and the desired rotaxanes 1.33 and 1.34 were isolated in yields of 19% and 
21% through this single synthetic procedure.
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1 equiv.
5 equiv.
TEA 2 equiv.,
H20
DMT-MM 2 equiv.,
2.4
3 equiv.
Scheme 6.1. Synthesis of the stilbenylnitroxide-based rotaxanes 1.33 and 1.34.
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Figure 6.1. Chromatogram obtained through reverse phase HPLC of the crude 
product mixture formed as outlined in Scheme 6.1.
Figure 6.2 shows the 'H NMR spectrum of the sample corresponding to the HPLC 
peak indicated by the blue asterisk in Figure 6.1. Preliminary observation of the 
spectrum suggests this sample is the orientational isomer of the rotaxane 1.34, as it 
differs from the spectrum of the rotaxane 1.34 reported by Maniam.135 Indeed, this 
sample was assigned as the rotaxane 1.33 by NMR analysis as described in the 
following pages. Initially the proton signals could not be assigned as they are broad 
due to the paramagnetic nature of the rotaxane 1.33. Hence, the rotaxane 1.33 was 
reduced to the hydroxylamine 6.5 using ascorbic acid 6.4 (Scheme 6.2).90 Figure 6.3 
shows the 'H NMR spectrum of the hydroxylamine 6.5 showing well resolved signals 
for analysis. The 'H NMR spectrum confirms the presence of the components, 
showing resonances of the CD, styrylisoindoline and arylamino protons. In order to 
verify the rotaxane formation and the orientation of the CD with respect to the 
dumbbell, 2D NMR analysis of the rotaxane 1.33 was also carried out on the reduced 
form 6.5.
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Figure 6.2. 500 MHz 'H NMR spectrum of the rotaxane 1.33 in CD3OD.
HO
Scheme 6.2. Reduction of the rotaxane 1.33 to the hydroxylamine 6.5 using ascorbic 
acid 6.4.
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Ascorbic acid
Figure 6.3. 500 MHz 'H NMR spectrum of the hydroxylamine 6.5 in CD3OD.
The general protocol used in Chapter 2 to determine the position of the CD along the 
axle and the conformation of CD-based [2]rotaxanes was followed for the rotaxane 
6.5.170 Figure 6.4 shows a section of the DQF-COSY NMR spectrum of the rotaxane 
6.5. where the CD proton cross-peaks are found. The most downfield CD resonance at 
64.93 is assigned to the CD-C1 anomeric protons. A !H-'H correlation between these 
protons and those giving rise to the signal at 63.46 is seen, and the latter is therefore 
assigned to the CD-C2 protons. Likewise, there is a cross-peak between the resonance 
at 63.46 (CD-C2) and the resonance at 63.86 which is therefore attributed to the CD- 
C3 protons. This resonance at 63.86 (CD-C3) also shows a cross-peak with the 
resonance at 63.57 which is therefore assigned to the CD-C4 protons. Again, the 
resonance at 63.57 (CD-C4) also shows a cross-peak with the resonance at 63.89 
which is therefore assigned to the CD-C5 protons. Finally, the resonances at 63.74 and 
3.59 corresponding to the CD-C6 protons show cross-peaks with each other.
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4 . 0 -
Figure 6.4. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the rotaxane 
6.5 in CD3OD showing cross-peaks between CD proton signals.
The structural assignment can then be completed by analysis of the nuclear 
Overhauser effect (NOE) interactions in the ROESY NMR spectrum. Figure 6.5 
shows a section of the 2D ROESY NMR spectrum with cross-peaks for the aromatic 
protons. Since the signal at 68.10, which integrates for two protons, shows a cross-
peak with the olefinic proton signal at 67.18, these two signals are assigned as the 
aromatic protons E and olefinic proton G respectively. Likewise, the signal at 67.68, 
which integrates for one proton, shows a cross-peak with the olefinic proton signal at 
67.36. Therefore, these signals are assigned as the aromatic proton I and olefinic 
proton F respectively. The signal at 68.13, which integrates for two protons and has 
the same coupling constant as the signal at 68.10 (protons E) is assigned as the 
aromatic protons D. The doublet at 67.39 with the same coupling constant as the
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resonance of proton I is assigned to the resonance of proton J, while the singlet at 
67.25 is assigned to resonance of proton H.
~T. 2 ~
& -------
FI (ppm)
Figure 6.5. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 6.5 
in CD3OD showing cross-peaks between aromatic proton signals.
Figure 6.6 shows a section of the 2D ROESY NMR spectrum with axle and aniline 
aromatic proton resonance cross-peaks with those of methyl and CD protons. The 
presence of the NOE cross-peaks labelled NOE1 and NOE2 indicates the resonances 
at 61.64 and 1.62 correspond to the methyls of the isoindoline moiety in proximity to 
the aromatic proton H (protons K and L), and the resonances at 61.57 and 1.56 
correspond to those in proximity to the aromatic proton J (protons M and N). The 
resonance of aniline protons A and B appears at 67.16. The presence of the NOE 
cross-peaks labelled NOE3 and NOE4 indicates that the resonance at 62.36
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corresponds to the methyls of the 2,6-dimethylaniline moiety (protons C). Looking at 
the cross-peaks between the aromatic and CD protons, the CD orientation can be 
assigned. Protons H, I and J show NOEs with the CD-C5 and CD-C6 protons, hence 
they are next to the narrow end of the CD as shown in Figure 6.6. Overall, from the 
structural assignment of the hydroxylamine 6.5, the analogous nitroxide can be 
assigned as the rotaxane 1.33, which is the orientational isomer of the rotaxane 1.34 
previously reported by Maniam.135
C3 C5 C6tNOE 4
NOE 3 <V %Q E
— N H
C3 C5 C6 NOE 1
NOE 1 NOE 2
M , N  —
K, L ~
NOE 3NOE 4
C4-H C2-H
C6-W -  -
C6-H------C3-H
C5-H
FI (ppm)
Figure 6.6. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 6.5 
in CD3OD showing axle and aniline aromatic proton resonance cross-peaks with those 
of methyl and CD protons.
Figure 6.7 shows the 'H NMR spectrum of the sample corresponding to the HPLC 
peak indicated by the pink asterisk in Figure 6.1. This sample was reduced as shown 
in Scheme 6.3. Figure 6.8 shows the 'H NMR spectrum of this sample in the reduced
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form. The spectral data shown in Figure 6.7 and Figure 6.8 are consistent with those 
of the rotaxane 1.34 and the corresponding hydroxy lamine 6.6 reported by Maniam.135
A____A_
Figure 6.7= 500 MHz 'H NMR spectrum of the rotaxane 1.34 in CD3OD.
HO
if
Scheme 6.3. Reduction of the rotaxane 1.34 to the hydroxylamine 6.6 using ascorbic 
acid 6.4.
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Figure 6.8 . 500 MHz ’H NMR spectrum of the hydroxylamine 6.6 in CD3OD.
Following the successful synthesis of the rotaxanes 1.33 and 1.34, the analogous 
rotaxanes 1.35 and 1.36 with 3,5-dimethylaniline blocking groups were also prepared 
using a similar procedure.13^ The stilbenylnitroxide axle 6.1 was equilibrated with 
excess a-CD 1.1 and two molar equivalents of TEA in water. Then DMT-MM was 
added, followed by 3,5-dimethylaniline 2.2 (Scheme 6.5). TLC of the reaction 
mixture showed a component with a different Rf value to a-CD 1.1, yet showing both 
the UV absorbance of an aromatic compound and the pink colouration characteristic 
of a CD on exposure to acidic naphthalene- 1,3-diol. Although only one new spot 
was detected by TLC, two components that presumably co-eluted on TLC were 
separated by HPLC. ESI mass spectrometry of each component showed a protonated 
molecular ion at m/z 1413 and the desired rotaxanes 1.35 and 1.36 were isolated in 
yields of 30% and 29%.
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5 equiv.
TEA 2 equiv.,
H20
DMT-MM 2 equiv.
2.2
3 equiv.
Scheme 6.4. Synthesis of the nitroxide-based rotaxanes 1.35 and 1.36.
Two fractions, each containing a rotaxane isomer, were collected through HPLC. The 
first eluting fraction was assigned as the rotaxane 1.35 and the later fraction as the 
rotaxane 1.36 by NMR analysis as described below. Figure 6.9 shows the 'H NMR 
spectrum of the first eluting fraction collected through HPLC. NMR analysis was 
carried out in the reduced form 6.7 as shown in Figure 6.10.
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Figure 6.9. 500 MHz 'H NMR spectrum of the rotaxane 1.35 in CD3OD.
8 7 6 5 4 3 2 ppm
Figure 6.10. 500 MHz 'H NMR spectrum of the hydroxylamine 6.7 in CD3OD.
To unambiguously determine the orientation of the CD with respect to the dumbbell 
and assign the structure of the rotaxane 6.7, 2D NMR analysis was carried out 
following the protocol described for the rotaxane 6.5. The CD proton resonances were 
assigned using the DQF-COSY NMR spectrum shown in Figure 6.11. The most 
downfield CD resonance at 64.93 is assigned to the CD-C1 anomeric protons. A 'H- 
'H correlation between these protons and those giving rise to the signal at 63.46 is 
seen, and the latter is therefore assigned to the CD-C2 protons. Likewise, there is a
1 1 1
cross-peak between the resonance at 63.46 (CD-C2) and the resonance at 63.81 which 
is therefore attributed to the CD-C3 protons. This resonance at 63.81 (CD-C3) also 
shows a cross-peak with the resonance at 63.53 which is therefore assigned to the CD- 
C4 protons. Again, the resonance at 63.53 (CD-C4) also shows a cross-peak with the 
resonance at 63.90 which is therefore assigned to the CD-C5 protons. Finally, the 
resonances at 63.72 and 3.58 corresponding to the CD-C6 protons show cross-peaks 
with each other.
C4-H - a e * !« « » -  - «
s ce-H
Figure 6.11. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the 
rotaxane 6.7 in CD3OD showing cross-peaks between CD proton signals.
Assignments were continued by examining a section of the 2D ROESY NMR 
spectrum with cross-peaks for the aromatic protons shown in Figure 6.12. Since the 
signal at 68.13, which integrates for two protons, shows a cross-peak with the olefinic 
proton signal at 67.22, these two signals are assigned as the aromatic protons E and 
olefinic proton G respectively. Likewise, the signal at 67.82, which integrates for one 
proton, shows a cross-peak with the olefinic proton signal at 67.40. Therefore, these 
signals are assigned as the aromatic proton I and olefinic proton F respectively. The 
signal at 68.08, which integrates for two protons and has the same coupling constant 
as the signal at 68.13 (protons E) is assigned as the aromatic protons D. The doublet at 
67.55 with the same coupling constant as the resonance of proton I can be assigned to
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the resonance of proton J, while the singlet at 67.56 can be assigned to resonance of 
proton H.
_  F _
T2 (ppm)
Figure 6.12. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 
6.7 in CD3OD showing cross-peaks between aromatic proton signals.
Figure 6.13 shows a section of the 2D ROESY NMR spectrum with axle and aniline 
aromatic proton resonance cross-peaks with those of methyl and CD protons. The 
presence of the NOE cross-peak labelled NOE1 indicates the resonances at 61.78 
correspond to the methyls of the isoindoline moiety in proximity to the aromatic 
proton J (protons M and N). Likewise, the presence of the NOE cross-peak labelled 
NOE2 indicates the resonances at 61.87 and 1.83 correspond to the methyls of the 
isoindoline moiety in proximity to the aromatic proton H (protons K and L). The 
resonances of aniline protons C appear at 67.48 and the aniline proton A at 66.85. The 
presence of the NOE cross-peaks labelled NOE3 and NOE4 indicates that the 
resonance at 62.35 corresponds to the methyls of the 3,5-dimethylaniline moiety 
(protons B). Looking at the cross-peaks between the aromatic and CD protons, the CD 
orientation can be assigned. As protons D and E show the strongest NOEs with the 
CD-C3 protons, they are next to the wider end of the CD. Protons H, I and J show 
NOEs with CD-C5 and CD-C6 protons, hence they are next to the narrow end of the 
CD as shown in Figure 6.13 and the structure is assigned as the rotaxane 6.7. From
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the structural assignment of the hydroxylamine 6.7, the analogous nitroxide can be 
assigned as the rotaxane 1.35.
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Figure 6.13. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 
6.7 in CD3OD showing axle and aniline aromatic proton resonance cross-peaks with 
those of methyl and CD protons.
Figure 6.14 shows the 'H NMR spectrum of the second eluting fraction collected 
through HPLC. NMR analysis was carried out in the reduced form 6.8 (Figure 6.15).
114
Figure 6.14. 500 MHz !H NMR spectrum of the rotaxane 1.36 in CD3OD.
Figure 6.15. 500 MHz 'H NMR spectrum of the hydroxylamine 6.8 in CD3OD.
Following the standard protocol carried out with the rotaxanes 6.5 and 6.7, the proton 
resonances of the rotaxane 6 .8  were assigned. First, the CD proton resonances were 
assigned in the same manner as described above using the DQF-COSY NMR 
spectrum shown in Figure 6.16. The resonance of the CD-C1 anomeric protons is 
assigned at 64.94. A 'H-'H correlation between these protons and those giving rise to 
the signal at 63.50 is seen, and the latter is therefore assigned to the CD-C2 protons. 
Likewise, there is a cross-peak between the resonance at 63.50 (CD-C2) and the 
resonance at 63.81 which is therefore attributed to the CD-C3 protons. This resonance
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at 63.81 (CD-C3) also shows a cross-peak with the multiplet at 63.57 which is 
therefore assigned to the CD-C4 protons. Again, the resonance at 63.57 (CD-C4) also 
shows a cross-peak with the resonance at 63.88 which is therefore assigned to the CD- 
C5 protons. Finally, the resonances at 63.72 and 3.57 corresponding to the CD-C6 
protons show cross-peaks with each other.
C1-H
JL_
3 . 6 “
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Figure 6.16. A section of the 500 MHz 2D DQF-COSY NMR spectrum of the 
rotaxane 6.8 in CD3OD showing cross-peaks between CD proton signals.
Next the aromatic region was assigned using the 2D ROESY NMR spectrum as 
shown in Figure 6.17. Since the signal at 67.60, which integrates for two protons, 
shows a cross-peak with the olefinic proton signal at 67.46, these two signals are 
assigned as the aromatic protons E and olefinic proton G respectively. Likewise, the 
signal at 68.21, which integrates for one proton, shows a cross-peak with the olefinic 
proton signal at 67.21. Therefore, these signals are assigned as the aromatic proton I 
and olefinic proton F respectively. The signal at 68.05, which integrates for two 
protons and has the same coupling constant as the signal at 67.60 (protons E) is 
assigned as the aromatic protons D. The doublet at 67.56 with the same coupling
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constant as the resonance of proton I can be assigned to the resonance of proton J, 
while the singlet at 67.64 can be assigned to resonance of proton H.
8 . 0 -
8 . 2 -
Figure 6.17. A section of the 500 MHz 2D ROESY NMR spectrum of the rotaxane 
6.8 in CD3OD showing cross-peaks between aromatic proton signals.
Finally, Figure 6.18 shows a section of the 2D ROESY NMR spectrum with axle and 
aniline aromatic proton resonance cross-peaks with those of methyl and CD protons. 
The presence of the NOE cross-peak labelled NOE1 indicates that the resonances at 
61.88 correspond to the methyls of the isoindoline moiety in proximity to the aromatic 
proton H (protons K and L). Likewise, the NOE cross-peak labelled NOE2 indicates 
the resonances at 61.88 correspond to the methyls of the isoindoline moiety in 
proximity to the aromatic proton J (protons M and N). The resonances of the aniline 
protons C appear at 67.40 and the aniline proton A at 66.85. The presence of the NOE 
cross-peaks labelled NOE3 and NOE4 indicate that the resonance at 62.34 
corresponds to the methyls of the 3,5-dimethylaniline moiety (protons B). Looking at 
the cross-peaks between the aromatic and CD protons, the CD conformation can be 
assigned. Protons H, I and J show NOEs with the CD-C3 protons, hence they are next
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to the wider end o f the CD. Protons E show NOEs with CD-C5 and CD-C6 protons, 
hence they are next to the narrow end o f the CD as shown in Figure 6.18, and the 
structure is assigned as the rotaxane 6.8. Thus by inference, the analogous nitroxide is 
assigned as the rotaxane 1.36, which is the orientational isomer o f the rotaxane 1.35 
described above.
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Figure 6.18. A section o f the 500 MHz 2D ROESY NMR spectrum o f the rotaxane 
6.8 in CD3OD showing axle and aniline aromatic proton resonance cross-peaks with 
those o f methyl and CD protons.
An interesting observation from the ID  'H NMR spectra o f the rotaxanes 1.33, 1.34, 
1.35 and 1.36 is that, while the paramagnetic nature o f the nitroxide group caused 
broadening o f stilbene proton resonance peaks, those o f the aniline moiety remained 
sharp. Conceivably this could be due to the lack o f through space interaction between 
the free radical and the aniline blocking group, or it might be attributable to the lack 
o f conjugation between the nitroxide containing axle and the aniline blocking group. 
As discussed in Chapter 4, the conformational analysis o f the rotaxanes 1.9, 4.1, 4.2 
and 1.18 in solution by UV/visible spectroscopy suggests that the 2,6-dimethylaniline 
blocking groups are twisted out-of-plane o f the axle while the 3,5-dimethylaniline
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blocking groups are co-planar to the axle. Hence the 2,6-dimethylaniline blocking 
groups of the rotaxanes 1.33 and 1.34 are most probably rotated out-of-the plane of 
the free radical containing axle, resulting in discontinued conjugation to the aniline 
moieties. On the other hand, the 3,5-dimethylaniline blocking groups of the rotaxanes 
1.35 and 1.36 can be envisaged to be co-planar and hence fully conjugated with the 
free radical containing axle. Therefore, the sharpness of the aniline aromatic and 
methyl proton resonance peaks appears to be independent of the conjugation between 
the aniline blocking group and the axle. Instead, as the aniline protons are the furthest 
from the free radical through space, the nature of the lack of line broadening is
O Q
conceivably due to distance.
To compare the photoisomerisation behaviour of the rotaxanes 1.33 and 1.35 with the 
analogous compound without the CD, the dumbbell 1.37 was prepared following a 
procedure adapted from Maniam. ‘ The stilbenylnitroxide axle 6.1 and BOP was 
added to DMF, followed by the addition of 2,6-dimethylaniline 2.4 and TEA (Scheme 
6.4). The product was isolated in a yield of 47% through reverse phase HPLC. The 
identity of the dumbbell 1.37 was confirmed using 'H NMR spectroscopic and mass 
spectrometric data which were found to be in agreement with those reported 
previously.1^
BOP, TEA,
Scheme 6.7. Synthesis of the dumbbell 1.37.
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The analogous dumbbell 1.38 with 3,5-dimethylaniline in place of 2,6-dimethylaniline 
was also prepared following an analogous procedure. The stilbenylnitroxide axle 6.1 
and BOP was added to DMF, followed by 3,5-dimethylaniline 2.2 and TEA (Scheme 
6.9). ESI mass spectrometry showed an ion at m/z 441, which corresponds to the 
protonated molecular ion, and the product was isolated in a yield of 82% through 
reverse phase HPLC.
BOP, TEA,
Scheme 6.8. The synthesis of the dumbbell 1.38.
NMR analysis was carried out in the reduced form 6.9 (Figure 6.19). The 'H NMR 
spectrum confirmed the presence of the components, showing resonances of the 
styrylisoindoline and arylamino protons.
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Figure 6.19. 500 MHz 'H NMR spectrum of the Hydroxylamine 6.9 in CD3OD.
Having prepared the compounds 1.33, 1.34, 1.35, 1.36, 1.37 and 1.38. investigating 
their photoisomerisation behaviour using UV/visible spectroscopy and HPLC analysis 
was the next objective.
121
CHAPTER 7 - Results and Discussion 
Photoisomerisation of Paramagnetic Profluorescent Nitroxides
7.1 Photoisomerisation Studies Using UV/visible Spectroscopy and HPLC 
Analysis
Having prepared the profluorescent rotaxanes 1.33, 1.34, 1.35 and 1.36, and the 
corresponding dumbbells 1.37 and 1.38, the next objective was to study their 
photoisomerisation. Unlike the dumbbells 1.37 and 1.38, which are virtually insoluble 
in water, the CDs make the rotaxanes 1.33, 1.34, 1.35 and 1.36 water-soluble. 
However, for consistency in experimental conditions, each compound was dissolved 
in an ACN/water mixture to prepare 70 pM solutions. Aliquots (3.5 mL) of each 
solution were transferred to a cuvette and the photoisomerisation was monitored at 
intervals during exposure to 300 nm light using UV/visible spectroscopy. A 
photoreactor equipped with a UV-B fluorescent lamp was used for irradiation.
The UV/visible spectra of the dumbbell 1.37 with a 2,6-dimethylaniline blocking 
group show an absorption band at 324 nm. This is typical for a /rara-stilbene moiety 
with symmetry-allowed jr-jt transition171’172 (Figure 7.1 (a)). Upon irradiation, a 
decrease in absorbance at 324 nm and a corresponding increase in absorbance at 232 
nm corresponding to the czs-stilbene moiety are observed. The photostationary state 
was reached after 10 min of irradiation. While the decrease in absorbance at 324 nm 
reflects the photoisomerisation of the fr<ms-stilbene moiety to the c/s-stilbene moiety, 
it is not a direct measure of the amount of trans-isomer present in solution as the cis- 
stilbene moiety also absorbs at 324 nm, but with a lower molar absorbance.
When the dumbbell 1.37 is protected by a-CD, the UV/visible spectra of the isomeric 
rotaxanes 1.33 (Figure 7.1 (b)) and 1.34 (Figure 7.1 (c)) both show trans-cis 
isomerisation over 10 min as described above. The significantly smaller change in 
absorbance upon irradiation of the isomeric rotaxanes 1.33 and 1.34 indicates that the 
trans-cis isomerisation is restricted compared to the unprotected dumbbell 1.37.
The analogous compounds with 3,5-dimethylaniline blocking groups show similar 
behaviour where the dumbbell 1.38 photoisomerises readily (Figure 7.1 (d)) as per
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the dumbbell 1.37, while the isomeric rotaxanes 1.35 and 1.36 show restricted trans- 
cis isomerisation as per the rotaxanes 1.33 (Figure 7.1 (e)) and 1.34 (Figure 7.1 (f)).
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Figure 7.1. UV/visible spectra of 70 pM solutions of (a) the dumbbell 1.37, (b) the 
rotaxane 1.33, (c) the rotaxane 1.34, (d) the dumbbell 1.38, (e) the rotaxane 1.35 and 
(f) the rotaxane 1.36 in ACN/water monitored at time intervals during exposure to 300 
nm light.
To determine and quantity the amount of cis and trans isomers present in solution, the 
photoisomerisation of the dumbbells 1.37 and 1.38 alone and when they are included
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in a-CD in the form of the rotaxanes 1.33, 1.34, 1.35 and 1.36 was also monitored 
using HPLC. Compounds were first dissolved in ACN/water. Then, aliquots (300 pL) 
of each solution were sealed and bubbled with nitrogen to maintain an inert 
atmosphere before being exposed to light at 300 nm at time intervals. Aliquots (20 
pL) of the irradiated solution were sampled and subject to HPLC analysis after each 
time interval. In each case, the HPLC chromatogram was monitored at the isosbestic 
UV absorbance point. At the isosbestic point, the molar absorptivity of the cis and 
tram isomers is the same. Therefore the relative proportions of each isomer present 
can be quantified by comparing the area underneath each peak.
When monitoring the HPLC chromatogram at the isosbestic point (280 nm) of the 
dumbbell 1.37, the peak at 7.9 min corresponding to the dumbbell 1.37 decreased 
upon irradiation, which was accompanied by an increase in a peak at 8.6 min over 
time. Mass spectrometric analysis showed that the mass of the material that eluted at 
8.6 min has the same mass as the dumbbell 1.37. The UV/visible profile of this 
material showed absorption bands at 232 and 293 nm, which correspond to the 
absorbance of a c/s-stilbene moiety. Hence, the peak at 8.6 min is assigned to the 
cis isomer of the dumbbell 1.37. After 10 min of irradiation, peak intensities no longer 
changed, indicating that the photostationary state was reached. This is consistent with 
the time required for the photostationary state to be reached with the UV/visible 
studies as shown above. The solution at the photostationary state contained 30% of 
the tram and 70% of the cis isomer (Figure 7.2).
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Figure 7.2. HPLC chromatograms of a solution of the dumbbell 1.37 in ACN/water 
monitored at time intervals during exposure to 300 nm light (monitored at 280 nm). 
Each chromatogram is offset for clarity.
Likewise, the HPLC chromatograms of the mixtures obtained after irradiation of a 
solution of the rotaxane 1.33 showed a decrease in the peak at 5.7 min corresponding 
to the rotaxane 1.33, which was accompanied by an increase in a peak at 7.2 min. 
Following the analysis above, the material that eluted at 7.2 min has the same mass as 
the rotaxane 1.33 and the absorbance of a cfv-stilbene moiety. Hence the peak at 7.2 
min is assigned to the cis isomer of the rotaxane 1.33. The solution at the 
photostationary state contained 84% of the tram and 16% of the cis isomer (Figure 
7.3).
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Figure 7.3. HPLC chromatograms of a solution of the rotaxane 1.33 in ACN/water 
monitored at time intervals during exposure to 300 nm light (monitored at 290 nm). 
Each chromatogram is offset for clarity.
Figure 7.4 shows a section of the HPLC chromatograms of the mixtures obtained 
after irradiation of a solution of the rotaxane 1.34. The peak at 6.8 min corresponding 
to the rotaxane 1.34 decreased upon irradiation, which was accompanied by an 
increase in a peak at 6.6 min over time. Again, the peak at 6.6 min is assigned to the 
cis isomer of the rotaxane 1.34 from mass spectrometric data and UV/visible analysis. 
The solution at the photostationary state contained 87% of the tram and 13% of the 
cis isomer.
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Figure 7.4. HPLC chromatograms of a solution of the rotaxane 1.34 in ACN/water
monitored at time intervals during exposure to 300 nm light (monitored at 290 nm). 
Each chromatogram is offset for clarity.
Upon irradiation of the dumbbell 1.38 solution, the peak at 12.5 min corresponding to 
the dumbbell 1.38 decreased, while a peak at 13.1 min increased (Figure 7.5). The 
peak at 13.1 min is assigned to the cis isomer of the dumbbell 1.38 using the 
procedure above. The solution at the photostationary state contained 40% of the tram 
and 60% of the cis isomer.
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Figure 7.5. HPLC chromatograms of a solution of the dumbbell 1.38 in ACN/water 
monitored at time intervals during exposure to 300 nm light (monitored at 288 nm). 
Each chromatogram is offset for clarity.
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In the HPLC chromatograms of the mixtures obtained after irradiation of a solution of 
the rotaxane 1.35 (Figure 7.6), a decrease in the peak corresponding to the rotaxane 
1.35 at 7.6 min was observed, as well as an increase in a peak corresponding the cis 
isomer of the rotaxane 1.35 at 10.3 min. The solution at the photostationary state 
contained 88% of the trans and 12% of the cis isomer.
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Figure 7.6. HPLC chromatograms of a solution of the rotaxane 1.35 in ACN/water 
monitored at time intervals during exposure to 300 nm light (monitored at 290 nm). 
Each chromatogram is offset for clarity.
Finally, a section of the HPLC chromatograms of the mixtures obtained after 
irradiation of a solution of the rotaxane 1.36 is shown in Figure 7.7. The peak at 9.6 
min corresponding to the rotaxane 1.36 decreased upon irradiation, which was 
accompanied by an increase in a peak for the cis isomer of the rotaxane 1.36. The 
solution at the photostationary state contained 88% of the trans and 12% of the cis 
isomer.
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Figure 7.7. HPLC chromatograms of a solution of the rotaxane 1.36 in ACN/water 
monitored at time intervals during exposure to 300 nm light (monitored at 290 nm). 
Each chromatogram is offset for clarity.
Through formation of CD-based rotaxanes, the profluorescent probes of all four of the 
rotaxanes 1.33, 1.34, 1.35 and 1.36 are better preserved than the dumbbells 1.37 and 
1.38. At the photostationary state, the CDs limit trans-cis isomerisation of the 
dumbbells 1.37 and 1.38 to 16% or less. Given that the fluorescence of cz's-stilbenes is 
less than 1% of that from /rara-stilbenes,111 the profluorescent properties of the 
rotaxanes 1.33, 1.34, 1.35 and 1.36 are preserved by at least 84%. In comparison, the 
dumbbells 1.37 and 1.38 show up to 70% trans-cis isomerisation. When 
profluorescent probes are used to detect free radicals in material, sufficient exposure 
would be required for the profluorescent probes to reach their photostationary state. 
Consequently, the composition of trans and cis isomers present in irradiated mixtures 
is likely to vary depending on the amount of trans-cis isomerisation that occurred. 
Based on up to 16% trans-cis isomerisation observed with the rotaxanes 1.33, 1.34, 
1.35 and 1.36, the amount of the profluorescent probes of rotaxanes preserved in 
material is expected to vary between 84-100%. Those of dumbbells are expected vary 
between 30-100% based on up to 70% trans-cis isomerisation observed with the 
dumbbells 1.37 and 1.38. Hence detection of free radicals using the rotaxanes 1.33, 
1.34, 1.35 and 1.36 is advantageous, as the error associated is less than a quarter of 
that using the dumbbells 1.37 and 1.38.
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The photoisomerisation studies by HPLC analysis are consistent with the UV/visible 
studies that show restricted trans-cis isomerisation when the stilbene moiety is 
protected by the CD. The restricted trans-cis isomerisation is presumably because the 
size of the a-CD cavity is not large enough to accommodate a c/s-stilbene moiety, and 
the length of the dumbbell is not sufficient for the a-CD to shift away from the 
stilbene moiety such that trans-cis isomerisation can occur.26
The dumbbell 1.37 isomerises somewhat more extensively than the dumbbell 1.38. 
According to the UV/visible spectra of the dumbbells 1.37 and 1.38. the molar 
absorptivity of the trans-dumbbeU 1.37 is stronger than the trans-dumbbell 1.38 at 
300 nm. As a result, the rate of trans-cis isomerisation is greater for the dumbbell 
1.37. On the other hand, the molar absorptivity of the c/T-dumbbell 1.37 is weaker 
than the dumbbell 1.38 at 300 nm. Hence the rate of cis-trans isomerisation is smaller 
for the dumbbell 1.37. This results in a photostationary state containing a lower 
concentration of the trans isomer and higher concentration of the cis isomer for the 
dumbbell 1.37 such that the overall rate of trans-cis isomerisation is equal to the rate 
of trans-cis isomerisation.
The amount of trans-cis isomerisation is similar between the isomeric rotaxanes 1.33 
and 1.34. The small difference may be attributable to the slight difference in the 
location of the CDs on the dumbbells, which may affect their abilities to 
photoisomerise. The amount of trans-cis isomerisation is the same for the isomeric 
rotaxanes 1.35 and 1.36. The rotaxanes with a 2,6-dimethylaniline blocking group 
1.33 and 1.34, and the rotaxanes with a 3,5-dimethylaniline blocking group 1.35 and
1.36 show similar amounts of trans-cis isomerisation. This suggests that when the 
dumbbells 1.37 and 1.38 are protected in a-CD in the form of rotaxanes, the two 
different blocking groups have little effect on the photoisomerisation as the CDs 
restrict isomerisation.
7.2 Retention of the Profluorescent Probe Under Extreme Conditions
Given that protecting the stilbene moieties in CDs in the form of rotaxanes restricts 
photoisomerisation, the profluorescent probes of the rotaxanes 1.33, 1.34, 1.35 and
1.36 are better preserved than the dumbbells 1.37 and 1.38 at their photostationary
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States. For detection of free radicals in cells, in pollution and for monitoring material 
degradation, profluorescent probes may be exposed to intense UV irradiation or used 
for monitoring degradation over a long period of time. Hence it was of interest to 
study whether the profluorescent probes of the rotaxanes 1.33, 1.34, 1.35 and 1.36 
would still be preserved even under more extreme conditions such as longer exposure 
and more intense irradiation. Due to time constraints, it was not feasible to monitor 
the profluorescent probes over extended periods of time. Hence to simulate long term 
exposure in an accelerated manner, solutions of the compounds 1.33, 1.34, 1.35, 1.36, 
1.37 and 1.38 were irradiated with UV light over 24 h using the method described 
above. Each solution was subject to HPLC analysis before and after irradiation for 24 
h while chromatograms were obtained at the wavelengths identical to the above 
(isosbestic points) and the relative proportions of each material present in solution 
were measured by peak area.
Figure 7.8 (a) shows the HPLC chromatograms of the dumbbell 1.37 solution before 
irradiation, and the mixture obtained after irradiation. After irradiation, the peak at 7.9 
min corresponding to the trans isomer decreased, while the intensity of two major 
peaks at 8.6 min corresponding to the cis isomer, and 9.0 min increased. c/T-Stilbenes 
are known to undergo electrocyclisation to give dihydrophenanthrenes, which can 
oxidise to form phenanthrenes.146'147 Mass spectrometric analysis of the irradiated 
solution showed an ion at m/z 440, which corresponds to the trans- and czs-dumbbells 
1.37, as well as an ion at m/z 438, which is two mass units smaller than that of the 
trans- and cA-dumbbells 1.37. The UV/visible profile of this material showed an 
absorption band at 258 nm, which corresponds to the absorbance of a phenanthrene 
moiety. Hence, the peak at 9.0 min is assigned to the phenanthrene 7.1. There are 
minor peaks unaccounted for, which presumably result from decomposition due to 
intense irradiation. The solution contained 19% of the trans isomer and 45% of the cis 
isomer. From the chromatogram shown in Figure 7.8 (a), the amount of the 
phenanthrene 7.1 present in solution cannot be obtained without the molar 
absorptivity of the compound at the measured wavelength. Hence an estimate was 
made by assuming that phenanthrenes have the same molar absorptivity as cis and 
/zwzs-stilbenes at the isosbestic point of the latter two. Based on this assumption, the 
amount of the phenanthrene 7.1 in solution is 33% by peak area, which leaves 3% of 
materials unaccounted for.
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The HPLC chromatogram of the mixture obtained after irradiation of the rotaxane 
1.33 solution showed the peak at 5.7 min corresponding to the tram isomer decreased, 
which was accompanied by an increase in a peak at 7.2 min corresponding to the cis 
isomer and other unknown peaks (Figure 7.8 (b)). The irradiated solution consisted of 
70% of the tram isomer and 14% of the cis isomer, leaving 16% of materials 
unaccounted for.
The mixture obtained after irradiation of the rotaxane isomer, the rotaxane 1.34, 
showed the peak at 6.8 min corresponding to the tram isomer decreased and an 
increase in a peak at 8.1 min corresponding to the cis isomer as well as other 
unknown peaks (Figure 7.8 (c)). Overall, the resulting solution was made up of 70% 
of the tram isomer and 12% of the cis isomer, leaving 18% of materials unaccounted 
for.
Similar to the dumbbell 1.37. the mixture obtained after irradiation of the dumbbell 
1.38 showed the peak at 12.5 min corresponding to the tram isomer decreased, which 
was accompanied by an increase in two major peaks at 13.1 min corresponding to the 
cis isomer, and 14.1 min (Figure 7.8 (d)). The peak at 14.1 min is assigned to the 
phenanthrene 7.2 from mass spectrometric data and UV/visible analysis as above. 
Based on the assumption that phenanthrenes have the same molar absorptivity as 
tram- and c/s-stilbenes, a solution containing 30% of the tram isomer, 36% of the cis 
isomer, 31% of the phenanthrene 7.2 and 3% of materials that are unaccounted for 
resulted.
The HPLC chromatogram of the mixture obtained after irradiation of the rotaxane 
1.35 showed the peak at 7.6 min corresponding to the tram isomer decreased, which 
was accompanied by an increase in peaks at 10.3 min corresponding to the cis isomer 
and others at higher retention times (Figure 7.8 (e)). Consequently a solution 
containing 60% of the trans isomer, 8% of the cis isomer, and 32% of materials that 
are unaccounted for resulted.
The HPLC chromatogram of the mixture obtained after irradiation of the rotaxane 
isomer, the rotaxane 1.36, showed the tram isomer peak at 9.6 min decreased, and 
increase in peaks at 7.6 min corresponding to the cis isomer as well as other retention
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times (Figure 7.8 (f)). After irradiation, the solution contained 69% of the trans 
isomer and 13% of the cis isomer leaving 18% of materials unaccounted for.
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Figure 7.8. HPLC chromatograms of 20 pM solutions of (a) the dumbbell 1.37, (b) 
the rotaxane 1.33, (c) the rotaxane 1.34, (d) the dumbbell 1.38, (e) the rotaxane 1.35 
and (f) the rotaxane 1.36 in ACN/water before irradiation, and after exposure to 300 
nm light for 24 h (obtained at the isosbestic point of tram and cis isomers of the 
related compound). Each chromatogram is offset for clarity.
Overall, the pro fluorescent probes of the rotaxanes 1.33, 1.34, 1.35 and 1.36 are better 
preserved compared to the dumbbells 1.37 and 1.38 even after extended exposure to 
UV light. Furthermore, oxidised by-products were not detected when the stilbene
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moieties are protected by the CD cavity. The oxidised by-products are formed via 
conversion of /r<ms-stilbenes to their cis isomers, which can then undergo cyclisation 
and oxidation to form phenanthrenes. One possible explanation for the lack of 
phenanthrene formation from the rotaxanes 1.33, 1.34, 1.35 and 1.36 could be the 
lower conversion to their cis isomers. Due to the small quantities of cis isomers 
forming, the subsequent cyclisation and oxidation products may not be forming in 
detectable amounts. Another possible explanation may be the limited size of an a-CD 
which may prevent the phenyl rings of cA-stilbenes from being in the same plane, 
which is required for the cyclisation. Although the profluorescent probes of the 
rotaxanes 1.33, 1.34, 1.35 and 1.36 are better preserved compared to the dumbbells
1.37 and 1.38. more non-specific decomposition was detected in the irradiated 
mixtures of the rotaxanes 1.33, 1.34, 1.35 and 1.36. As observed in the UV/visible 
spectra above, trans-stilbenes have a higher molar absorptivity than cA-stilbenes at 
300 nm. Hence when more material remains in the form of /r<ms-stilbenes as observed 
with the rotaxanes 1.33, 1.34, 1.35 and 1.36, extended irradiation at 300 nm may 
cause further non-specific decomposition that gives rise to peaks of unaccounted 
materials.
Under natural circumstances entailing a broader spectrum and lower intensity of light, 
non-specific decomposition is less likely. As a result, the fluorescent probes of the 
rotaxanes 1.33, 1.34, 1.35 and 1.36 are expected to be better preserved, and 
consequently, the vast majority of the rotaxanes 1.33, 1.34, 1.35 and 1.36 would each 
be present as a single species. On the other hand, it is probable that the dumbbells
1.37 and 1.38 would undergo trans-cis isomerisation and irreversible phenanthrene 
formation under natural circumstances causing loss of fluorescent probes. When a 
single species with known profluorescent properties abstracts free radicals and causes 
fluorescence, radical degradation can be monitored accurately by measuring the 
fluorescence emission. In comparison, when a mixture of profluorescent compounds 
are present, the species present in the mixture and the profluorescent properties of 
each species are required for quantitative analysis of radical degradation. The amount 
of trans-cis isomerisation, cyclisation and phenanthrene formation of the dumbbells
1.37 and 1.38 can be expected to vary depending on the duration, intensity and type of 
irradiation as well as the penetration of irradiated light to the matrix that contains the
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profluorescent probes and the amount of oxygen present that could oxidise 
dihydrophenanthrenes to phenanthrenes. The number of variables makes it difficult to 
predict the species present in a given mixture. Therefore it would be advantageous to 
use the rotaxanes 1.33, 1.34, 1.35 and 1.36 rather than the dumbbells 1.37 and 1.38 
for monitoring free radicals.
7.3 Conclusion
The profluorescent probes of the dumbbells 1.37 and 1.38 were preserved through 
formation of the CD-rotaxanes 1.33, 1.34, 1.35 and 1.36 making them advantageous 
for fluorescence detection. In addition, through formation of the CD-rotaxanes 1.33, 
1.34, 1.35 and 1.36, the hydrophobic stilbene moieties of the dumbbells 1.37 and 1.38 
are encapsulated in the cavity of CDs. As a result, the profluorescent probes that are 
otherwise virtually insoluble in water are now water-soluble. This enables the 
fluorescent probes to be used under physiological conditions and in in vivo studies. In 
this study, samples were exposed to intense irradiation compared to intensities natural 
light would provide. Under natural circumstances, the rotaxanes 1.33, 1.34, 1.35 and
1.36 are expected to be predominantly preserved, while the dumbbells 1.37 and 1.38 
will undergo decomposition.
For the rotaxanes 1.33, 1.34, 1.35 and 1.36 to be used to monitor radical degradation, 
the profluorescent properties of the dumbbells 1.37 and 1.38 must be maintained. To 
study if the profluorescent properties of the dumbbells 1.37 and 1.38 are preserved 
when they are insulated in CDs in the form of the rotaxanes 1.33, 1.34, 1.35 and 1.36, 
preliminary work has been carried out to measure the fluorescence of the nitroxides 
1.33, 1.34, 1.35, 1.36, 1.37 and 1.38 in their reduced hydroxylamine forms. Upon 
reduction, each of the nitroxides 1.33, 1.34, 1.35, 1.36, 1.37 and 1.38 showed similar 
fluorescence. Therefore the rotaxanes 1.33, 1.34, 1.35 and 1.36 are suitable for use as 
profluorescent probes. Future work to determine the profluorescent behaviour of the 
products of irradiation of the rotaxanes 1.33, 1.34, 1.35 and 1.36, and the dumbbells
1.37 and 1.38 is beyond the scope of this work. When a mixture of species is present, 
the fluorescence is not exclusively due to the fluorescence of the trans-stilbene 
moiety. Instead, each species may affect the overall fluorescence of the mixture. To 
measure the fluorescence due to the profluorescent probes, determining the 
composition of the species present after irradiation and the fluorescence quantum
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yields of each species is required. Nonetheless, due to the profluorescent probes of the 
rotaxanes 1.33, 1.34, 1.35 and 1.36 being preserved, the fluorescent properties of 
these compounds are also preserved. Consequently, CD-based rotaxanes with 
profluorescent nitroxides can be used for monitoring radical degradation.
Since CDs have many hydroxyl groups that can be functionalised, they can be 
covalently attached to polymers.174' 176 Hence preparation of CD-based rotaxanes can 
be a useful method to incorporate the profluorescent probes into polymers to monitor 
degradation. Furthermore, CD-based rotaxane formation is a promising method to 
change the reactivity of compounds that can be exploited as CD guests and preserve 
the properties of CD guests, making this method ideal for material science 
applications.
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CHAPTER 8 - Experimental
8.1 General
NMR spectroscopy was conducted using a Varian Inova 500 MHz spectrometer 
operating at 500 MHz for *H NMR and 125.7 MHz for 13C NMR spectroscopy, a 
Varian Mercury 300 MHz spectrometer operating at 300 MHz for 'H NMR and 75.5 
MHz for 13C NMR spectroscopy, or a Bruker Avance 800 MHz spectrometer 
operating at 200 MHz for l3C NMR spectroscopy. 8 h And 8 C values are reported in 
parts per million (ppm), while ./values are given in Hz. CD3OD was referenced at 8  = 
3.31 for 'H and 49.0 for 13C NMR spectroscopy. DMSO-d  ^was referenced at 8  = 2.50 
for 'H and 39.5 for l3C NMR spectroscopy. CDiCbwas referenced at 8  = 5.32 for 'H 
and 54.0 for l3C NMR spectroscopy. CDCI3 was referenced at 8  = 77.2 for ,3C NMR 
spectroscopy. Acetone was referenced at 8  = 2.05 for 'H NMR spectroscopy.
Low resolution (LR) electrospray ionisation (ESI) mass spectra were recorded using a 
Micromass-Waters LC-ZMD single quadrupole liquid chromatograph mass 
spectrometer. LR mass spectral data are reported as mass-to-charge ratios (m/z). 
Assignments and percentage abundances are reported where in parentheses. High 
resolution (HR) ESI mass spectra were recorded using a Waters LCT premier1 M XE 
orthogonal acceleration time-of-flight (oa-TOF) mass spectrometer, while HR 
electron impact (El) mass spectra were recorded using a Micromass VG AutoSpec M 
mass spectrometer. HR mass spectral data are reported as mass-to-charge ratios (m/z).
Thin layer chromatography (TLC) was performed on Merck Silica gel 60 F254 TLC 
plates, visualised with a 254 nm UV lamp and by treatment with a naphthalene-1,3- 
diol solution (0.1% w/v) in ethanol:water.H2SO4 (200:157:43 v/v/v) followed by 
heating. 138
Elemental analyses were performed by the Australian National University 
Microanalytical Service. Melting points were recorded using an SRS OptiMelt 
Automated Melting Point System.
Analytical high performance liquid chromatography (HPLC) was performed with a 
Waters 2695 Separation Module with a Waters 2996 Photodiode Array Detector 
running with Empower 2 software. Semi-preparative and preparative HPLC were
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performed with a Waters 600 Controller with a Waters 717 plus Autosampler and a 
Waters 2996 Photodiode Array Detector running with Empower Pro Empower 2 
software. Eluting fractions were collected using a Waters Fraction Collector III. 
Preparative HPLC was carried out using a Grace Alltima C l8 5 pm, 22 x 250 mm 
with a Grace Alltima C l8 10 pm, 33 mm guard column or a Waters XBridge Prep 
Cl 8 5 pm, 19 x 150 mm column. A Phenomenex Luna 5 pm C l8(2) 100 Ä, 10 x 250 
mm column was used for semi-preparative HPLC. A YMC Pack ODS-AQ 3 pm, 150 
x 3.0 mm column was used for analytical HPLC. A prepacked ODS column 
[LiChroprep RP-18, size B (25 x 310 mm), Merck] was used for low-pressure RP 
column chromatography. Waters clear glass snap neck total recovery vials (12 x 32 
mm) or Grace shell vials (8 x 30 mm) were used for analytical HPLC.
UV/visible spectrophotometric studies were conducted using a Shimadzu UV-2450 
UV/visible spectrophotometer with a Shimadzu CPS-temperature controller running 
with UV Probe Version 2.10 software. A Luzchem photoreactor was used to irradiate 
samples using UV-B fluorescent lamps (8 W) for 300 nm irradiation.
Crystal data collections were undertaken using a Nonius Kappa CCD diffractometer. 
The structures were solved by Dr Anthony C. Willis at the Research School of 
Chemistry, Australian National University. Further refinements were undertaken by 
Prof. Peter J. Steel at University of Canterbury. Discovery Studio 3.1 was used to 
visualise crystal structures.
Microscope images were obtained using an OLYMPUS SZ40 binocular optical 
microscope fitted with a cross-polarising lens. Scanning electron microscope (SEM) 
images were obtained by the Research School of Biological Science Electron 
Microscopy Unit, using a Zeiss UltraPlus FESEM microscope.
a-CD 1.1 (99.1% purity) was purchased from Nihon Shokuhin Kako Co., Japan and 
dried overnight under vacuum at 60 C to constant weight before use. Azobenzene- 
4,4'-dicarboxy lie acid 2.1, azobenzene-4,4'-dicarbonyl dichloride 4.3 and 2,4,6- 
trinitrobenzene-1-sulfonic acid sodium salt dihydrate 5.3 were purchased from Tokyo 
Kasei Kogyo Co. Ltd., Japan. Stilbene-4,4’-dicarboxylic acid 1.9 was purchased from
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Alfa Aesar, USA. TEA, DMT-MM, 3,5-dimethylaniline 1.8, 2,6-dimethylaniline 1.10, 
PPh3 , 4-vinylaniline 5.7, 4-iodobenzoic acid 5.8 and palladium(II) acetate were 
purchased from Aldrich, USA. BOP was purchased from Merck, Germany. The acid
6.1 was prepared by Prof. Steven Bottle’s group, Queensland University of 
Technology, Brisbane. Water was purified using an ELGA Purelab Classic UV 
system.
8.1.1 Procedure to Prepare Buffer Solutions
0.2 M Sodium Carbonate Buffer (pH 10.0, 0.2 M)
A solution of 100 mL of 0.2 M sodium carbonate buffer (pH 10.0) was prepared by 
adding NaHCCE (1.13 g) and Na2 CC>3 (0.69 g) to a 100 mL volumetric flask, adjusting 
the pH with either HC1 or NaOH and adding water to make 100 mL.
0.5 M Sodium Phosphate Buffer (pH 7.0)
A solution of 1.0 L of 0.5 M sodium phosphate buffer (pH 7.0) was prepared by 
adding NaH2 P0 4 .2 H2 0  (78.0 g) to a 1.0 L volumetric flask, adjusting the pH with 
NaOH and adding water to make 1.0 L.
8.1.2 Procedure to Record NMR Spectra of Free Radical Species
For NMR spectroscopic analysis in Section 8.6: Ascorbic acid 6.4 was added to 
DMSO-t/ö until it no longer dissolved. 3 Drops of saturated ascorbic acid in DMSO-db 
were added to NMR sample solutions (ca. 700 pL) before the mixture was shaken. 
The resulting solution was left to stand for 3 days to ensure that paramagnetic 
nitroxide radicals were fully reduced to their corresponding diamagnetic 
hydroxylamines.
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8.2 Experimental for Chapter 2
|//Yiws-4,4’-Bis(3,5-dimethylphenylaminocarbonyl)azobenzene]-[a-cyclodextrin]- 
[2]rotaxane 1.9
A mixture of the azobenzene 2.1 (100 mg, 3.7 x 1 O'4 mol) and a-CD 1.1 (3.0 g, 3.1 x 
10'3 mol) in 0.2 M sodium carbonate buffer (pH 10, 25 mL) was equilibrated for 2 h at 
room temperature. DMT-MM (1.6 g, 5.6 x 10'3 mol) and 3,5-dimethylaniline 2.2 (180 
mg, 1.5 x 10' mol) were added to the reaction mixture and stirred overnight at room 
temperature. Water (70 mL) was added to the reaction mixture and the mixture was 
washed with EtOAc (3 x 100 mL). The aqueous layer was concentrated under reduced 
pressure. The resulting mixture was dissolved in MeOH and purified by HPLC. The 
fractions containing the product 1.9 were concentrated and lyophilised to give the title 
compound 1.9 (16 mg, yield 3%) as orange powder.
Physical and spectral properties were consistent with those reported previously.
TLC (5:4:3:2 v/v/v/v /-propanol:ethanol:water:acetic acid) /?f 0.80.
Melting point 306-308 °C (dec.) [lit.135 307-308 °C (dec.)].
'H NMR (500 MHz, CD3OD) 5,i 8.65 (2H, d. J  8.5, Azo-H), 8.26 (2H, d, J  8.5, Azo- 
H), 8.20 (2H, d, J  8.5, Azo-H), 8.04 (2H, d. J  8.5, Azo-H), 7.46 (2H, s, aniline-H), 
7.37 (2H, s, aniline-H), 6.87 (1H, s, aniline-H), 6.86 (1H, s, aniline-H), 4.88 (6H, d, J  
3.0, CD-C1-H), 3.83-3.80 (6H, m, CD-C5-H), 3.75-3.72 (12H, m, CD-C3-H and CD- 
C6-H), 3.58 (6H, m, CD-C6-H), 3.51 (6H, apparent t, J  9.0, CD-C4-H), 3.43 (6H, dd, 
J3.0, 9.5, CD-C2-H), 2.36 (6H, s, Me), 2.34 (6H, s, Me).
Mass spectrum (ESI, positive ion mode) m/z (%) 1450 [(M+H+), 35], 1472 
[(M+Na+), 100].
HPLC (Preparative) /r  5.8 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min MeOH/H20 50:50 isocratic, detection wavelength: 352 nm].
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[//Y//fs-4,4’-Bis(2,6-dimethylphenylaininocarbonyl)stilbene]-[a-cyclodextrin]- 
[2]rotaxane 1.10
The stilbene 2.3 (50 mg, 1.9x1 O'4 mol) was suspended in a saturated solution of a- 
CD 1.1 in water (25 mL) and TEA (57 mg, 5.6 x 10'4 mol) was then added to the 
mixture to solubilise the stilbene 2.3. The mixture was sonicated to allow 
equilibration for 2 h at room temperature. DMT-MM (206 mg, 7.4 x 1 O’4 mol), 2,6- 
dimethylaniline 2.4 (113 mg, 9.3 x 10‘4mol) and TEA (57 mg, 5.6 x 10'1 mol) were 
added to the reaction mixture and stirred overnight at room temperature. After another 
addition of DMT-MM (206 mg, 7.4 x 10'4 mol), the reaction mixture was stirred 
overnight. Water (70 mL) was added to the reaction mixture and the mixture was 
washed with EtOAc (3 x 100 mL). The aqueous layer was concentrated under reduced 
pressure. The resulting mixture was dissolved in MeOH and purified by HPLC. The 
fractions containing the product 1.10 were concentrated and lyophilised to give the 
title compound 1.10(11 mg, yield 14%) as colourless powder.
Physical and spectral properties were consistent with those reported previously.177
TLC (5:4:3 v/v/v /7-butanol:ethanol:water) /?f 0.74.
Melting point 275-277 °C (dec.) [lit.177 275 °C (dec.)].
’H NMR (500 MHz, CD3OD) 5„ 8.14 (4H, s, stilbene-H), 8.10 (2H, d, J  8.5, stilbene- 
H), 7.72 (2H, d, J  8.5, stilbene-H), 7.50 (1H, d, J  16.5, olefinic-H), 7.35 (1H, d, J
16.5, olefinic-H), 7.16 (6H, apparent s, aniline-H), 4.94 (6H, d, J  3.5, CD-C1-H), 
3.91-3.87 (12H, m, CD-C3-H and CD-C5-H), 3.75 (6H, dd, J3.5, 12.0, CD-C6-H), 
3.61 (6H, dd, J  1.5, 12.0, CD-C6-H), 3.57 (6H, t, y 9.0, CD-C4-H), 3.47 (6H, dd, J
3.5, 10.0, CD-C2-H), 2.35 (6H, s, Me), 2.30 (6H, s, Me).
Mass spectrum (ESI, positive ion mode) m/z (%) 1448 [(M+H+), 90], 1470 
[(M+Na+), 30].
HPLC (Preparative) /r  9.2 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min MeOH/H20 30:70 isocratic, detection wavelength: 334 nm].
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|//*fl/is-4,4’-Bis(3,5-diiiiethylphenylaminocarbonyl)stilbene|-[a-cyclodextrinl- 
[2]rotaxane 1.17
The stilbene 2.3 (100 mg, 3.7 x 1 O'4 mol) was suspended in water (25 mL) and TEA 
(110 mg, 1.1 x 10° mol) was then added to the mixture to solubilise the stilbene 2.3. 
a-CD 1.1 (1.8 g, 1.9 x 10° mol) was added and the mixture was sonicated to allow 
equilibration for 2 h at room temperature. DMT-MM (1.6 g, 5.6 x 10'3mol), 3,5- 
dimethylaniline 2.2 (180 mg, 1.5 x 10'3 mol) and TEA (110 mg, 1.1 x 10'3 mol) were 
added to the reaction mixture and stirred for 2 h at room temperature. After another 
addition of DMT-MM (1.6 g, 5.6 x 10' mol), the reaction mixture was stirred 
overnight. Water (70 mL) was added to the reaction mixture and the mixture was 
washed with EtOAc (3 x 100 mL). The aqueous layer was concentrated under reduced 
pressure. The resulting mixture was dissolved in MeOH and purified by HPLC. The 
fractions containing the product 1.17 were concentrated and lyophilised to give the 
title compound 1.17 (8 mg, yield 2%) as colourless powder. Crystals of the rotaxane 
1.17 were obtained through slow evaporation of MeOH/water over a period of several 
weeks.
TLC (5:4:3 v/v/v /7-butanol:ethanol:water) Rf 0.80.
Melting point 290-291 °C (dec.).
'H NMR (500 MHz, CDjOD) 5H 8.12 (2H, d, J  8.0, stilbene-H), 8.08 (2H, d, 8.0, 
stilbene-H), 8.04 (2H, d, J  8.0, stilbene-H), 7.67 (2H, d, 8.0, stilbene-H), 7.48 (1H, 
d, J  16.0, olefinic-H), 7.39 (2H, s, aniline-H), 7.34 (2H, s, aniline-H), 7.32 (1H, d, J  
16.0, olefinic-H), 6.84 (2H, apparent s, aniline-H), 4.94 (6H, d, J3.0, CD-C1-H), 3.90 
(6H, m, CD-C5-H), 3.87 (6H, m, CD-C3-H), 3.75 (6H, dd, J3.5, 12.0, CD-C6-H), 
3.60 (6H, m, CD-C6-H), 3.57 (6H, m, CD-C4-H), 3.47 (6H, dd, J3.0, 10.0, CD-C2- 
H), 2.34 (6H, s, Me), 2.33 (6H, s, Me).
,3C NMR (125.7 MHz, CD3OD) 6c 168.9 and 167.8 (C=0), 140.6, 140.1, 139.6(4), 
139.5(7), 136.6, 136.0, 134.0, 133.3, 131.7, 130.4, 129.6, 129.2, 129.1, 127.8, 127.3, 
127.3, 120.2, 104.0, 83.3, 75.1, 73.9, 73.8. 61.5, 21.5 (Me, two coincident 
resonances).
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Mass spectrum m/z (ESI-HR, positive ion mode) Found 1469.5372 [(M+Na ), 
C68H9oN2032+Na+]. Requires 1469.5374.
Elemental analysis Found C, 50.22; H, 6.31; N, 1.41%. C68H90N2O3 2 9 .5 H2O 
requires C, 50.45; FI, 6.80; N, 1.73%.
X-ray crystallographic data are presented in Appendix 1.
HPLC (Semi-preparative) /r  16.5 min [column: Phenomenex Luna 5 pm C l8(2) 100 
Ä, 10 x 250 mm; 3 mL/min MeOH/FEO 50:50 isocratic, detection wavelength: 337 
nm],
[f/*flr/fs-4,4’-Bis(2,6-dimethylphenylaminocarbonyl)azobenzene]-[a-cyclodextrin]- 
[2]rotaxane 1.18
A mixture of the azobenzene 2.1 (50 mg, 1.9 x 10‘4 mol) and a-CD 1.1 (540 mg, 5.5 x 
1 O'4 mol) in 0.5 M sodium phosphate buffer (pH 7.0, 10 mL) was equilibrated for 2 h 
at room temperature. DMT-MM (1.5 g, 5.6 x 10‘ mol) and 2,6-dimethylaniline 2.4 
(90 mg, 7.4 x 1 O'4 mol) were added to the reaction mixture and stirred overnight at 
room temperature. Water (100 mL) was added to the reaction mixture and the mixture 
was washed with EtOAc (5 x 100 mL). The aqueous layer was concentrated under 
reduced pressure and the residue was dissolved in water (10 mL), which was then 
subjected to low-pressure RP chromatography. Elution with water (1 L) and gradient 
elution from 5% MeOH to 30% MeOH were applied to obtain the crude product of 
1.18. The resulting solution was concentrated under reduced pressure and further 
purified using the HPLC. The fractions containing the product 1.18 were concentrated 
and lyophilised to give the title compound 1.18 (21 mg, yield 8%) as orange powder. 
Crystals of rotaxane 1.18 were obtained through slow evaporation of MeOH/water 
over a period of several days.
TLC (5:4:3 v/v/v «-butanol:ethanol:water) R\ 0.78.
Melting point 250-251 °C (dec.).
'H NMR (500 MHz, CD3OD) 8H 8.67 (2H, d, 8.5, Azo-H), 8.32 (2H, d, 8.5, Azo- 
H), 8.27 (2H, d, J  8.5, Azo-H), 8.09 (2H, d, J  8.5, Azo-H), 7.17 (6H, apparent s,
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aniline-H), 4.91 (6H, d,J3.5, CD-C1-H), 3.82 (6H, apparent d, J9.0, CD-C5-H), 3.77 
(6H, m, CD-C3-H), 3.74 (6H, m, CD-C6-H), 3.60 (6H, apparent d, J  12.0, CD-C6-H), 
3.51 (6H, apparent t,.7 9.0, CD-C4-H), 3.43 (6H, dd, J3.5, 10.0, CD-C2-H), 2.39 (6H, 
s, Me), 2.32 (6H, s, Me).
,3C NMR (125.7 MHz, CD3OD) 8c 168.6 and 167.9 (C=0), 155.1, 154.8, 139.2, 
138.6, 137.5, 137.2, 135.7, 135.6, 130.2, 129.5, 129.2, 129.1, 128.6(9), 128.6(7), 
126.4, 124.5, 103.9, 83.3,75.0, 73.7, 73.4,61.7, 18.9 and 18.5 (Me).
Mass spectrum m/z (ESI-HR, positive ion mode) Found 1471.5281 [(M+Na ), 
C66HggN4032+Na+]. Requires 1471.5279.
Elemental analysis Found C, 50.62; H, 6.40; N, 3.37%. C66HggN4032-6.5H20 
requires C, 50.59; H, 6.51; N, 3.58%.
X-ray crystallographic data are presented in Appendix 1.
HPLC (Preparative) /r  14.9 min [column: Grace Alltima C l8 5 pm, 22 * 250 mm 
with Grace Alltima C l8 10 pm, 33 mm guard column; 10 mL/min MeOH/H20 40:60 
isocratic, detection wavelength: 340 nm].
8.3 Experimental for Chapter 3
8.3.1 Procedure to Obtain SEM and Optical Microscope Images Described in 
Section 3.2
(a) SEM Images
Crystals for SEM were obtained by evaporating aliquots (ca. 1 mL) of solutions of the 
rotaxanes 1.9, 1.10, 1.17 and 1.18 with concentrations ranging from approximately 10 
to 100 pM. Dried crystals were mounted on adhesive carbon tape and each sample 
was coated with conductive gold-palladium at 15 mA for 4 min before scanning.
(b) Optical Microscope Images
Lyophilised samples of the rotaxanes 1.9, 1.10, 1.17 and 1.18 were added to water (5 
mL) while being heated until they did not dissolve further. Each mixture was filtered 
before the solutions were cool to room temperature to give supersaturated solutions. 
Aliquots (ca. 300 pL) of the resulting solutions were transferred to quartz cuvettes* 
and sealed. These solutions were left to stand in a 25 °C constant temperature room 
and monitored until crystals did not grow further. An optical microscope fitted with a 
polarising lens was used to monitor crystal growth.
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*Pathlength 1mm, chamber volume 350 mL, fitted with a PTFE stopper. The sealed 
cuvettes provided a flat surface where crystals can grow whilst being monitored under 
the microscope. Polarising lens prevents unpolarised light from passing. As crystals 
polarise light, they are more clearly observed, as the polarised light contrasts the black 
background.
8.3.2 Procedure to Monitor Crystal Growth Behaviour Described in Section 3.3
(a) Time Dependent Crystal Growth: A 250 pM stock solution of the rotaxane 1.9 was 
prepared by adding the rotaxane 1.9 (1.81 mg) to water (5 mL), heating the mixture in 
a water bath set to 95 °C and cooling to room temperature. An aliquot (<ca. 300 pL) of 
the resulting solution was transferred to a cuvette (as specified in Section 8.3.1), 
sealed and left to stand in a 25 °C constant temperature room. Crystals were 
monitored using an optical microscope fitted with a polarising lens after 2 and 90 h.
(b) Concentration Dependent Crystal Growth: The 250 pM stock solution of the 
rotaxane 1.9 prepared as described in the Section above was diluted to 25 pM by 
combining 0.5 mL of the stock solution with 4.5 mL of water, followed by heating in 
a water bath set to 95 °C and cooling to room temperature. Aliquots (ca. 300 pL) of 
the stock solution (250 pM) and the diluted solution above (25 pM) were transferred 
to respective cuvettes (as specified in Section 8.3.1) and sealed. The solutions were 
left to stand in a 25 °C constant temperature room. Crystals were observed after 90 h 
using an optical microscope fitted with a polarising lens.
(c) Temperature Dependent Crystal Growth: Aliquots (ca. 300 pL) of the stock 
solution (250 pM) of the rotaxane 1.9 were transferred to respective cuvettes (as 
specified in Section 8.3.1), sealed and the two samples were incubated at 4 °C and 18 
°C for 72 h. Crystals grown at 18 °C were observed with an optical microscope fitted 
with a polarising lens. Those at 4 °C were monitored without a polarising lens as the 
crystals were too fine to be observed otherwise.
(d) Sonication Experiment: A mixture containing crystals of the rotaxane 1.9 was 
sonicated for 30 min at room temperature. The mixture was observed before and after 
sonication using an optical microscope fitted with a polarising lens.
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8.4 Experimental for Chapter 4 
8.4.1 Synthesis
[/AY?/fs-4-(2,6-Dimethylphenylaminocarbonyl)-4’-(3,5-
dimethylphenylaminocarbonyl)azobenzene]-[a-cyclodextrin]-[2]rotaxanes 4.1 
and 4.2
The asymmetrically substituted axle 4.4 (15 mg, 4.0 x 1 O'5 mol) was suspended in 
water (3 mL) and TEA (73 mg, 7.2 x 10'4mol) was added, followed by a-CD 1.1 
(117 mg, 1.2 x 1 O'4 mol), and the mixture was stirred overnight at room temperature. 
DMT-MM (44 mg, 1.6 x 1 O'4 mol) and 2,6-dimethylaniline 2.4 (45 mg, 3.6 x 10*4mol) 
were added and the mixture was stirred for 4 h before further addition of DMT-MM 
(44 mg, 1.6 x 10‘4 mol). After that mixture was stirred overnight, more DMT-MM (44 
mg, 1.6 x 10‘4 mol) was added twice at 24 h intervals. Water (70 mL) was then added 
to the reaction mixture and the mixture was washed with EtOAc (3 * 70 mL). The 
combined organic layers were extracted with water (70 mL) and the aqueous extract 
was washed with EtOAc (70 mL). The combined aqueous solutions were concentrated 
under reduced pressure. The residue was dissolved in MeOH and subjected to HPLC. 
Respective fractions containing the isomeric products 4.1 and 4.2 were concentrated 
and lyophilised to give the title compounds 4.1 (20 mg, yield 34%) and 4.2 (13 mg, 
yield 22%) as orange powders. Crystals of the rotaxanes 4.1 and 4.2 were obtained 
through slow evaporation of MeOH over a period of several weeks.
For compound 4.1:
TLC (5:4:3 v/v/v w-butanol:ethanol:water) R{ 0.55.
Melting point 245-247 °C (dec.).
‘H NMR (500 MHz, CD3OD) 8h 8.65 (2H, d, 8.5, Azo-H), 8.27 (2H, d, J  8.5, Azo- 
H), 8.26 (2H, d. J8.5, Azo-H), 8.07 (2H, d, 8.5, Azo-H), 7.45 (2H, s, aniline-H), 
7.17 (3H, apparent s, aniline-H), 6.87 (1H, s, aniline-H), 3.83 (6H, m, CD-C5-H), 
3.77 (6H, m, CD-C3-H), 3.72 (6H, m, CD-C6-H), 3.59 (6H, m, CD-C6-H), 3.50 (6H,
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m, CD-C4-H), 3.42 (6H, dd, J  3.5, 10, CD-C2-H), 2.35 (6H, s, Me), 2.31 (6H, s, Me). 
,3C NMR (125.7 MHz, CD3OD) 5c 168.3 and 167.9 (C=0), 155.1, 154.6, 140.1, 
139.6, 139.4, 138.6, 137.2, 135.6, 130.2, 129.4, 129.2, 128.7, 127.5, 126.4, 124.5, 
120.3, 103.9, 83.2, 75.0, 73.8, 73.4, 61.7, 21.5 and 18.5 (Me).
Mass spectrum (ESI-HR, positive ion mode) m/z Found 1471.528 [(M+Na+), 
C66H88N4 0 32+Na+]. Requires 1471.527.
Elemental analysis Found C, 51.73; H, 6.62; N, 3.56%. CööHss^ O ^  5H20  requires 
C, 51.49; H, 6.42; N, 3.64%.
X-ray crystallographic data are presented in Appendix 1.
HPLC (Preparative) /r  4.6 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min MeOH/H20  (0.1% TFA) gradient - 50-70% MeOH, 0-20 min, 
detection wavelength: 346 nm].
For compound 4.2:
TLC (5:4:3 v/v/v A7-butanol:ethanol:water) Rf 0.60.
Melting point 245-248 °C (dec.).
'H NMR (500 MHz, CD3OD) 5H 8.66 (2H, d, 8.5, Azo-H), 8.32 (2H, d, 8.5, Azo- 
H), 8.20 (2H, d , ,/ 8.5, Azo-H), 8.05 (2H, d, 8.5, Azo-H), 7.37 (2H, s, aniline-H), 
7.17 (3H, apparent s, aniline-H), 6.86 (1H, s, aniline-H), 3.81 (6H, m, CD-C5-H) 3.77 
(6H, m, CD-C3-H), 3.74 (6H, m, CD-C6-H), 3.59 (6H, m, CD-C6-H), 3.51 (6H, m, 
CD-C4-H) 3.43 (6H, m, CD-C2-H), 2.39 (6H, s, Me), 2.34 (6H, s, Me).
,3C NMR (125.7 MHz, CD3OD) 5c 168.6 and 167.5 (C=0), 154.9, 154.8, 139.6, 
139.5, 139.4, 139.1, 137.5, 135.7, 130.2, 129.4, 129.1, 128.7, 127.5, 126.4, 124.3, 
120.1, 103.9, 83.3, 75.0, 73.7, 73.3, 61.7, 21.5 and 18.9 (Me).
Mass spectrum (ESI-HR, positive ion mode) m/z Found 1449.543 [(M+H+), 
C66Hs8N4 0 32+H+]. Requires 1449.546.
Elemental analysis Found C, 52.96; H, 6.99; N, 3.88%. CööHgs^O^ 4.5CH3OH 
requires C, 53.13; H, 6.70; N, 3.52%.
X-ray crystallographic data are presented in Appendix 1.
HPLC (Preparative) /r  5.9 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min MeOH/H20  (0.1% TFA) gradient - 50-70% MeOH, 0-20 min, 
detection wavelength: 346 nm].
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f/Y?/fs-4’-(2,6-Dimethylphenylaminocarbonyl)azobenzene-4-carboxylic acid 4.4 
and f^lrtx-4,4’-bis(2,6-Dimethylphenylaminocarbonyl)azobenzene 4.5
Under dry nitrogen atmosphere, azobenzene-4,4’-dicarbonyl dichloride 4.3 (200 mg, 
6.5 x 10'4 mol) was dissolved in dry DCM (10 mL) and a solution of 2,6- 
dimethylaniline 2.4 (63 mg, 5.2 x 1 O'4 mol) in dry DCM (60 mL) was added dropwise 
over 30 min while the temperature was maintained at < -5 C using an ice bath with 
sodium chloride. TEA (80 mg, 7.9 x 10"4mol) was added to the reaction mixture, 
which was then stirred at room temperature for 1 h, before additional 2,6- 
dimethylaniline 2.4 (32 mg, 2.6 x 1 O'4 mol) dissolved in dry DCM (5 mL) was added 
dropwise. The reaction mixture was stirred for further 2 h at room temperature, and 
then concentrated under reduced pressure. THF/water (150 mL, 2:1 v/v) was added to 
the residue and the mixture was sonicated at 50 C for 1 h. The resulting solution was 
concentrated under reduced pressure. That residue was chromatographed over silica 
gel column, which was eluted with a MeOH-DCM solvent gradient. The di-capped 
byproduct 4.5 was eluted with 1-3% MeOH in DCM, followed by the mono-capped 
product 4.4 with 5% MeOH in DCM. The fractions containing each material were 
combined and concentrated under reduced pressure to give the title compounds 4.4 
(103 mg, yield 42%) and 4.5 (87 mg, yield 28%) as orange powders.
For compound 4.4:
TLC (5:95 v/v MeOH:DCM) Rf 0.16.
Melting point 289-290 °C (dec.).
'H NMR (300 MHz, Acetone-*) 5H 8.29 (2H, d, J  8.5, Azo-H), 8.26 (2H, d, 8.5, 
Azo-H), 8.09 (4H, m, Azo-H), 7.13 (3H, apparent s, aniline-H), 2.28 (6H, s, Me).
,3C NMR (75.5 MHz, CDCI3) 8c 167.9 and 166.1 (C=0), 154.7, 154.0, 136.4, 135.5, 
133.7, 132.7, 130.6, 128.3, 127.9, 127.3, 122.9, 122.6, 17.9 (Me).
Mass spectrum (EI-HR) m/z Found 373.143 [(M+), C22Hi9N3Ü3+]. Requires 373.143.
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Elemental analysis Found C, 71.00; H, 5.36; N, 11.39%. C22H19N3O3 requires C, 
70.76; H, 5.13; N, 11.25%.
For compound 4.5:
TLC (5:95 v/v MeOFFDCM) Rr 0.70.
Melting point 227-229 °C (dec.).
'H NMR (300 MHz, DMSO-A) 8H 10.01 (2H, s, NH), 8.24 (4H, d, J  8.5, Azo-H),
8.09 (4H, d, J8.5, Azo-H), 7.15 (6H, apparent s, aniline-H), 2.22 (12H, s, Me).
,3C NMR (75.5 MHz, DMSO-</6) 8c 164.2 (C=0), 153.4, 136.9, 135.5, 135.0, 128.9, 
127.7, 126.8, 122.7, 18.0 (Me).
Mass spectrum (EI-HR) m/z Found 476.221 [(M+ ), C3oH28N4Ü2+ ]. Requires 476.221.
8.4.2 Determination of the Solubility of [2]Rotaxanes
8.4.2.1 Procedure to Obtain the Solubility Plot Described in Section 4.6
A 100 pM stock solution of the rotaxane 1.9 was prepared by adding the rotaxane 1.9 
(4.35 mg) to water (30 mL) and heating the mixture to 80 °C in a water bath to 
dissolve. The stock solution cooled to ambient temperature. Solutions of the rotaxane
1.9 (5, 10, 20 and 50 pM) were prepared as described in the following. The stock 
solution was diluted to 50 pM by combining water (9 mL) with the stock solution (9 
mL). The stock solution also was diluted to 20 pM by combining water (6 mL) with 
the stock solution (24 mL). The 20 pM solution was then diluted to 10 pM by 
combining water (15 mL) with the 20 pM solution (15 mL). Finally, the 10 pM 
solution was diluted to 5 pM by combining water (15 mL) with the 10 pM solution 
(15 mL). All solutions (5, 10, 20, 50 and 100 pM) were heated at 80 °C in a water 
bath, placed in three separate vials (5 mL each) and incubated at 80 °C, 50 °C, and 10 
°C. The UV/visible spectra of the supernatants were monitored during incubation over 
7 days, after which time no further change in absorbance was observed. Absorbance at 
350 nm was plotted against moles of the rotaxane 1.9/litre of water as shown in 
Figure 4.14.
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8.4.2.2 Procedure to Monitor Crystallisation Described in Section 4.6
A 100 pM solution of the rotaxane 1.9 was prepared by adding the rotaxane 1.9 (1.45 
mg) to water (10 mL) and heating the mixture to 80 °C in a water bath. The 
UV/visible spectra of the supernatant were obtained over 12 days during incubation at 
30 °C.
8.4.3 Procedure to Study Crystal Growth Inhibition Described in Section 4.7
8.4.3.1 Procedure for Co-crystallisation
Lyophilised solids which contain both crystalline and amorphous solids were used to 
prepare solutions required for experiments to regulate crystal growth. Prior to 
crystallisation experiments, mixtures containing rotaxanes were heated at a higher 
temperature to form supersaturated solutions.
The stock mixture of the rotaxane 1.9 (200 pM) was prepared by adding the rotaxane 
1.9 (1.45 mg) to water (5 mL), heating the mixture in a water bath set to 95 °C and 
cooling to ambient temperature. The stock mixture of respective inhibitor rotaxanes 
was also prepared as above. The stock mixtures of the rotaxanes 1.9 and inhibitor 
rotaxanes were not completely clear solutions, as they are above the saturation 
concentration. However, they were mixed thoroughly before 200 pM solution of the 
rotaxane 1.9 (500 pL) was combined with solutions of the respective inhibitor 
rotaxane (500 pL) and heated in a water bath set to 95 °C. The resulting solutions 
were cooled to 25 °C in a constant temperature room, transferred to cuvettes, sealed 
and monitored using an optical microscope fitted with a polarising lens at this 
temperature.
8.4.3.2 Procedure to Determine the Relative Proportions of Rotaxanes in Grown 
Crystals
To measure the relative proportions of the rotaxane 1.9 and respective inhibitor 
rotaxanes present in grown crystals prepared, crystals were collected and analysed by 
HPLC. Firstly, assayed samples were transferred to 1.5 mL microcentrifuge tubes and 
centrifuged for 1 min at 13,200 rpm to collect crystals. They were resuspended in 
water (1 mL) to remove excess rotaxane in the solution and centrifuged for another 1 
min at 13,200 rpm. Collected crystals were dissolved in MeOH (ca. 500 pL) and 
aliquots (50 pL) of each sample were subject to HPLC. HPLC chromatograms were
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obtained at the isosbestic point of the relevant rotaxanes and the percentage 
composition of the two rotaxanes was estimated by integrating the areas underneath 
each peak.
8.4.3.3 Crystal Growth Inhibition Study Using the Rotaxane 4.1
Co-crystallisation of the rotaxanes 4.1 and 1.9 was carried out as described in Section
8.4.3. U The stock mixture of the rotaxane 4.1 (200 pM) was prepared by adding the 
rotaxane 4.1 (1.45 mg) to water (5 mL) and heating the mixture in a water bath set to 
95 °C, then cooling to ambient temperature. Solutions (20 and 100 pM) of the 
rotaxane 4.1 were prepared using the 200 pM stock mixture of the rotaxane 4.1 and 
water. The rotaxane 4.1 (0, 20, 100 or 200 pM) and the rotaxane 1.9 (200 pM) were 
combined. The final concentrations of the rotaxane 4.1 were 0, 10, 50 or 100 pM 
respectively and all four solutions contained 100 pM of the rotaxane 1.9. The 
resulting solutions were monitored for 3.5 days. HPLC analysis was carried out as 
described in Section 8.4.3.2 to measure the relative proportions of the rotaxanes 1.9 
and 4.1 present in grown crystals.
HPLC /r  5.5 min (rotaxane 4.1), 7.3 min (rotaxane 1.9) [column: Phenomenex Luna 
5 pm C l8(2) 100 Ä, 250 x 10 mm; 3 mL/min H2O/ACN 60:40 isocratic, detection 
wavelength: 349 nm].
8.4.3.4 Crystal Growth Inhibition Study Using the Rotaxane 4.2
Co-crystallisation of the rotaxanes 4.2 and 1.9 was carried out as described in Section
8.4.3. L The stock mixture of the rotaxane 4.2 (400 pM) was prepared by adding the 
rotaxane 4.2 (2.90 mg) to water (5 mL) and heating the mixture in a water bath set to 
95 °C, then cooling to ambient temperature. Solutions (200 and 300 pM) of the 
rotaxane 4.2 were prepared using 400 pM stock mixture of the rotaxane 4.2. The 
rotaxane 1.9 (200 pM) and the rotaxane 4.2 (0, 200, 300 or 400 pM) were combined. 
The final concentration of the rotaxane 4.2 were 0, 100, 150 or 200 pM respectively 
and all four solutions contained 100 pM of the rotaxane 1.9. The resulting solutions 
were monitored for 36 days. HPLC analysis was carried out as described in Section 
8.4.3.2 to measure the relative proportions of the rotaxanes 1.9 and 4.2 present in 
grown crystals.
HPLC /r  18.7 min (rotaxane 4.2), 27.0 min (rotaxane 1.9) [column: Waters XBridge
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Prep C l8 5 pm, 19 x 150 mm; 10 mL/min H2O/ACN 50:50 isocratic, detection 
wavelength: 349 nm].
8.4.3.5 Crystal Growth Inhibition Study Using the Rotaxane 1.18
Co-crystallisation of the rotaxanes 1.18 and 1.9 was carried out as described in 
Section 8.4.3.I. The stock mixture of the rotaxane 1.18 (200 pM) was prepared by 
adding the rotaxane 1.18 (1.45 mg) to water (5 mL) and heating the mixture in a water 
bath set to 95 °C, then cooling to ambient temperature. Solutions (20 and 100 pM) of 
the rotaxane 1.18 were prepared using the 200 pM stock mixture of the rotaxane 1.18 
and water. The rotaxane 1.18 (0, 20, 100 or 200 pM) and the rotaxane 1.9 (200 pM) 
were combined. The final concentrations of the rotaxane 1.18 were 0, 10, 50 or 100 
pM respectively and all four solutions contained 100 pM of the rotaxane 1.9. The 
resulting solutions were monitored for 10 days. HPLC analysis was carried out as 
described in Section S.4.3.2 to measure the relative proportions of the rotaxanes 1.9 
and 1.18 present in grown crystals.
HPLC tR 7.3 min (rotaxane 1.9) [column: Phenomenex Luna 5 pm C l8(2) 100 Ä, 
250 x 10 mm; 3 mL/min H2O/ACN 60:40 isocratic, detection wavelength: 346 nm].
8.5 Experimental for Chapter 5 
8.5.1 Synthesis
j//*fl/ix-4-(3,5-Dimethylphenylaminocarbonyl)-4’-(2,4,6- 
trinitrophenylamino)stilbene]-[a-cyclodextrin]-[2]rotaxane 5.5
A mixture of the /ram-4-(3,5-dimethylphenylaminocarbonyl)-4,-aminostilbene 5.9 (5 
mg, 1.5 x 1 0  " mol) and ot-CD 1.1 (568 mg, 5.8 x 10"4 mol) in 0.2 M sodium 
carbonate buffer (pH 10.0, 40 mL) was equilibrated for 2 h at room temperature. 
Dihydrate of 2,4,6-trinitrobenzene-1-sulfonic acid sodium salt 5.3 (10 mg, 2.8 x 10'5 
mol) was added and the mixture was stirred for 24 h at room temperature. The 
resultant solution was washed with EtOAc (5 x 100 mL). The aqueous layer was
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concentrated under reduced pressure and then subjected to HPLC. The fractions 
containing the product 5.5 were concentrated and lyophilised to give the title 
compound 5.5 (3 mg, yield 13%) as orange powder. Crystals of rotaxane 5.5 were 
obtained through slow evaporation of MeOH/water over a period of several weeks. 
TLC (5:4:3 v/v/v «-butanol:ethanol:water) Rf 0.79.
Melting point 245-246 °C (dec.).
‘H NMR (500 MHz, CDjOD) 5h 9.90 (1H, s, NH), 9.10 (2H, s, trinitrophenyl-H), 
8.08 (2H, d, J 8.5, stilbene-H), 8.05 (2H, d, 8.5, stilbene-H), 7.45 (2H, d, 8.0, 
stilbene-H), 7.38 (2H, s, aniline-H), 7.32 (1H, d, J 16.0, olefinic-H), 7.27 (2H, d, J8.0, 
stilbene-H), 7.20 (1H, d, J 16.0, olefinic-H), 6.84 (1H, s, aniline-H), 4.93 (6H, d, y 3.5, 
CD-C1-H), 3.87 (6H, apparent d, J 9.0, CD-C5-H), 3.86 (6H, apparent t, J 9.0, CD- 
C3-H), 3.75 (6H, dd, J3.5, 12.0, CD-C6-H), 3.64 (6H, apparent d, J 12.0, CD-C6-H), 
3.58 (6H, apparent t, J  9.0 CD-C4-H), 3.45 (6H, dd, J 3.5, 9.0, CD-C2-H), 2.33 (6H, s, 
Me).
,3C NMR (200 MHz, CD3OD) 6c 168.9, 141.0, 140.6(1), 140.5(7), 139.5(8), 
139.5(6), 139.5, 137.8. 136.2, 134.8, 130.4, 129.6, 129.0, 128.9, 128.7, 128.0, 127.3, 
122.9, 120.2, 104.0, 83.2, 75.1, 73.9, 73.8, 61.5, 21.5.
Mass spectrum m/z (ESI-HR, positive ion mode) Found 1526.4847 [(M+H+), 
C6 5 Hs3 N 5 C>3 7 +H+]. Requires 1526.4845.
X-ray crystallographic data are presented in Appendix 1.
HPLC (Preparative) /r  14.6 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min MeOH/H20 30:70 isocratic, detection wavelength: 333 ran].
4-(4’-Aminostilbene) carboxylic acid 5.8
4-Vinylaniline 5.6 (590 mg, 5.0 x 10'3mol) and 4-iodobenzoic acid 5.7 (1.1 g, 4.4 x 
10'3 mol) were dissolved in DMF (6 mL) and TEA (6 mL). PPh3 (12 mg, 4.6 x 10'5 
mol) and palladium(II) acetate (10 mg, 4.5 x 10° mol) were added and the solution 
was then refluxed for 48 h. The reaction mixture was concentrated under reduced 
pressure. EtOAc (300 mL) was added to the solid residue, and insoluble precipitate 
was removed by filtration. The product was extracted with 2 M HC1 (3 x 100 mL)
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from the filtrate, and the aqueous layer containing the product was neutralised with 
aqueous NaOH solution. Precipitate was formed, and it was collected though 
centrifugation. The precipitate was washed with water (2 x 40 mL) and Et20 (40 mL) 
before drying under vacuum to give the desired compound 5.8 (194 mg, yield 18%). 
Physical and spectral properties were consistent with those reported previously.164 
TLC (5:2 v/v EtOAc:Hexane) R\ 0.80.
Melting point 293-296 °C (dec.) [lit.164 292-300 °C (dec.)].
'H NMR (300 MHz, DMSO-t/ö) 5 ii 7.79 (2H, d, 7.5, stilbene-H), 7.40 (2H, d, 7.5, 
stilbene-H), 7.28 (2H, d, J7.5, stilbene-H), 7.06 (1H, d, 16.0, olefinic H), 6.89 (1H, 
d. J  16.0, olefinic H), 6.56 (2H, d,./7.5, stilbene-H), 5.30 (2H, s, NH2).
Mass spectrum m/z (ESI-HR, negative ion mode) Found 238.0868 [(M-ET), 
C15H,3N02-H]. Requires 238.0868.
f/*tf/fs-4-(3,5-Dimethylphenylaminocarbonyl)-4’-aininostilbene 5.9
Under dry nitrogen atmosphere, the stilbene 5.8 (100 mg, 4.2 * 1 O'4 mol) and BOP 
(279 mg, 6.3 x 10'4mol) were dissolved in 3,5-dimethylaniline 2.2 (12 mL, 9.6 x 10'2 
mol) and stirred overnight at room temperature before further addition of BOP (279 
mg, 6.3 x 1 O'4 mol). After the mixture was stirred for 48 h at room temperature, more 
BOP (93 mg, 2.1 x 1 O'4 mol) was added and stirred overnight at room temperature. 
The crude reaction mixture was passed through a silica gel column using hexane-Et20  
solvent gradient (0-100% Et20) to remove unreacted 3,5-dimethylaniline 2.2. The 
product mixture was recovered by flushing this column with MeOH. The crude 
product mixture was purified by silica gel chromatography with EtOAc-hexane 
solvent gradient. The title compound 5.9 was eluted with 20-100% EtOAc. The 
fractions containing the desired compound 5.9 were combined, concentrated and 
further purified by HPLC (22 mg, yield 15%).
TLC (5:2 v/v Hexane:EtOAc) Rf 0.51.
Melting point 190-195 °C (dec.).
'H NMR (300 MHz, CD2C12) 8H 7.82 (2H, d, J  8.1, stilbene-H), 7.81 (1H, s, NH),
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7.58 (2H, d, J8.1, stilbene-H), 7.36 (2H, d, .78.4, stilbene-H), 7.28 (2H, s, aniline-H), 
7.15 (1H, d, .7 16.0, olefinic-H), 6.96 (1H, d, .7 16.0, olefinic H), 6.81 (1H, s, aniline- 
H), 6.68 (2H, d, J  8.4, stilbene-H), 3.89 (2H, s, NH2), 2.33 (6H, s, Me).
,3C NMR (125.7 MHz, CD2C12) 6c 165.6 (C=0), 147.8, 142.1, 139.3, 138.6, 133.6, 
131.6, 128.6, 128.0, 127.6, 126.7, 126.6, 123.9, 118.4, 115.5 and 21.7 (Me).
Mass spectrum m/z (ESI-HR, positive ion mode) Found 343.1810 [(M+H+), 
C23H22N20+H+]. Requires 343.1810.
Elemental analysis Found C, 78.54; H, 6.52; N, 7.77%. C23H22N20  0.5H2O requires 
C, 78.59; H,6.61;N, 7.97%.
HPLC (Preparative) / r  44.6 min [column: Grace Alltima C l8 5 pm, 22 x 250 mm 
with a Grace Alltima C l8 10 pm, 33 mm guard column; 10 mL/min ACN/H20  57:43 
isocratic, detection wavelength: 333 nm].
8.5.2 Procedure to Determine the Relative Proportions of the Rotaxane 5.5 in the 
Crystals of the Rotaxane 1.9
Co-crystallisation of the rotaxanes 5.5 and 1.9 were carried out according to the 
procedure described in Section 8.4.3.1. The stock mixture of the rotaxane 5.5 (200 
pM) was prepared by adding the rotaxane 5.5 (1.53 mg) to water (5 mL) and heating 
the mixture in a water bath set to 95 °C, then cooling to ambient temperature. 
Solutions (20 and 100 pM) of the rotaxane 5.5 were prepared using the 200 pM stock 
mixture of the rotaxane 5.5 and water. The rotaxane 5.5 (0, 20, 100 or 200 pM) and 
the rotaxane 1.9 (200 pM) were combined. The final concentrations of the rotaxane 
5.5 were 0, 10, 50 or 100 pM respectively and all four solutions contained 100 pM of 
the rotaxane 1.9. The resulting solutions were monitored for 4 days. HPLC analysis 
was carried out as described in Section 8.4.3.2 to measure the relative proportions of 
the rotaxanes 1.9 and 5.5 present in grown crystals.
HPLC / r  9.9 min (rotaxane 5.5), 10.9 min (rotaxane 1.9) [column: YMC Pack ODS- 
AQ 3 pm, 150 x 3.0 mm; 0.7 mL/min H20/ACN gradient- 5-30% ACN, 0-10 min, 
detection wavelength: 332 nm].
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8.6 Experimental for Chapter 6
|/rör/ix-Ar-(2,6-Dimethylphenyl)-4-(2-(l,133-tetramethylisoindolin-2-yl)oxyl-5-yl) 
vinyl)benzamidel-[a-cyclodextrin]-[2]rotaxanes 1.33 and 1.34
The stilbene 6.1 (25 mg, 7.4 x 10° mol) was suspended in water (25 mL) and TEA 
(15 mg. 1.5 x 1 O'4 mol) was added to the mixture to dissolve. cx-CD 1.1 (360 mg, 3.7 
x 1 O'4 mol) was added to the mixture, and the mixture was sonicated to give a clear 
solution. Following equilibration of the mixture for 2 h at room temperature, DMT- 
MM (410 mg, 1.5 x 1 O'4 mol) and 2,6-dimethylaniline 2.4 (27 mg, 2.2 x 1 O'4 mol) 
were added to the mixture and stirred for 17 h at room temperature. The resultant 
mixture was concentrated under reduced pressure. The residue was then suspended in 
20 mL water, and centrifuged to remove precipitate. The solid residue was washed 
with water (3 x 20 mL) and centrifuged to separate solids. All soluble fractions were 
combined, and subjected to HPLC. The fractions containing the desired isomeric 
products 1.33 and 1.34 were concentrated and lyophilised to give the title compounds 
1.33 (20 mg, yield 19%) and 1.34 (22 mg, yield 21%) as colourless powders. Purified 
samples showed decomposition. Therefore, small-scale purification was carried out 
by analytical HPLC, where fractions containing the pure compounds were collected 
under light shielded conditions and lyophilised immediately to prevent isomerisation 
after purification.
For compound 1.33:
TLC (5:4:3 v/v/v «-butanol:ethanol:water) Rf 0.57.
Melting point 222-225 °C (dec.).
'H NMR (500 MHz, CD3OD containing ascorbic acid 6.4, see Section 8.1.2) 5h 8.13 
(2H, d, J  8.5, Ar-H), 8.10 (2H, d, J  8.5, Ar-H), 7.68 (1H, d, J  7.5, Ar-H), 7.39 (1H, d, 
J  7.5, Ar-H), 7.36 (1H, d, J  16.5, olefinic-H), 7.25 (1H, s, Ar-H), 7.18 (1H, d, J  16.5, 
olefinic-H), 7.16 (3H, apparent s, aniline-H), 4.93 (6H, d, J  3.5, CD-C1-H), 3.92-3.83 
(12H, m, CD-C3-H and CD-C5-H), 3.74 (6H, dd, y 3.0, 12.0, CD-C6-H), 3.59-3.55 
(12H, m, CD-C4-H and CD-C6-H), 3.46 (6H, dd, J3.5, 10.0, CD-C2-H), 2.36 (6H, s,
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Me), 1.64 (3H, s, Me), 1.62 (3H, s, Me), 1.57 (3H, s, Me), 1.56 (3H, s, Me).
Mass spectrum m/z (ESI-HR, positive ion mode) Found 1412.5630 [(M+H+), 
C65H9iN2032+H+]. Requires 1412.5633.
Elemental analysis Found C, 49.90; H, 6.92; N, 1.95%. C65H91N2O32 8H2O requires 
C, 50.15; H, 6.94; N, 1.80%.
HPLC (Preparative) /r  5.4 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min MeOH/H20  25:75 isocratic, detection wavelength: 324 nm].
HPLC (Analytical) /r  5.7 min [column: YMC Pack ODS-AQ 3 pm, 150 x 3.0 mm; 
0.7 mL/min H2O/ACN gradient- 5-30% ACN, 0-10 min, detection wavelength: 324 
nm].
For compound 1.34:
Physical and spectral properties were consistent with those reported previously.135 
TLC (5:4:3 v/v/v «-butanol:ethanol:water) Rf 0.57.
Melting point 253-257 °C (dec.) [lit.135 248-250 °C (dec.)].
!H NMR (500 MHz, CD3OD containing ascorbic acid 6.4, see Section 8.1.2) 6h 8.12 
(1H, d, J  8.0, Ar-H), 8.08 (2H, d, J8 .0 , Ar-H), 7.62 (2H, d, J  8.0, Ar-H), 7.58 (1H, s, 
Ar-H), 7.47 (1H, d, .7 8.0, Ar-H), 7.47 (1H, d, J  16.0, olefinic-H), 7.19 (1H, d, J  16.0, 
olefinic-H), 7.15 (3H, apparent s, aniline-H), 4.92 (6H, d, .7 3.5, CD-C1-H), 3.91-3.88 
(12H, m, CD-C3-H and CD-C5-H), 3.90 (6H, dd, J  3.5, 12.5, CD-C6-H), 3.59-3.54 
(12H, m, CD-C4-H and CD-C6-H), 3.48 (6H, dd, J3 .5 , 10.0, CD-C2-H), 2.30 (6H, s, 
Me), 1.71 (6H, br s, Me), 1.62 (6H, br s, Me).
Mass spectrum (ESI, positive ion mode) m/z (%) 1413 [(M+H+), 20], 1435 
[(M+Na+), 100].
HPLC (Preparative) / r  8.3 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min MeOH/H20  25:75 isocratic, detection wavelength: 324 nm].
HPLC (Analytical) /r  6.8 min [column: YMC Pack ODS-AQ 3 pm, 150 x 3.0 mm; 
0.7 mL/min H2O/ACN gradient- 5-30% ACN, 0-10 min, detection wavelength: 324 
nm].
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[fra«s-yV-(3,5-Dimethylphenyl)-4-(2-(l,lr33-teti'amethylisoindolin-2-yl)oxyl-5-yl)
vinyl)benzamide]-[a-cyclodextrin]-|2]rotaxanes 1.35 and 1.36
The stilbene 6.1 (25 mg, 7.4 x 1 O'5 mol) was suspended in water (25 mL) and TEA 
(15 mg, 1.5 x 1 O'4 mol) was added to the mixture to dissolve. a-CD 1.1 (360 mg, 3.7 
x 10‘4 mol) was added to the mixture, and the mixture was sonicated to give a clear 
solution. Following equilibration of the mixture for 2 h at room temperature, DMT- 
MM (410 mg, 1.5 x 1 O'4 mol) and 3,5-dimethylaniline 2.2 (27 mg, 2.2 x 1 O'4 mol) 
were added to the mixture and stirred for 14 h at room temperature. The resultant 
mixture was concentrated under reduced pressure. The residue was then suspended in 
20 mL water, and centrifuged to remove precipitate. The solid residue was washed 
with water (3 x 20 mL) and centrifuged to separate solids. All soluble fractions were 
combined, and subjected to HPLC. The fractions containing the desired isomeric 
products 1.35 and 1.36 were concentrated and lyophilised to give the title compounds 
1.35 (31 mg, yield 30%) and 1.36 (30 mg, yield 29%) as colourless powders. Purified 
samples showed decomposition. Therefore, small-scale purification was carried out 
using the procedure described for the compounds 1.33 and 1.34.
For compound 1.35:
TLC (5:4:3 v/v/v /7-butanol :ethanol: water) Rf 0.68.
Melting point 223-225 °C (dec.).
*H NMR (500 MHz, CD3OD containing ascorbic acid 6.4, see Section 8.1.2) 6h 8.13 
(2H, d, J  8.0, Ar-H), 8.08 (2H, d, J8 .0 , Ar-H), 7.82 (1H, d, J8 .5 , Ar-H), 7.56 (1H, s, 
Ar-H), 7.55 (1H, d, J  8.5, Ar-H), 7.48 (2H, s, aniline-H), 7.40 (1H, d, J  16.0, olefinic- 
H), 7.22 (1H, d, J  16.0, olefinic-H), 6.85 (1H, s, aniline-H), 4.93 (6H, d, J3 .5 , CD- 
Cl-H), 3.90 (6H, m, CD-C5-H), 3.81 (6H, dd, J  10.0, CD-C3-H), 3.72 (6H, dd, J3 .5 , 
12.0, CD-C6-H), 3.58 (6H, dd, J3 .5 , 12.0, CD-C6-H), 3.53 (6H, apparent t, J  9.0, 
CD-C4-H), 3.46 (6H, dd, J3 .5 , 10.0, CD-C2-H), 2.35 (6H, s, Me), 1.87 (3H, s, Me), 
1.83 (3H, s, Me), 1.78 (6H, s, Me).
Mass spectrum m/z (ESI-HR, positive ion mode) Found 1434.5464 [(M+Na+),
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C65H9]N2032+Na+]. Requires 1434.5453.
Elemental analysis Found C, 49.89; H. 6.60; N, 1.88%. C65H91N2O32 9H2O requires 
C, 49.57; H, 6.99; N, 1.78%.
HPLC (Preparative) /r  6.9 min [column: Waters XBridge Prep C l8 5 pm, 19 * 150 
mm; 10 mL/min MeOH/H20  35:65 isocratic, detection wavelength: 328 nm].
HPLC (Analytical) /r  7.6 min [column: YMC Pack ODS-AQ 3 pm, 150 x 3.0 mm; 
0.7 mL/min H2O/ACN gradient- 5-30% ACN, 0-10 min, detection wavelength: 328 
nm].
For compound 1.36:
TLC (5:4:3 v/v/v /7-butanol :ethanol: water) R\ 0.68.
Melting point 207-211 °C (dec.).
'H NMR (500 MHz, CD3OD containing ascorbic acid 6.4, see Section 8.1.2) 5h 8.21 
(1H, d, J  8.0, Ar-H), 8.05 (2H, d, J  8.5, Ar-H), 7.64 (1H, s, Ar-H), 7.60 (2H, d, J  8.5, 
Ar-H), 7.56 (1H, d, .7 8.0, Ar-H), 7.46 (1H, d, J  16.5, olefinic-H), 7.37 (2H, s, aniline- 
H), 7.21 (1H, d, J  16.5, olefinic-H), 6.85 (1H, s, aniline-H), 4.94 (6H, d, J  3.5, CD- 
Cl-H), 3.88 (6H, m, CD-C5-H), 3.81 (6H, m, CD-C3-H), 3.72 (6H, dd, J3.5, 12.0, 
CD-C6-H), 3.57 (12H, m, CD-C6-H and CD-C4-H), 3.50 (6H, dd, J3.5, 10.0, CD- 
C2-H), 2.34 (6H, s, Me), 1.88 (6H, s, Me), 1.80 (6H, s, Me).
Mass spectrum m/z (ESI-HR, positive ion mode) Found 1434.5457 [(M+Na+), 
C65H9iN2032+Na+]. Requires 1434.5453.
Elemental analysis Found C, 49.73; H, 6.57; N, 1.80%. C65H91N2O32.9H2O requires 
C, 49.57; H, 6.99; N, 1.78%.
HPLC (Preparative) /r  15.4 min [column: Waters XBridge Prep C l8 5 pm, 19 * 150 
mm; 10 mL/min MeOH/H20  35:65 isocratic, detection wavelength: 328 nm].
HPLC (Analytical) /r  9.6 min [column: YMC Pack ODS-AQ 3 pm, 150 x 3.0 mm; 
0.7 mL/min H2O/ACN gradient- 5-30% ACN, 0-10 min, detection wavelength: 328 
nm].
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/ra«5-Ar-(2,6-Dimethylphenyl)-4-(2-(l,l,33-teti'amethylisoindolin-2-yl)oxyl-5-yl) 
vinyl)benzamide 1.37
The acid 6.1 (20 mg, 6.0 * 10° mol) and BOP (39 mg, 9.0 x 10° mol) were dissolved 
in anhydrous DMF (2 mL) under dry nitrogen atmosphere. 2,6-Dimethylaniline 2.4 (7 
mg, 6.0 x 10'4 mol) and TEA (9 mg, 9.0 x 1 O'4 mol) were added to the solution and 
stirred overnight at room temperature. The reaction mixture was subjected to HPLC. 
The fractions containing the product 1.37 were concentrated and dried under vacuum 
to give the title compound 1.37 (12 mg, yield 47%). Purified samples showed 
decomposition. Therefore, small-scale purification was carried out using the 
procedure described for the compounds 1.33 and 1.34.
Physical and spectral properties were consistent with those reported previously. 
Melting point 226-228 °C (dec.).
NMR (300 MHz, DMS O -c/ö containing ascorbic acid 6.4, see Section 8.1.2) 5 h  
9.78 (1H, s, NH), 8.01 (2H, d,J8.4, Ar-H), 7.74 (2H, d, J8.4, Ar-H), 7.57 (1H, s, Ar- 
H), 7.53 (1H, d, J  7.5, Ar-H), 7.43 (1H, d, J  16.5, olefinic-H), 7.34 (1H, d, J  16.5, 
olefinic-H), 7.26 (1H, d, J  7.5, Ar-H), 7.12 (3H, apparent s, aniline-H), 2.18 (6H, s, 
Me), 1.40 (6H, br s, Me), 1.37 (6H, br s, Me).
Mass spectrum m/z (ESI-HR, positive ion mode) Found 440.2466 [(M+H+), 
C29H31N2O2+H ]. Requires 440.2464.
HPLC (Analytical) /r 7.9 min [column: Phenomenex Luna 5 pm C l8(2) 100 Ä, 250 
x 4.6 mm; 1 mL/min H2O/ACN 30:70 isocratic, detection wavelength: 324 nm].
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/rö/is-yV-(3,5-Dimethylphenyl)-4-(2-(l,133-teti*amethylisoindolin-2-yl)oxyl-5-yl)
vinyl)bcnzamide 1.38
The acid 6.1 (20 mg, 6.0 x 10'5 mol) and BOP (39 mg, 9.0 x 10° mol) were dissolved 
in anhydrous DMF (2 mL) under dry nitrogen atmosphere. 3.5-Dimethylaniline 2.2 (7 
mg, 6.0 x 10‘4mol) and TEA (9 mg, 9.0 x 10'4mol) were added to the solution and 
stirred overnight at room temperature. The reaction mixture was subjected to HPLC. 
The fractions containing the product 1.38 were concentrated and dried under vacuum 
(22 mg, yield 82%). Purified samples showed decomposition. Therefore, small-scale 
purification was carried out using the procedure described for the compounds 1.33 
and 1.34.
Melting point 238-240 °C (dec.)
'H NMR (500 MHz, CD3OD containing ascorbic acid 6.4, see Section 8.1.2) 6h 7.95 
(2H, d, J  8.5, Ar-H), 7.73 (2H, d, J8.5, Ar-H), 7.67 (1H, d, J8.0, Ar-H), 7.60 (1H, s, 
Ar-H), 7.39 (1H, d, J 16.5, olefinic-H), 7.35 (1H, d, J  16.5, olefinic-H), 7.35 (1H, d, J  
8.0, Ar-H), 7.33 (2H, s, aniline-H), 6.83 (1H, s, aniline-H), 2.33 (6H, s, Me), 1.69 
(6H, br s, Me), 1.65 (6H, br s, Me).
Mass spectrum m/z (ESI-HR, positive ion mode) Found 440.2464 [(M+H+), 
C29H3iN202+H+]. Requires 440.2464.
HPLC (Preparative) /r  22.0 min [column: Waters XBridge Prep C l8 5 pm, 19 x 150 
mm; 10 mL/min ACN/H20  70:30 isocratic, detection wavelength: 328 nm].
HPLC (Analytical) /r 12.5 min [column: Phenomenex Luna 5 pm C l8(2) 100 Ä, 250 
x 4.6 mm; 1 mL/min H20/ACN 30:70 isocratic, detection wavelength: 328 nm].
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8.7 Experimental for Chapter 7 
8.7.1 Calibration
In order to determine the concentration of the solutions prepared from small quantities 
of purified samples dissolved in ACN/water mixture, a calibration curve was used.
To determine the calibration curves, stock solutions (70 pM) were prepared for each 
of the rotaxanes 1.33, 1.34, 1.35, and 1.36 (2.0 mg) in ACN/water (v/v 2:1, 20 mL). 
Stock solutions (70 pM) were also prepared for each of the dumbbells 1.37 and 1.38 
(1.5 mg) in ACN/water (v/v 2:1, 50 mL). The stock solutions prepared were then 
diluted to 10, 20, 40, 60 and 70 pM. Aliquots (5 pL) of each solution were subjected 
to HPLC and the area underneath the peaks were measured and plotted against 
concentration to give calibration curves as shown in Figure 8.1 and Figure 8.2.
1200000
1000000
y -  12366x 
y = 11376x 
y = 11174x 41.33
800000
600000
H i .34
400000
X I.36
200000
Concentration (pM)
Figure 8.1. Plot of the peak area on the reverse phase HPLC chromatogram versus 
concentration to obtain calibration curves for the rotaxanes 1.33, 1.34, 1.35, and 1.36.
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Figure 8.2. Plot of the peak area on the reverse phase HPLC chromatogram versus 
concentration to obtain calibration curves for the dumbbells 1.37 and 1.38.
8.7.2 Photoirradiation and Monitoring
For UV/visible analysis: Solutions (70 pM) were prepared for each of the rotaxanes 
1.33, 1.34, 1.35, and 1.36 (2.0 mg) in ACN/water (v/v 2:1, 20 mL). Solutions (70 pM) 
were prepared for each of the dumbbells 1.37 and 1.38 (1.5 mg) in ACN/water (v/v 
2:1, 50 mL). Aliquots (3 mL) of the solutions were sealed in quartz cuvettes. Prior to 
photoirradiation, UV/visible spectra of respective compounds were recorded. Then, 
the solutions were irradiated with one 300 nm UV-B lamp (8 W) in the photoreactor. 
The solutions were removed at 1,2, 3, 4, 5, 10 and 20 min from the reactor to record 
UV/visible spectra.
For HPLC analysis: Samples further purified by analytical HPLC were reconstituted 
using 300 pL of ACN/water (v/v 2:1). Prior to analyses, concentration of respective 
solutions were determined using calibration curves in Section 8.7.1. Once the 
concentrations were determined, each solution concentration was adjusted to 20 pM 
by adding appropriate amount of solvent. Aliquots (300 pL) of respective solutions 
were placed in HPLC shell vials (8 * 30 mm) and sealed. These solutions were then 
irradiated with one 300 nm UV-B lamp (8 W) in the photoreactor. Aliquots (20 pL) of 
the irradiated solutions were placed in HPLC total recovery vials (12 x 32 mm) at 1,
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2, 3, 4, 5, 10, 20 min and 24 h, and loaded into the HPLC carousel (maintained at 4 °C 
and dark) to inject 5 pL of the sample and monitor the progress of the reaction.
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